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ABSTRACT 
 
PATHOLOGICAL UPREGULATION OF THE CALCIUM STIMULATED 
PHOSPHATASE, CALCINEURIN, IN TWO MODELS OF NEURONAL INJURY 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2006 
Director: Severn B. Churn, Ph.D.  
Associate Professor, Departments of Neurology; 
Anatomy and Neurobiology; Pharmacology and Toxicology; 
and Physiology 
 
 
 
Excitotoxic calcium influx and activation of calcium-regulated systems is a 
common event in several types of neuronal injury. This mechanism has been the 
focus of intense research, with the hope that a more complete understanding of 
how neuronal injury affects calcium-regulated systems will provide effective 
treatment options. This study examines one such calcium-stimulated enzyme, 
calcineurin, in the context of two common neurological pathologies, status 
epilepticus and traumatic brain injury.  
Status epilepticus was induced by pilocarpine injection. NMDA-dependent 
increases in calcineurin activity were observed in cortical and hippocampal 
homogenates. Upon closer examination, the most profound increases in activity 
were found to be present in crude synaptoplasmic membrane fractions isolated 
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from cortex and hippocampus. A concurrent status epilepticus-induced increase 
in calcineurin concentration was observed in membrane fractions from cortex and 
hippocampus. Immunohistochemical analysis revealed an increase in calcineurin 
immunoreactivity in apical dendrites of hippocampal pyramidal neurons. We 
examined a cellular effect of increased dendritic calcineurin activity by 
characterizing a calcineurin-dependent loss of dendritic spines. Increased 
dendritic calcineurin led to increased dephosphorylation and activation of cofilin, 
an actin-depolymerizing factor. Calcineurin-activated cofilin induced an increase 
in actin depolymerization, a mechanism shown to cause spine loss in other 
models. Finally, via Golgi impregnation, we demonstrated that status epilepticus-
induced spine loss is blocked by calcineurin inhibitors. 
 To demonstrate that the increase in dendritic calcineurin activity was not 
model-specific, we examined a moderate fluid-percussion model of brain injury. 
Calcineurin activity was significantly increased in hippocampal and cortical 
homogenates. This increased activity persisted for several weeks post-injury, and 
may be involved in injury-induced neuronal pathologies. Also similar to the SE 
model, calcineurin immunoreactivity was dramatically increased in 
synaptoplasmic membrane fractions from cortex and hippocampus, and 
immunohistochemistry revealed increased calcineurin content in dendrites of 
hippocampal CA1-3 pyramidal neurons. These changes in calcineurin distribution 
also persisted for several weeks post-injury. 
xi 
 
 These studies demonstrate a novel, cellular mechanism of calcium-
mediated pathology in two models of neuronal injury. Elucidation of cellular 
events involved in the acute and chronic effects of brain trauma is essential for 
the development of more effective treatment options. 
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INTRODUCTION 
 
 Excitotoxic calcium influx and the subsequent activation of calcium-
regulated systems is a common event in several types of neuronal injury [1]. This 
pathological mechanism has been the focus of intense research, with the hope 
that a more complete understanding of how neuronal injury affects calcium-
regulated systems will eventually provide effective neuroprotective and 
therapeutic treatment options. The present study examines one such calcium-
stimulated enzyme, calcineurin, in the context of two common neurological 
pathologies, status epilepticus and traumatic brain injury.  
 
Calcineurin – Structure, Function, Regulation, and Neuronal Substrates: 
Structure and Function: 
Calcineurin (CaN) was first discovered as a calmodulin-dependent 
inhibitor of CaM Kinase II that was highly enriched in neuronal tissue [2]. CaN 
was subsequently identified as a calcium-calmodulin dependent serine-threonine 
phosphatase [3, 4]. As one of the few serine-threonine phosphatases directly 
regulated by a second messenger, CaN plays an important role in many cellular 
functions, including regulation of other phosphatases and kinases, regulation of 
apoptosis, modulation of neurotransmitter release and receptor function, 
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modulation of learning and memory [5], regulation of gene transcription, and 
activation of immune cells [6]. CaN’s involvement in numerous essential cellular 
properties, coupled to its neuronal enrichment, have made the enzyme an 
intriguing subject of research into the mechanisms underlying neuronal injury and 
disease states.  
CaN is composed of two subunits: the catalytic “A” subunit, and the 
regulatory “B” subunit. Each of these subunits is subject to a number of 
regulatory mechanisms. The 58-64 kDa catalytic A subunit consists of catalytic, 
calmodulin-binding, autoinhibitory, and calcineurin-B binding domains [7, 8]. In 
the presence of 20 micromolar calmodulin, calcineurin has a Km of 0.6 µM for 
calcium. Calcium-calmodulin binding to CaN is highly cooperative, with a Hill 
coefficient of 2.5-3 [8, 9]. Binding of calcium/calmodulin to the calmodulin binding 
domain releases the catalytic domain from the influence of the autoinhibitory 
domain, permitting the enzyme’s phosphatase activity [10, 11]. The existence of 
these functional domains is supported by proteolysis studies. Partial proteolytic 
cleavage of the A subunit by the calcium-stimulated protease calpain (as well as 
members of the caspase family) can result in the removal of both the 
autoinhibitory and calmodulin-binding domains, resulting in a constitutively active 
enzyme with greatly increased phosphatase activity [12-15].  
The CaN A subunit exists in several isoforms, including Aα1, Aα2, 
Aβ1, and Aβ2 [8]. CaN A α and A β are both broadly expressed (including in most 
neurons and glia), although expression levels of the two isoforms vary between 
different cell types [16], and the α isoforms tend to be more strongly expressed in 
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neural tissue [16]. A testis-specific splice variant of CaN (CaN Aγ) exists in both 
rodents and humans [8], and may play a role in sperm maturation [17]. From a 
practical standpoint, no functional difference has been demonstrated between 
the various CaN A isoforms, and all are highly homologous [8].  
CaN B, the 19 kDa regulatory subunit of the enzyme, is a member of the 
EF-hand superfamily of calcium-binding proteins [18]. CaN B is tightly bound to 
CaN A, even in very low (nanomolar) calcium concentrations [8]. CaN B can bind 
4 calcium ions with high (Kd = 10-7M) affinity, and several more with micromolar 
(Kd = 0.5 to 1 micromolar) affinity [18]. Binding of calcium to the high affinity sites 
appears to be structural, while binding of calcium to the low-affinity sites causes 
a small, calmodulin-independent activation of the enzyme. The presence of CaN 
B is also essential for the calcium/calmodulin-dependent activation of the 
enzyme; it has been suggested that binding of calcium to the low-affinity sites on 
CaN B induces a conformational change in the catalytic A subunit, facilitating 
calmodulin binding [19]. Mammalian CaN B exists in 2 isoforms, CaN B1, found in 
all tissues, and CaN B2, which is testis-specific. The structure of CaN B is highly 
conserved from yeast to man, and both isoforms are typically myristoylated on 
the N-terminal glycine, a post-translational modification that is not essential for 
function [20]. 
 
Regulation: 
In addition to its regulation by calcium/calmodulin, CaN is also activated 
by other divalent cations, including nickel, magnesium and manganese [21], with 
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the most potent activation by Ni and the least by Mg. There is some debate about 
the physiological relevance of this activation, with some early studies suggesting 
that CaN requires one of these cations in addition to Ca for activity [22], while 
other researchers have not found any tightly associated Ni or Mn ions [23]. 
Calcineurin is sensitive to oxidation, and prolonged activation by calcium can 
result in inactivation of the enzyme through an oxidative mechanism [24]. Activity 
lost in this manner can be restored by ascorbate or another mild reducing agent 
in enzyme assays.  
Various endogenous peptides have been identified that act as 
physiological inhibitors of CaN activity. One such peptide (calcineurin 
autoinhibitory peptide, referred to in the literature as CAIN or CAP) binds to the 
autoinhibitory domain of CaN [25]. This peptide has been shown to negatively 
modulate CaN-mediated endocytosis, demonstrating that it has some 
physiological function [26]. More research remains to be done on this topic. In 
addition to the autoinhibitory peptide, other endogenous CaN inhibitory proteins 
have been recently identified. These include the calcineurin B homologous 
protein (CHP) and calcipressin 1. CHP (and a highly similar protein, tescalcin, 
expressed during the development of mouse testes [27]) is highly homologous 
with both calcineurin B and calmodulin and is capable of calcium binding [28]. It 
has been shown to potently inhibit calcineurin when overexpressed in cultured 
cells or when added in purified form to calcineurin assays [28]. Calcipressin 1 is 
the peptide product of the DSCR1 gene, located in a region thought to be critical 
to the defects associated with Down’s Syndrome [29, 30]. Calcipressin 1 is a 
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potent inhibitor of calcineurin [30, 31], through a mechanism that likely involves 
direct binding to the enzyme [30] and may involve competition with CaN 
substrates [32]. A final potential peptide regulator of CaN activity is the astrocyte 
calcium binding protein S100B, which seems to increase CaN activity [33], 
although this effect still requires further study.   
Regulation of CaN by phosphorylation of the enzyme remains 
controversial. For example, CaN can be phosphorylated at the same site (Ser 
411) by CaM kinase II and PKC [34-37]. While early research suggested that this 
phosphorylation modulated CaN activity [35], the effects were generally small 
and differed between activation and inhibition depending on the substrate and 
assay protocol used [38]. This site is rapidly autodephosphorylated by CaN itself 
[35]. CaN can also be phosphorylated at two sites by casein kinase I, no effect 
on CaN enzymatic activity has yet been attributed to this phosphorylation, and 
further research is required to determine its functional significance [39]. 
Finally, CaN is also regulated by its binding to the scaffolding protein 
AKAP79/150. In general, the AKAP family of proteins anchor protein kinase A 
near its substrates. Specifically, the AKAP79/150 molecule anchors PKA, CaN 
and PKC in the vicinity of AMPA receptors. Binding of CaN to the AKAP molecule 
results in an inhibition of CaN phosphatase activity [40]. 
 
Substrates and Potential Role in Disease States: 
 Calcineurin is highly enriched in neurons, and modulates a number of 
neuronal systems that are of interest in disease states. These systems include 
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management of neuronal calcium homeostasis, modulation of neurotransmitter 
function, and regulation of the neuronal cytoskeleton. An understanding of the 
role of CaN in these systems is essential to determining its role in clinical 
disease. 
 Maintenance of a low level of free intracellular calcium is essential to the 
proper function of neurons and allows calcium ions to work effectively as a 
second messenger in several key steps of neurotransmission. Due to its high 
affinity for calcium ions and relatively low dissociation constant for Ca2+ [2], CaN 
is one of the first post-synaptic enzymes activated after a calcium influx [41]. 
Thus CaN is ideally placed for the regulation of intracellular free calcium via 
negative feedback on several systems, including several types of voltage-gated 
ion channels, NMDA receptor-associated channels, and endoplasmic reticulum 
calcium stores.  
 Calcineurin has been shown to exhibit negative feedback on calcium entry 
through both L [42-44] and N [44, 45] type voltage-gated calcium channels 
(VGCC). In L-type channels, CaN overexpression reduced channel availability 
and increased the rate of channel inactivation in a cell line derived from rat 
neuroblastoma cells [42, 44]. These effects on L-type calcium currents were 
reversed by the inclusion of FK506 in the patch pipette, further implicating CaN in 
the effect [42]. A similar negative modulation of L-type channels has been seen 
in other, non-neuronal cell types, such as smooth muscle [46]. The precise 
mechanism for this effect has not yet been described, however the authors 
suggested that it was not G-protein mediated. This is in contrast to the regulation 
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of N-type calcium channels by CaN, which does appear to be G-protein 
mediated. In rat sympathetic neurons, CaN was shown to positively modulate the 
binding of an inhibitory G-protein to the N-type channel, enhancing channel 
inhibition. Addition of cyclosporin A in this study enhanced N-type calcium 
currents [45].  Some controversy exists over the CaN-dependent regulation of 
VGCC’s. For example, one study has suggested that calcineurin increases L-
type calcium channel activity in hippocampal neurons in culture [47]. The authors 
state that since VGCC regulation often varies greatly between cell types and 
even with the age of the neuron, it is possible for CaN to negatively modulate 
voltage sensitive calcium entry in some neurons while positively modulating it in 
others. If true, this hypothesis adds another layer of complexity to the role of CaN 
in regulating calcium entry.  
 In addition to its ability to retard calcium entry through some types of 
calcium channels, CaN also regulates intracellular calcium storage, particularly 
that of the endoplasmic reticulum. The ER is capable of sequestering calcium 
ions via a Mg/ATP-ase pump, then releasing this calcium in response to second 
messengers, including IP3 and calcium itself (through the ryanodine receptor). 
CaN has been shown to downregulate both the IP3 and ryanodine receptors 
through dephosphorylation of a PKC-dependent site [48, 49]. This 
dephosphorylation reduces the affinity of both receptors for their respective 
ligands, thus preventing excessive calcium discharge from the ER. CaN also 
regulates intracellular calcium dynamics on a transcriptional level. For example, 
CaN-mediated dephosphorylation of the transcription factor NF-ATc4 has been 
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shown to upregulate IP3 expression [50, 51]. CaN has also been shown (in some 
neuronal populations) to modulate expression of the plasma membrane calcium 
ATP-ase pump [52, 53] and the Na/Ca exchanger [54].  
 With the few exceptions noted above, the net effect of CaN is to provide 
negative feedback on calcium influx and ER calcium release, preventing 
excessive intracellular calcium levels in response to neuronal stimuli, and 
possibly downregulating downstream neurotransmission.  
 In excitatory neurons, CaN is highly enriched in the post-synaptic density. 
This places the enzyme in an ideal location for the regulation of neurotransmitter 
receptors. Indeed, several classes of receptors have been identified as either 
direct CaN substrates or indirectly regulated by CaN. These receptors include the 
NMDA-associated receptor, the AMPA/kainate glutamate receptor, and the 
GABAA receptor. In the PSD, CaN is highly bound to scaffolding proteins, 
including AKAP 79/150 [55, 56] and MAP-2. This interaction of CaN with these 
molecules serves several purposes. First, binding of CaN to specific molecular 
scaffolds aids in the compartmentalization of CaN substrates and downstream 
effectors, increasing the efficiency with which CaN regulates target mechanisms. 
For example, AKAP 79/150 holds CaN in a complex with PKA near AMPA 
receptors, facilitating the regulation of these receptors [55]. Additionally, binding 
of CaN to AKAP 79/150 directly regulates CaN activity. CaN activity has been 
shown to be decreased by approximately 25% when bound to the AKAP 79/150 
molecule [40]. Finally, molecular scaffolds can recruit further neurotransmitter 
receptors and other PSD proteins in response to neuronal activity.  
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 The anchoring of CaN near AMPA receptors by AKAP 79/150 suggests 
strongly that the enzyme may regulate these receptors. Recent research has 
demonstrated that this is, in fact, the case. CaN has been shown to negatively 
modulate these ligand-gated ion channels by several mechanisms. First, CaN 
appears to directly dephosphorylate the AMPA receptor GluR1 subunit at Ser 
845 [57]. Phosphorylation at this serine site potentiates the response of AMPA 
receptors to glutamate [58], thus CaN-mediated dephosphorylation of this site 
depotentiates the receptor. Further evidence for CaN-mediated negative 
modulation of AMPA receptors is provided by a study where the calcineurin 
autoinhibitory peptide was diffused into neurons via patch pipette. Under the 
influence of the autoinhibitory peptide, the amplitude of glutamate-induced fast 
EPSC’s increased [59]. Finally, some recent evidence suggests that CaN plays a 
role in NMDA receptor-triggered endocytosis of AMPA receptors, thus indirectly 
limiting AMPA receptor activity [60]. These mechanisms have all been proposed 
as a possible explanation of CaN’s effects on LTP and LTD. 
Calcineurin also appears to negatively modulate the other major class of 
glutamate-gated ion channels, NMDA receptors. Lieberman and Mody 
discovered that FK506 prolonged NMDA receptor channel open time in granule 
cells of the dentate gyrus [61], although they did not determine if this was due to 
a direct dephosphorylation of the receptor protein. A later study discovered that 
calcineurin was involved in glycine-insensitive desensitization of the NMDA 
receptor in outside-out patches from hippocampal neurons (a type of 
desensitization in which the NMDA receptor becomes desensitized to glutamate 
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due to extended binding of ligand to the receptor) [62]. Inhibition of CaN with an 
autoinhibitory peptide reduced desensitization of the receptor. It was 
subsequently discovered that this effect of CaN on NMDA receptor 
desensitization was due to a direct dephosphorylation of the receptor on the C-
terminus of the NR2A subunit [63]. This densensitization of NMDA receptors was 
observed under more physiological conditions (and found again to be CaN-
dependent) using synaptic NMDA receptors in hippocampal cell culture. Synaptic 
NMDA receptors were stimulated by causing glutamate release from presynaptic 
neurons. Desensitization was observed under these conditions, and 
desensitization was blocked through the use of CaN inhibitors [64].  
GABAA receptors are the primary receptor responsible for the fast 
inhibitory response in neuronal tissue [65]. Several recent studies have 
demonstrated a down-regulation of GABAA receptor function by CaN [66-68]. 
This modulation of GABAA receptor function may occur through direct 
dephosphorylation of receptor subunits. For example, a recent study described a 
direct interaction of CaN with the gamma 2 subunit of GABA receptors. CaN-
mediated dephosphorylation of this subunit was shown to produce long-term 
depression (LTD) of inhibitory synapses [69]. 
 Finally, CaN also regulates a number of cytoskeletal elements. CaN has 
been shown to dephosphorylate several microtubule-associated proteins, 
including MAP2 and tau [70]. MAP2 is a protein that co-purifies with tubulin and 
is present in neuronal cell bodies, axons and dendrites, and is important for the 
crosslinking of microtubules to one another and to other cytoskeletal elements. 
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MAP2 is highly phosphorylated in vivo, and this phosphorylation seems to be 
involved in the crosslinking and assembly of microtubules. A number of studies 
have demonstrated a CaN-dependent dephosphorylation of MAP2. This 
dephosphorylation was induced by activation of the NMDA receptor in several 
studies, suggesting that CaN may regulate the microtubule structure in response 
to neuronal excitation. Like MAP2, tau has also been shown to crosslink 
microtubules to one another [71] and CaN has been shown to dephosphorylate 
tau [72]. In fact, exogenous CaN added to cultured neurons resulted in 
dephosphorylation of at least four tau phosphorylation sites [73], while reduction 
of CaN expression by antisense oligonucleotides resulted in 
hyperphosphorylation of tau at two sites [74]. Loss of CaN-mediated tau 
dephosphorylation has been a topic of intense interest in Alzheimer’s disease, as 
hyperphosphorylated tau is a major component of the neurofibrillary tangles that 
are a hallmark of the disease [75]. In a more normal physiological role, CaN-
mediated tau dephosphorylation has also been shown to be involved in the 
acquisition of polarity in cultured neurons [76]. Finally, in addition to its actions on 
microtubule-associated proteins, CaN is also capable of modulating actin 
stability. Calcineurin has been shown to be involved in extension of neuronal 
growth cones by encouraging actin depolymerization and turnover, likely by 
dephosphorylating a number of factors [77, 78]. CaN has also been observed to 
alter dendritic spine morphology, both in neuronal cultures and in a hippocampal 
slice model of LTD [79, 80]. Finally, CaN has been shown to regulate several 
actin-associated proteins, including cofilin and calponin [81]. Cofilin acts as an 
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actin-depolymerizing factor, and is stimulated by CaN-mediated 
dephosphorylation, while calponin is an actin binding protein that is associated 
with smooth muscle contraction. Both proteins have been identified in neurons 
and have been implicated in dendritic spine plasticity [82, 83].  
 Given its essential role in modulating neuronal excitability and its ability to 
regulate the architecture of the neuronal cytoskeleton, alterations in CaN 
expression or activity by disease states have a great deal of pathological 
potential. The present study investigates the role of CaN in two such conditions, 
traumatic brain injury and status epilepticus. 
 
Traumatic Brain Injury: 
 Traumatic brain injury is a major cause of death and disability in the 
United States, particularly among young adults and the elderly [84], has been 
associated with a number of long-term neurological pathologies, including 
cognitive deficits and the development of post-traumatic epilepsy [85]. Limiting 
the mortality and long-term neurological pathology associated with these injuries 
has been a major focus of research for many years. A number of delayed 
processes are thought to contribute to the neuronal pathology associated with 
these injuries. The current hope is that a better understanding of these 
secondary processes will help provide neuroprotective clinical treatments for the 
brain-injured patient. Preventing this secondary damage of brain tissue may 
allow for better post-injury outcomes, especially in patients with mild to moderate 
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injuries, where the area of primary damage may be small. One pathological 
mechanism that has been of great interest is excitotoxic neuronal damage. 
 Following TBI, widespread neuronal depolarization leads to excessive 
release of glutamate [86]. The presence of such large amounts of excitatory 
neurotransmitter leads to toxic activation of post-synaptic receptors, influx of 
calcium ions, and pathological overactivation of calcium-stimulated systems. 
These calcium-stimulated enzymes and transcription factors are then thought to 
lead to a number of pathological changes in neurons, including axonal sprouting 
and synaptic reorganization, dendritic pull-back, neuronal hyperexcitability and 
cell death. This excessive glutamate release has been observed both in several 
animal models of injury and clinically (via the use of microdialysis probes) [87-
89]. Interestingly, the rise in glutamate levels can be delayed anywhere from 
several hours to a day after the initial brain injury. Ideally, this presents a clinical 
window for the administration of neuroprotective agents. Unfortunately, efforts at 
pharmacological treatments that focus on this pathway, while promising in animal 
models, have been unsuccessful clinically [90]. A more complete understanding 
of the calcium-regulated mechanisms that are activated by this post-traumatic 
glutamate release may help with the development of more focused and effective 
treatment options. 
 A mounting body of evidence suggests that CaN may be one such TBI-
modulated system. CaN activation has been observed in vitro in several studies 
of glutamate excitotoxicity [91, 92]. Additionally, both of the immunosuppressive 
CaN inhibitors, cyclosporin A and FK506 (tacrolimus), have been shown to be 
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neuroprotective in several animal models of TBI. Singleton and colleagues 
demonstrated protection by FK506 against diffuse axonal injury [93], this 
protection was shown to be a result of FK506 preventing TBI-induced impairment 
of axonal transport [93]. Some controversy exists over the mechanism of action 
of these inhibitors in TBI, as cyclosporin in particular has other actions in addition 
to inhibition of CaN, and may be providing neuroprotection through more than 
one pathway. Cyclosporin blocks the mitochondrial permeability transition pore, 
thought to be a key step in both the induction of apoptosis and axonal injury [94]. 
However, the efficacy of FK506 (which is more specific in its effects) in 
preventing a number of pathological processes tends to argue for a CaN-
dependent mechanism. Further research is required to accurately determine the 
involvement of CaN in TBI-associated neuronal pathology.  
 
Status Epilepticus: 
Epilepsy and other seizure disorders are one of the most common 
neurological conditions in the United States today. These disorders can have a 
negative impact on quality of life for a number of reasons [95]. Depending on the 
patient’s seizure frequency and severity, seizure disorders can limit cognitive 
development in children [96], prevent daily activities such as driving a car or 
working [97], and may require a lifetime of medication, often with unpleasant side 
effects [98, 99]. In spite of this, in most seizure disorders the seizures themselves 
are self-limiting – lasting a few minutes at most – and thus are not life threatening 
on their own. However, seizures that do not self-terminate after a few minutes 
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are life threatening and merit aggressive treatment. This condition of continuous 
seizure activity is known as status epilepticus (SE). 
 SE, affecting over 100,000 people annually [100], is defined as continuous 
seizure activity that exceeds thirty minutes in duration, or a number of individual 
seizures that total more than thirty minutes and between which the patient does 
not regain consciousness. SE can be subdivided into convulsive and non-
convulsive SE (NCSE). Convulsive SE, which can be generalized (GCSE) or 
patrial manifests both behavioral and electrographic seizures, and is associated 
with a higher acute mortality. On the other hand, NCSE is characterized by 
electrographic seizures without convulsions and has several possible 
presentations, ranging from mild confusion to coma [101]. NCSE requires 
electroencephalography (EEG) for definitive diagnosis. Both subtypes of SE 
represent a severe neurological emergency associated with significant morbidity 
and mortality [102, 103]. SE is of particular concern in the elderly population, with 
a higher incidence among these patients. SE also has a markedly higher 
mortality rate among elderly patients, partly due to the greater incidence of other 
complicating conditions in this population [104]. 
  Many of these cases of SE may be attributed to a causative event, such 
as an injury or illness. Underlying epilepsy is perhaps the most common cause of 
SE, especially in patients without adequate antiepileptic drug therapy [105]. 
Traumatic brain injury is also associated with the development of SE [106, 107]. 
The onset of continuous seizures often greatly complicates the treatment of 
traumatic brain injury and is associated with lower rates of recovery [108]. Other 
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causes of SE include brain neoplasms, drug overdose or withdrawal, infection, 
fever (especially in children) and stroke [105]. However, in many cases a 
causative event cannot be identified.  
 Regardless of the cause, SE requires urgent treatment to prevent long-
term injury or mortality. Unfortunately, common anti-epileptics are not effective in 
some cases of SE, especially as the duration of the seizure activity increases 
[109]. As a result, SE often requires aggressive treatment with general 
anesthetics, placing the patient in a drug-induced coma to reduce or eliminate 
electrographic seizure activity. Additionally, patients require cardiovascular and 
respiratory support to help them survive the SE episode [110]. While termination 
of the seizure activity is essential for patient survival (particularly in GCSE), these 
treatments are not without risks and are not always optimally effective. 
Understanding why SE becomes refractory to first- and second-line treatments 
and devising new treatment options are currently major focuses of a number of 
research studies. 
 Even among patients that survive SE, long-term neurological 
complications are a common consequence of a prolonged seizure episode. 
Potential consequences of SE include cognitive deficits and the development of 
spontaneous recurrent seizures (i.e. epileptogenesis) [105, 111]. Developmental 
delay has been associated with SE in children, especially in non-febrile, non-
idiopathic cases [96]. A more complete understanding of the cellular mechanisms 
underlying these pathologies may help limit the morbidity currently associated 
with continuous seizure activity. 
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As with TBI, glutamate-mediated excitotoxicity and calcium-mediated 
injury are thought to be a major cause of SE-mediated neuronal damage [1, 112]. 
Acutely, blockade of the NMDA receptor has been shown to preserve 
benzodiazepine efficacy well into SE, suggesting that calcium-regulated systems 
may be partially responsible for refractoriness to anti-epileptic drugs [113]. 
Additionally, blockade of glutamate receptors limits neuronal death in SE. 
Chronically, excitotoxic/calcium-mediated mechanisms are important in the 
development of several SE-associated pathologies. For example, in the 
pilocarpine model of SE, several studies have demonstrated that post-SE 
cognitive dysfunction and epileptogenesis were dependent on NMDA-receptor 
mediated calcium influx [114-116].  
 NMDA-mediated calcium influx leads to toxically high levels of calcium 
inside of neurons during the seizure event. However, this acute spike in free 
calcium is not the only source of excessive intracellular calcium implicated in the 
pathology of SE. It appears that calcium levels remain chronically high in neurons 
well after SE, due to a reset of the neuron’s normal resting calcium levels [117, 
118]. Additionally, after SE neurons respond more slowly to a calcium challenge, 
requiring more time to remove calcium once it has entered the neuron [119]. 
Since calcium is such a pervasive second messenger in cellular processes, this 
SE-induced increase in resting calcium concentrations can lead to chronic 
activation of calcium-stimulated enzymes and subsequent disregulation of 
synaptic function. Neuronal free calcium levels are normally maintained in at 
nanomolar concentrations through the actions of several calcium sinks, including 
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plasma membrane calcium pumps, calcium-binding proteins, and calcium 
sequestration by the mitochondria and smooth endoplasmic reticulum. Recent 
research has implicated at least one of these mechanisms in SE-induced altered 
calcium handling. Parsons et al [120] demonstrated that the ATP-dependent 
calcium pumps of the smooth ER are damaged by SE, resulting in an uncoupling 
of their ATP usage from their calcium pumping activity and a loss of efficiency in 
ER calcium sequestration. These calcium-related pathological mechanisms have 
made calcium-regulated systems an intriguing area of research in SE. One such 
calcium-regulated system that may play a role in the pathology of SE is CaN. 
 Some evidence points to a role for CaN in SE. As with TBI, CaN inhibitors 
have proven neuroptotective in some seizure models. Moriwaki et al 
demonstrated that CaN inhibitors prevented epileptogenesis and behavioral 
deficits after kainite-induced SE, although no effect was observed on the acute 
seizure activity of SE, suggesting that CaN may be important for the 
development of SE-associated chronic pathologies [121]. However, the 
mechanism underlying this neuroprotective effect has not been elucidated. Moia 
and colleagues observed a similar anti-epileptogenic effect in a kindling model, 
with administration of FK506 or cyclosporin A preventing electrical-stimulation 
kindling in rats [122]. In the same study, CaN was shown to translocate into post-
synaptic membrane fractions as a result of kindling, possibly indicating that CaN 
modulates neuronal excitability post-synaptically during epileptogenesis.  
Sanchez et al. [123] suggested one potential seizure-induced post-synaptic effect 
of CaN in a model of hypoxic seizures in immature rats. In this study, CaN 
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activity was increased post-seizure, and this increase in CaN activity appeared to 
modulate the activity of the GABAA receptor. In spite of these intriguing results in 
other seizure models, no study has yet examined the effects of SE on CaN 
activity, or demonstrated the role of CaN in SE-associated pathology. 
 
The present study characterizes the effects of two different models of 
neuronal injury on the activity and subcellular distribution of CaN. In chapter one, 
we examine basal and maximal CaN activity in forebrain homogenates after a 
one-hour SE event. In this chapter, we also describe SE-induced changes in 
CaN substrate kinetics. Finally, chapter one also examines the NMDA receptor-
dependence of these changes in CaN activity, and determines whether the 
observed SE-induced changes in CaN activity are due to an overall increase in 
enzyme concentration. In chapter two, through the use of western and 
immunohistochemical analysis, we show an SE-dependent increase in the 
amount of CaN present in the post-synaptic region of hippocampal and cortical 
neurons. This SE-induced increase in synaptoplasmic CaN concentration is 
accompanied by a dramatic increase in CaN activity in this fraction. Chapter two 
also presents data on SE-induced changes in CaN enzyme activity in subcellular 
fractions taken from cortex and hippocampus. Taken together, the results 
presented in the first two chapters of this study describe a profound increase in 
post-synaptic CaN concentration and activity after one hour of SE, changes that 
could have major implications in the pathology of SE. In chapters three and four 
we present TBI-induced changes in CaN activity and post-synaptic concentration 
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in the moderate fluid percussion model of traumatic brain injury. These changes 
in CaN activity and subcellular distribution persist for several weeks post-injury, a 
time-course which corresponds to a number of TBI-associated pathologies. 
Finally, in chapter five, we discuss a major physiological consequence of SE-
induced increases in post-synaptic CaN activity and concentration: loss of 
dendritic spines. CaN was shown to be part of a cellular mechanism of SE-
induced dendritic spine loss, possibly implicating the enzyme in SE-induced 
chronic neurological pathology. Altogether, the results presented in this study 
provide compelling evidence that CaN is involved in neuronal damage in two 
disparate models of injury, and support the hypothesis that SE-induced increases 
in CaN activity lead to decreased dendritic spine density. Ideally, further research 
in this topic will provide a basis for future neuroprotective and therapeutic 
treatments. 
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CHAPTER I 
A SIGNIFICANT INCREASE IN BOTH BASAL AND MAXIMAL 
CALCINEURIN ACTIVITY IN THE RAT PILOCARPINE MODEL OF 
STATUS EPILEPTICUS 
 
 
INTRODUCTION 
 Status epilepticus (SE) is a severe medical condition, affecting 102,000 to 
152,000 people per year in the United States [100, 103]. Defined as continuous 
seizure activity lasting thirty minutes or greater, SE is a life-threatening medical 
emergency, associated with significant mortality rates [103, 105, 124]. According 
to recent studies, status epilepticus results in between 22,000 and 42,000 
fatalities every year in the U.S. [100, 103]. In addition, SE is also associated with 
physiological and neurochemical changes which take place during the seizure 
activity [105, 125, 126]. These cellular changes may later manifest themselves as 
spontaneous recurrent seizure activity (i.e. epilepsy), through a process known 
as epileptogenesis [105, 111]. Therefore, victims of status epilepticus incur both 
an immediate, serious risk of death, and another, long-term risk of developing 
recurrent seizure activity.  
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 Modulation of intracellular calcium levels is important in a number of 
normal neuronal processes including regulation of gene expression, development 
of learning and memory, and neurotransmitter synthesis and release [127, 128]. 
However, alterations in calcium-regulated systems and loss of calcium 
homeostasis have also been implicated in many pathological conditions, such as 
ischemia [129-131], traumatic brain injury [132, 133], and SE [118, 120]. 
Specifically, influx of calcium through the NMDA subtype of glutamate receptor is 
suspected to be important for physiological changes occurring after SE [116, 
118, 126]. NMDA-linked increases in intracellular calcium affect a number of 
calcium-controlled cellular mechanisms and enzymes including 
calcium/calmodulin-dependent kinase II (EC 2.7.1.123, CaM Kinase II) [127, 
134], calpain I (EC 3.4.22.17) [135] and calcineurin (EC 3.1.3.16 CaN) [136]. 
Calcineurin is a calcium/calmodulin-stimulated phosphatase enriched in 
neural tissue [137]. CaN-mediated dephosphorylation is an important modulatory 
factor in many cellular processes, including development of learning and memory 
[138], regulation of LTP and LTD [139], and induction of apoptosis [140]. 
Additionally, CaN may depress the activity of the GABA receptor, an important 
inhibitory receptor in the brain [67]. These characteristics make CaN an intriguing 
enzyme for study in SE. In spite of this, no studies have yet focused on SE-
dependent changes in CaN activity.   
This study was undertaken to characterize changes in calcineurin activity 
in specific brain regions following status epilepticus. Basal and maximal CaN 
activities were investigated, with an NMDA-receptor activation-dependent 
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increase present in both. Since CaN regulates many important neuronal 
processes, an increase in the activity of this important enzyme may be involved 
in SE-induced alterations of neuronal function. 
 
METHODS AND MATERIALS: 
 All materials were reagent grade and were purchased from Sigma 
Chemical Co. (St. Louis, MO) unless otherwise noted. Bio-Rad protein assay 
concentrate, sodium dodecyl sulfate (SDS), 2-mercaptoethanol, blotting grade 
dry milk, and Mini-Protean II SDS-PAGE apparatus and power supplies were 
purchased from Bio-Rad Laboratories (Richmond, CA). Okadaic Acid was 
purchased from BioMol (Plymouth Meeting, PA). ABC reagents were obtained 
from Vector Laboratories (Burlingame, CA). Absolute ethyl alcohol was 
purchased from AAPER Alcohol and Chemical Co. (Shelbyville, KY). Adult male 
Sprague-Dawley rats were obtained from Harlan Laboratories (Indianapolis, IN).  
 
Pilocarpine model of status epilepticus: 
 All animal use procedures were in strict accordance with the Guide for the 
Care and Use of Laboratory Animals described by the National Institutes of 
Health and were approved by the Virginia Commonwealth University Animal Use 
Committee. SE was induced in adult male Sprague-Dawley rats by the method 
described in Mello et al [141]. Rats were handled regularly for approximately one 
week to acclimate them to handling prior to drug administration. Adult rats 
weighing 175-230g were injected intraperitoneally (i.p.) with 350mg/kg 
pilocarpine HCl, a potent muscarinic agonist. 30 minutes prior to the pilocarpine 
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injection, all rats were treated i.p. with 1mg/kg methylscopolamine. 
Methylscopolamine is a peripheral muscarinic antagonist; administering it prior to 
pilocarpine injection minimizes adverse peripheral effects. Control rats received 
all injections, except that pilocarpine was administered at 1/10th its seizure-
inducing dose. Control animals did not exhibit any behavioral seizure activity. 
When appropriate, rats were injected with the non-competitive NMDA antagonist, 
MK-801 (4 mg/kg, i.p.), 20 minutes before pilocarpine injection. All drugs were 
dissolved in 0.9% saline. 
 Behavioral seizures typically began 20 minutes following pilocarpine 
injection. Seizures were rated according to the scale described by Racine [142]. 
Only animals reaching stage 5 seizures were included in this study. Stage 5 was 
classified as the most severe level of seizure activity, characterized by rearing 
and falling. Rats not responding to the initial pilocarpine injection received a 
second injection, often of a lower dose. Rats that still did not display stage 5 
seizure activity following a second pilocarpine injection were excluded from the 
SE group [134].  
 
Isolation and homogenization of brain regions: 
Rats were rapidly decapitated after 1 hour of SE. Brains were dissected 
on a petri dish on ice to preserve post-mortem enzyme activity. Cortical, 
hippocampal, and cerebellar brain regions were quickly isolated and immediately 
homogenized with 10 strokes (up and down) at 12,000 rpm, using a motorized 
homogenizer (TRI-R Instruments, Inc. Rockville Center, NY). Brain regions were 
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homogenized into ice-cold homogenization buffer containing 5mM HEPES (pH 
7.0), 7mM EGTA, 5mM EDTA, 1mM dithiothreitol (DTT), 0.3mM PMSF, and 
300mM sucrose. Cortical regions were homogenized into 7ml of buffer, 
hippocampal regions into 3ml of buffer, and cerebellar regions into 5ml. All brain 
homogenates were normalized for protein, separated into aliquots and stored at 
–80°C until used. 
 
pNPP assay of phosphatase activity: 
 Calcineurin activity was assayed using a modification of the procedure 
detailed by Pallen and Wang [143]. All reaction tubes were prepared on ice and 
contained the following: 25mM MOPS (pH 7.0), 1mM DTT, 2mM p-nitrophenol 
phosphate (pNPP). Some basal tubes also contained 2mM EGTA and 2mM 
EDTA. Maximal tubes contained the same reagents as basal reactions, with the 
addition of 2mM MnCl2. Final reaction volumes were 1ml. Both Mn2+ and 
Ca2+/calmodulin activate calcineurin in this assay; however, Mn2+ activates 
calcineurin more strongly than calcium [21]. Therefore, Mn2+ was used instead of 
calcium in maximal reactions to better visualize the cation-stimulated activity of 
the enzyme. When called for, 150nM okadaic acid, 50µM okadaic acid (sodium 
salt), or 100µM NaVO4 was added to both basal and maximal tubes. Prior to use, 
the protein concentration of all homogenates was determined using the method 
of Bradford et al. [144]. Reactions were initiated by the addition of 200 mg/ml 
brain region homogenate. Unless otherwise specified, standard reactions were 
incubated at 37°C for 15 minutes in a shaking water bath. Tubes were then 
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removed from the water bath and placed in ice to stop the reaction. Absorbance 
of the reaction mixture was immediately measured at 405nm in a 
spectrophotometer (UV-2101, Shimadzu Scientific Instruments, Inc. Columbia, 
MD). Absorbance units were converted to nmol of pNP produced by comparison 
to a pNP concentration standard absorption curve. 
 
pNPP substrate kinetics: 
Basal reaction tubes were prepared containing 25mM MOPS, 1mM DTT, 
2mM EGTA, 2mM EDTA, and 150nM okadaic acid to minimize the influence of 
other phosphatases on the results of the assay.  Maximal reaction tubes 
contained 25mM MOPS, 1mM DTT, 2mM MnCl2, and 150nM okadaic acid. All 
reaction tubes were prepared on ice. pNPP was added to the tubes for final 
concentrations of 0, 0.1, 0.2, 0.5, 1, 2, 4, 8, 16 and 24mM. CaN reactions were 
initiated by the addition of homogenate and assayed as described above. Values 
for Km and Vmax were obtained via a non-linear regression analysis of the 
substrate isotherm. 
 
CaN protein level analysis: 
 Western analysis was performed essentially as described previously [145, 
146]. Briefly, homogenates were resolved on SDS-PAGE and transferred to a 
nitrocellulose membrane using the Geni blot system (Idea Scientific, Minneapolis, 
MN). Nitrocellulose was then immersed for one hour in blocking solution 
containing phosphate buffered saline (PBS, pH 7.4), 0.05% (v/v) polyoxyethylene 
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sorbitan monolaurate (tween-20), 50 g/L Bio-Rad blotting grade dry milk, and 
horse serum (Vector Laboratories Inc., diluted 50 µl/10ml). The nitrocellulose 
membrane was then incubated with primary antibody in blocking solution for one 
hour. Anti-CaN A antibody (clone CN-A1, mouse monoclonal IgG, Sigma 
Chemical Co.) was diluted 1:10,000 for western analysis. Membranes were then 
washed three times in a wash solution containing PBS, tween-20, and dry milk. 
Nitrocellulose was then reacted with a secondary antibody in blocking solution for 
45 minutes. The membrane was then washed three times and incubated with an 
avidin-biotinylated horseradish peroxidase complex for 30 minutes. Nitrocellulose 
was then washed three times in PBS for 10 minutes per wash. Blots were 
developed with a solution containing 10 ml PBS, 0.025% (v/v) H2O2, and 8 mg 4-
chloro-1-napthol dissolved in 2ml of methanol. Specific immunoreactive bands 
were quantified by computer-assisted densitometry (Inquiry, Loats Associates, 
Westminster, MD).    
 
Statistical analysis: 
 All statistical analysis of data was performed using GraphPad Prism 3.0 
(GraphPad Software, San Diego, CA), or Sigma Stat 2.03 (SPSS Inc, Richmond, 
CA). Levels of phosphatase activity were compared to control using the Student’s 
t-test (two-tailed distribution, unpaired or paired where appropriate) or one-way 
ANOVA with Tukey post analysis to control for type 1 errors in multiple 
comparisons. Values for Vmax and Km were determined by a non-linear regression 
curve for single-site substrate binding, included with the Prism software. 
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Computer assisted densitometric analysis was performed using Inquiry (Loats 
Associates Inc, Westminster, MD). 
 
RESULTS:  
Status epilepticus results in an increase in calcineurin activity in specific 
brain regions: 
 Calcineurin dephosphorylates the low molecular weight compound p-
nitrophenolphosphate (pNPP) with high affinity, producing p-nitrophenol (pNP) 
[143]. It is possible to measure this dephosphorylation spectrophotmetricaly, 
providing a simple and accurate method for quantifying calcineurin activity. In the 
present study, CaN activity was measured via the pNPP assay in homogenates 
obtained from the cortex, hippocampus, and cerebellum of SE and control rats. 
 Both basal and maximal CaN activity were measured in SE and control 
animals (Figure 1). In every sample studied, SE caused an increase in 
phosphatase activity above control levels in both the cortex and hippocampus, 
but not the cerebellum. Average basal activity in control samples was 0.79 ± 0.10 
µg pNP /min in cortical homogenates, and 0.86 ± 0.03 µg pNP/min in 
hippocampal homogenates. Following SE, basal CaN activity was elevated 48.6 
± 14.5% above control in the cortex (Figure 1A) (1.18 ± 0.04µg pNP/min, p < 
0.01, n=6, two-tailed unpaired Student’s t-test) and 20.8 ± 4.9% in the 
hippocampus (Figure 1B) (1.04±0.03µg pNP/min, p < 0.001, n=9). The elevated 
activity was biological, and could be eliminated by boiling the homogenate prior 
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to beginning the reaction. The increase was present in spite of the addition of ion 
chelators to the reaction mix (see methods).  
Unlike homogenates from the cortex and hippocampus, basal activity in 
cerebellar homogenate was not significantly increased after SE. Basal activity in 
cerebellar homogenates isolated from control animals was 0.92 ± 0.08µg 
PNP/min. After SE, activity in the cerebellum was elevated to 1.00 ± 0.05µg 
PNP/min, an increase of 8.0 ± 10.1% (Figure 1C). This was not a significant 
increase (p > 0.05, n=7). The difference in the response of the cerebellum from 
that of the forebrain suggests that different mechanisms are involved in the 
expression of SE in the cerebellum from that of the forebrain.  
Maximal activity, like basal activity, was increased after SE in both the 
cortex and hippocampus, but not the cerebellum. In cortical homogenates 
isolated from control animals, pNPP dephosphorylation was found to be 1.34 ± 
0.18µg pNP/min. Following SE, maximal cortical dephosphorylation activity was 
elevated to 1.80 ± 0.05µg pNP/min, an increase of 34.2 ± 10.2% (Figure 1A, p < 
0.01, n=6). An increase in maximal activity was also observed in hippocampal 
homogenates. Control maximal activity was 1.36 ± 0.05µg pNP/min. SE resulted 
in a 13.7 ± 5.1% increase in activity, to a post-SE value of 1.55 ± 0.02µg 
pNP/min. (Figure 1B, p < 0.05, n=9). No significant change in maximal activity 
was observed in the cerebellum. Control maximal activity was 1.54 ± 0.12µg 
pNP/min in cerebellar homogenates. After SE, maximal activity increased to 1.60 
± 0.08µg pNP/min. This was an increase of 4.0 ± 3.4% over control, which was 
not statistically significant (Figure 1C, p > 0.05, n=7). 
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The SE-dependent increase in CaN activity is due to an alteration in 
enzyme kinetics: 
 To further characterize the SE-dependent effect on calcineurin activity, 
several experiments were conducted in cortical homogenate to examine the 
effects of SE on CaN-mediated pNPP dephosphorylation kinetics. Figure 2 
shows the linear regression analysis of the time course for pre-steady state 
pNPP dephosphorylation under basal and maximal CaN conditions. The slope of 
the linear regression for each condition was used to estimate the rate of pNPP 
dephosphorylation. The rate of CaN-dependent dephosphorylation of pNPP in 
cortical homogenates from control animals was estimated to be 0.26 µg/min 
under basal conditions. SE resulted in a 36.7 ± 7.6% increase in the rate of 
pNPP dephosphorylation, to 0.36 µg/min (Figure 2A, p < 0.001, n=3, unpaired 
student’s t-test). The increase in pNPP dephosphorylation rate was also 
observed in maximal CaN reactions (Figure 2B). The rate of control pNPP 
dephosphorylation was 0.68 µg/min under maximal conditions. SE resulted in a 
significant increase in pNPP dephosphorylation, to a value of 0.80 µg/min (17.6 ± 
4.7%, p < 0.05, n=3, unpaired student’s t-test). The data demonstrate a 
significant increase in both basal and maximal pNPP dephosphorylation rates in 
cortical homogenate 
To determine the effect of SE on CaN affinity for pNPP, cortical 
homogenates from SE and control animals were tested in the presence of 
specific pNPP concentrations. (Figure 3). Through non-linear regression analysis 
of the data, maximal pNPP dephosphorylation (Vmax) and substrate affinity (Km) 
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for the dephosphorylation of pNPP were calculated. The control value for Vmax 
was 1.21 ± 0.06µg pNP/min under basal reaction conditions. Following SE, Vmax 
increased to 1.46 ± 0.03µg pNP/min, an increase of 20.5 ± 5.3% above the 
control value (p < 0.05, n=3, two-tailed unpaired Student’s t-test). Substrate 
affinity was also increased under basal conditions. In homogenates isolated from 
control animals, Km was found to have a value of 1.25 ± 0.22mM. Post-SE, Km 
decreased to 0.54 ± 0.06mM. This decrease in Km corresponded to a 56.8 ± 
14.5% increase in substrate affinity in SE homogenates when compared to 
control (p < 0.05, n=3). Under maximal conditions, Vmax was also increased after 
SE. In control homogenates, Vmax was determined to be 1.73 ± 0.05µg pNP/min. 
Following SE, Vmax was elevated to 1.93 ± 0.04µg pNP/min, an increase of 12.8 ± 
3.5% over control (p < 0.05, n=3). Substrate affinity appeared to increase in SE 
homogenates under maximum conditions; however, this difference was not 
statistically significant (p > 0.05, n=3). 
 
The increase in both basal and maximal pNPP dephosphorylation is due to 
CaN: 
 The enzyme activity observed in the various brain regions is consistent 
with CaN activity: calcineurin dephosphorylates pNPP readily, is stimulated by 
Mn2+, and is most active at pH 6.8 - 7.0 [21, 143]. However, pNPP is a versatile 
substrate, and is also dephosphorylated by some tyrosine and alkaline 
phosphatases [147]. All experiments were conducted at a neutral, rather than 
alkaline, pH (see methods). Therefore, it would be expected that alkaline 
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phosphatases have only a minimal contribution to the observed 
dephosphorylation of pNPP. To rule out tyrosine phosphatases and other 
serine/threonine phosphatases, the phosphatase inhibitors sodium 
orthovanadate and okadaic acid were tested. 
 Sodium orthovanadate (NaVO4) is a potent inhibitor of tyrosine 
phosphatases (IC50 = 10µM) [148]. Additionally, orthovanadate is a strong 
inhibitor of the Mn2+-stimulated activity of calcineurin (IC50 = 1µM) [149]. It does 
not, however, inhibit any non-Mn2+ stimulated calcineurin activity [149]. 
Dephosphorylation reactions were carried out in cortical homogenates in the 
presence of 100µM NaVO4 under both basal and maximal (Mn2+-stimulated) 
conditions (Figure 4). The addition of orthovanadate did not cause any significant 
change in basal pNPP dephosphorylation in either control or SE homogenates (p 
> 0.05, n=4, one-way ANOVA). Therefore, even in the presence of NaVO4, basal 
pNPP dephosphorylation in homogenates isolated from SE animals was still 
significantly greater when compared to control homogenates (p < 0.001, n=4, 
unpaired student’s t-test). Thus, SE induced a NaVO4-resistant increase in pNPP 
dephosphorylation. The data support the hypothesis that the SE induced 
dephosphorylation was not due to tyrosine phosphatases.  
As expected, the inclusion of orthovanadate did have a significant effect 
on maximal pNPP dephosphorylation. Orthovanadate reduced maximal enzyme 
activity to basal levels in both SE and control homogenates. The addition of 
NaVO4 reduced control maximal activity from 1.19µg pNP/min to 0.62µg 
pNP/min, a decrease of 48.1 ± 4.6% (p < 0.001, n=4, two-tailed paired student’s 
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t-test). In SE homogenates, maximal activity was reduced by 40.7 ± 8.9%, from 
1.67µg pNP/min to 0.99µg pNP/min (p < 0.001, n=4). The NaVO4-inhibited 
maximal activity was significantly greater in SE homogenates when compared to 
control homogenates (p < 0.001, n=4, two-tailed unpaired student’s t-test). Since 
orthovanadate specifically inhibits only Mn2+-stimulated CaN activity, the 
observed inhibition of maximal activity, but not basal activity, is consistent with 
CaN-dependent dephosphorylation.  
 To further characterize the CaN-dependent dephosphorylation of pNPP, 
okadaic acid was utilized. Okadaic acid (OA) is a potent inhibitor of 
serine/threonine phosphatases 1 and 2A [150], with an IC50 of 10-15 nM for PP1, 
and an IC50 of 100 pM for PP2A. Okadaic acid is also an inhibitor of calcineurin, 
although with a much lower affinity (IC50 =5mM) [150]. This difference in 
sensitivity makes OA a valuable tool in differentiating between the activities of 
these three phosphatases. CaN activity was first assayed in the presence of 
150nM OA, a concentration sufficient to inhibit both PP1 and 2A, but not high 
enough to significantly affect CaN activity. The inclusion of 150nM OA did not 
significantly affect pNPP dephosphorylation in cortical homogenates (Fig. 5A). 
The lack of OA-dependent inhibition was observed under both basal and 
maximal conditions for CaN activation. SE basal activity in the presence of 
150nM OA was 1.03µg pNP/min, only 1.7% lower than the 1.05µg pNP/min that 
was measured in the absence of inhibitor. This difference was not significant (p > 
0.05, n=4, two-tailed paired student’s t-test). SE maximal activity was 2.14µg 
pNP/min in the absence of inhibitor, and 2.00µg pNP/min in the presence of 
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150nM OA, a decrease of 8.3% that was not statistically significant (p > 0.05, 
n=4). Similarly, control basal activity was not significantly modified by low 
concentrations of OA (p > 0.05, n=4). Control basal activity in the absence of OA 
was 0.62µg pNP/min, and in the presence of OA activity was 0.69µg pNP/min. 
Control maximal activity was 1.61µg pNP/min without OA and 1.68µg pNP/min 
with OA, a difference of 4.7% (p > 0.05, n=4). These results indicated that PP1 
and 2A are not responsible for the SE-dependent increase in phosphatase 
activity observed under either basal or maximal conditions.  
Dephosphorylation of pNPP was also carried out at a higher concentration 
(50µM) of OA. This concentration of OA was high enough to block the activity of 
CaN, and was found to significantly decrease pNPP dephosphorylation in both 
control and SE cortical homogenates (Fig. 5B). Maximal activity in control 
homogenates was reduced from 1.29µg pNP/min to 1.20µg pNP/min by the 
addition of inhibitor (a decrease of 8.8 ± 2.8%, p < 0.01, n=6). Similarly, maximal 
activity was reduced in SE homogenates by 10.7 ± 4.2%, from a value of 1.57µg 
pNP/min without inhibitor to a value of 1.40µg pNP/min in the presence of OA (p 
< 0.01, n=6, two-tailed paired student’s t-test). However, basal activity was not 
inhibited by 50µM OA in control homogenates (p>0.05, n=6). Under basal 
reaction conditions, most of the required ions for CaN activation are either not 
present or bound to chelators, and CaN activity in control basal reactions is 
probably very limited. Therefore, it is not surprising that 50µM OA does not inhibit 
the control basal pNPP dephosphorylation. However, it is interesting to note that 
the SE basal activity, unlike the control basal activity, was inhibited by high-
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concentration OA. Basal activity in the SE homogenate was reduced from 1.06µg 
pNP/min to 0.94 µg pNP/min by the addition of 50µM OA, a decrease of 11.2 ± 
4.4% (p < 0.01, n=6). The data suggest that SE results in the production of a 
Ca2+-independent form of CaN that is sensitive to inhibition by high 
concentrations of OA. However, the activity in SE homogenates was not entirely 
reduced to control levels by the addition of 50µM OA. This may be due to the 
solubility or efficacy limits of OA as a CaN inhibitor under these conditions, or it 
may suggest that another, OA-insensitive phosphatase is also contributing to the 
observed SE-dependent increase in phosphatase activity.  
The lack of response to low concentrations of OA, the significant inhibition 
by high concentration OA, and the distinctive reaction of the homogenate to 
orthovanadate, all strongly suggest that CaN is responsible for the observed 
increase in activity. In addition, the response of the SE homogenate to high 
concentration OA under basal conditions suggests that the observed increase in 
basal activity is due to the presence of a calcium independent form of CaN.  
 
The increase in enzyme activity is not due to an increase in protein: 
 A potential explanation for the observed SE-dependent changes in CaN 
activity and kinetics is an increase in the amount of enzyme present in the cell. 
To investigate this possibility, western blot analysis was performed on 
homogenate isolated from the cortex and hippocampus (Figure 6). Cerebellar 
homogenate was not tested since there was no SE-dependent change in CaN 
activity in the cerebellum. Immunoreactivity of the catalytic A subunit was 
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determined using a monoclonal antibody to CaN A (CN-1, Sigma, St. Louis, MO). 
In both the cortex (Figure 6A) and hippocampus (Figure 6B), a single band with 
molecular weight of 61kDa was resolved. This size corresponds with the size of 
the CaN A subunit [8]. Computer assisted densitometric analysis was performed 
on SE and control fractions (see methods and materials). Optical density of the 
immunoreactive band in SE homogenate was found to be 93.62 ± 3.01% of 
control in the cortex and 104.17 ± 14.57% of control in the hippocampus. No 
significant difference in the density of the 61kDa band was found in either brain 
region, indicating equal total amounts of the enzyme in both SE and control 
animals in both regions (p>0.05, n=4, two-tailed unpaired student’s t-test). The 
data suggest that the increase in enzyme activity was not due to increased 
protein synthesis, but due to another mechanism, such as post-translational 
modification of the enzyme, or increased Ca/CaM binding to the enzyme 
following SE. 
 
The increase in calcineurin activity occurs through an NMDA-dependent 
mechanism: 
Calcium influx through the NMDA subtype of glutamate receptor is 
essential for the development of a number of SE-dependent alterations in 
neurochemical and physiological processes [115, 120, 127, 134]. To investigate 
the involvement of NMDA-regulated calcium influx on the SE-dependent increase 
in calcineurin activity, MK-801 was used to block the NMDA receptor-associated 
calcium channel during seizure activity. Pre-injection of MK-801 has been shown 
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to prevent many of the NMDA-receptor dependent consequences of SE, but 
does not prevent or inhibit the pilocarpine-induced seizures in this model [115].  
Cortical (Figure 7A) and hippocampal (Figure 7B) homogenates from MK-
801 treated SE animals were assayed for phosphatase activity via the pNPP 
assay as described. Injection of MK-801 alone (no SE) did not induce a 
significant change in calcineurin activity. However, MK-801 injection did block the 
SE-induced increase in calcineurin activity. In the cortex, basal calcineurin 
activity in MK-801 animals was 0.88µg pNP/min, only slightly higher than the 
control activity of 0.82µg pNP/min. The observed increase was not statistically 
significant (7.2 ± 16.8% increase over control, p > 0.05, n=4, one-way ANOVA 
with Tukey post-hoc analysis). Maximal activity of MK-801 and control animals 
was also not significantly different: 1.38µg pNP/min for control homogenates and 
1.48µg pNP/min for MK-801 homogenates (an increase of 7.1 ± 11.4%, p > 0.05, 
n=4). Cortical calcineurin activity was significantly higher in pilo-SE animals than 
in either control or MK-801 treated animals. SE basal CaN activity was 1.21µg 
pNP/min, an increase of 37.8 ± 11.0% over the MK-801 group (p < 0.05, n=4). 
Maximal activity was 1.86µg pNP/min, 26.0 ± 6.8% higher than that of the MK-
801 homogenates (p < 0.05, n=4). This data suggests that NMDA-dependent 
calcium influx during SE is essential for the observed increase in calcineurin 
activity in the cortex.  
Hippocampal homogenates from MK-801 treated animals had significantly 
lower basal and maximal CaN activity than hippocampal SE homogenates (p < 
0.05, n=4, one-way ANOVA with Tukey post-hoc analysis). However, unlike the 
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cortex, CaN activity was not entirely reduced to control levels by MK-801 pre-
injection. A significant increase in CaN activity was still found in MK-801 
homogenates (Figure 7B). The MK-801 basal value of 1.23µg pNP/min was 
elevated 19.1% above the control value of 1.03µg pNP/min, but still significantly 
lower than the activity in SE homogenates, which was 1.35µg pNP/min, or a 
31.1% increase over control (p < 0.05, n=4).  Likewise, maximal activity was 
elevated above control in the MK-801 group, with a value of 1.67µg pNP/min, a 
24.6% increase over the control value of 1.34µg pNP/min. However, this increase 
was not as large as the increase in activity found in SE homogenates. SE 
maximal activity was 31.3% above control, with a value of 1.76µg pNP/min. This 
suggests that either the MK-801 did not entirely block the NMDA receptor in 
hippocampal neurons, or that the SE-dependent increase in calcineurin activity is 
controlled by additional mechanisms in the hippocampus. Overall, NMDA 
receptor activation was found to play a significant role in the SE-induced increase 
in CaN activity in both brain regions.  
 
DISCUSSION: 
 Understanding the cellular and molecular changes that take place during 
SE is essential to understanding the physiological mechanisms that cause this 
severe seizure activity. This study characterizes the changes in both basal and 
Mn2+-stimulated CaN activity in specific brain regions following SE. The data 
demonstrate a significant increase in CaN activity in cortical and hippocampal 
homogenates. The increase in phosphatase activity in cortical homogenates was 
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found to be OA-sensitive. SE did not significantly affect CaN activity in 
homogenates isolated from the cerebellum. In addition, the SE-induced increase 
in CaN activity was NMDA-receptor activation-dependent. The present study is 
the first definitive investigation of SE-dependent modulation of calcineurin 
activity. The data supports the hypothesis that SE results in an NMDA-dependent 
increase in both basal and maximal calcineurin activity in the rat forebrain, but 
not in the cerebellum.  
There are several possible mechanisms that could account for the 
increase in CaN-mediated dephosphorylation. Calcineurin is a 
calcium/calmodulin-stimulated enzyme [8] and would be stimulated by increased 
intracellular calcium concentrations. SE induces a loss of function of the 
endoplasmic reticulum Mg2+/Ca2+ ATPase [120]. This enzyme sequesters 
calcium ions into the microsomes of the smooth ER, providing a high-affinity 
mechanism for regulating intracellular calcium concentration [151, 152]. After SE, 
ATPase-mediated uptake of calcium into the microsomes is less efficient [120], 
which could potentially result in higher than normal resting calcium 
concentrations inside the cell. In fact, an increase in intracellular free calcium has 
been found during and after SE [118]. The increased intracellular calcium 
associated with SE could be responsible for activating CaN above its normal 
physiological level. However, it is unlikely that increased calcium observed in vivo 
is directly responsible for the increase in CaN activity following SE observed in 
this study. Increasing chelator concentrations did not effect the SE-induced 
increase in CaN dephosphorylation (Data not shown). Additionally, no difference 
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in free calcium between SE and control homogenates was present, as 
determined by calcium-specific electrode measurements as described by 
Parsons et al [130] (93-20 calcium electrode, Orion, Boston, MA). Thus, the 
effects of any alterations in intracellular free calcium would be minimal under the 
conditions used in the present study. 
 Another possible explanation for the observed increase in CaN activity is 
an increase in the amount of enzyme present in the cell. This is unlikely, since it 
would require translation of a significant amount of enzyme in a relatively short 
amount of time (animals actively seized for slightly less than 1 hr). Western 
analysis of SE and control homogenates further eliminated this possibility, as no 
significant increase in total enzyme level was observed in any brain region 
studied.   
 Another possible mechanism is post-translational modification of CaN, 
producing a more active form of the enzyme. One such modification could be 
limited proteolysis by the calcium-stimulated neutral protease, calpain I. Calpain 
may be activated by the increased intracellular calcium concentrations present 
during and after SE. Supporting this hypothesis, calpain is activated in other 
neurotraumatic events that involve glutamate excitotoxicity, such as ischemia 
[153] and traumatic brain injury [154]. Calpain proteolysis could account for the 
increased Vmax, decreased Km, and increased enzyme activity observed post-SE 
in this study. Calpain cleaves the catalytic CaN A subunit, removing the 
calmodulin binding domain and creating a highly active, 43 kDa, calcium-
independent form of the enzyme [12, 14]. Some researchers also surmise that 
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calpain-mediated proteolysis removes the autoinhibitory domain present in the A 
subunit [14], although other studies suggest that this may not be the case [155].  
 Significant proteolysis of CaN was not responsible for the observed 
alteration in enzyme function, since no decrease in total enzyme was observed in 
western analysis of the SE homogenate. Additionally, no degradation products 
reacted with the anti-CaN A antibody. However, it is possible that the total 
amount of enzyme broken down by calpain was too small to detect in the western 
analysis that was used. Calpain-degraded CaN is reported to be 1100% more 
active than normal enzyme, while SE produced only a 20-50% increase in 
activity. The magnitude of this difference suggests that, if the calcium-
independent 43 kDa fragment is present, it constitutes only a small amount (3-
5%) of total enzyme. A difference in protein levels of this magnitude would be 
difficult to detect through western blot analysis. It is also possible that the epitope 
recognized by the antibody was no longer present following proteolysis, 
explaining why no small fragments appeared on the western blot. 
Finally, post-translational modification other than calpain proteolysis may 
be taking place, activating CaN through another, unidentified mechanism. For 
example, calcineurin is phosphorylated at the same location by both protein 
kinase C and CaM kinase II, inhibiting the enzyme through a decrease in 
substrate affinity [35, 37]. Calcineurin and CaM kinase II share a similar 
distribution in the brain [156], and regulation of CaN by CaM kinase II is not 
unlikely. However, long-lasting inhibition of CaM kinase II has been observed 
following SE in multiple models [134, 157, 158]. It is possible that a decrease in 
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the CaM kinase II-mediated phosphorylation of CaN produces a net increase in 
the amount of active calcineurin. While this mechanism would account for the 
observed increase in maximal calcineurin activity, it does not explain the SE-
dependent development of calcium-independent CaN activity.  
 Calcium influx through the NMDA receptor has been implicated in many of 
the physiological changes that take place following SE [115, 134]. For this 
reason, it was of interest to determine if the observed SE-dependent increase in 
CaN activity was also NMDA-dependent. Blocking the NMDA receptor-
associated Ca2+ channel with MK-801 completely prevented the SE-dependent 
increase in CaN activity in the cortex, and significantly reduced the magnitude of 
the increase in the hippocampus. This data suggests that calcium influx through 
the NMDA-receptor associated channel is involved in the SE-induced increase in 
calcineurin activity. 
The increase in CaN activity described in this study was not observed in 
the cerebellum. Although pilocarpine-induced seizure activity generalizes into the 
cerebellum, many SE-induced physiological changes do not develop in this 
region. For example, CaM kinase II activity is altered in the cortex and 
hippocampus following SE, but not in the cerebellum [134]. Similarly, the 
spontaneous recurrent seizures that develop following pilocarpine treatment do 
not generalize into the cerebellum [141]. Considering this, it is not surprising that 
SE-induced increase in calcineurin activity was not noted in the cerebellum. It is 
possible that SE activates different mechanisms in the cerebellum than in the 
forebrain, or that an enzyme or receptor necessary for the SE-dependent 
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activation of CaN is not present in the cerebellum. 
The observed SE-dependent increase in CaN activity has broad 
physiological implications. Neuronal mechanisms which are regulated by CaN 
dephosphorylation under normal conditions could be highly altered as a result of 
elevated enzyme activity. One important CaN-mediated mechanism is 
modulation of the GABAA receptor. GABA receptors are the primary receptor 
responsible for the fast inhibitory response in neuronal tissue [65], and play a 
major role in preventing the neuronal hyperexcitability associated with epilepsy 
and SE [124]. Several recent studies have demonstrated an inhibitory modulation 
of GABAA receptor function by CaN [66-68, 159, 160]. A post-SE elevation in 
CaN activity may result in increased dephosphorylation of GABAA receptors, 
producing a net disinhibition of cellular excitability. This hypothesis is 
strengthened by the fact that recent studies have described a post-SE decrease 
in GABAA activity [161]. Chronic increases in CaN-mediated dephosphorylation, 
could lead to a long-term loss of GABA receptor function, which may play a role 
in epileptogenesis. The results of one kindling study already suggest that 
calcineurin may have an epileptogenic role [122], and disinhibitory mechanisms 
have been found to be epileptogenic in several studies. 
This study is the first to detail an SE-dependent effect on calcineurin 
activity. The results presented above describe an SE- induced increase in CaN 
activity which has far-reaching implications, from possible avenues for SE 
treatment to a potential role in development of epilepsy following SE. While this 
study focused on the total enzyme pool contained in the homogenate, future 
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studies will investigate the effect of SE on CaN activity in specific cellular 
fractions, as well as on purified enzyme. A great deal of further research on this 
topic is possible, offering exciting insight into the mechanisms underlying status 
epilepticus. 
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Figure 1. SE resulted in a significant increase in basal and maximal CaN 
activity.    Basal (white) and maximal (black) calcineurin activity was assayed in 
cortical, hippocampal, and cerebellar homogenates isolated immediately after 1 
hour of SE. A) Cortical homogenates isolated from SE animals displayed a 
significant increase in both basal and maximal CaN activity.  (** p < 0.01, n=6, 
two-tailed unpaired Student’s t-test). B) Basal and maximal CaN activity was also 
elevated in the hippocampal homogenates isolated from SE animals when 
compared to control animals (* p < 0.05, n=9; ** p < 0.01, n=9, two-tailed 
unpaired Student’s t-test). C) No significant differences were observed in either 
basal or maximal calcineurin activity in cerebellar homogenates.(p>0.1, n=7). 
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Figure 2. SE modulates the rate of CaN-mediated dephosphorylation in rat 
cortical homogenates.  
CaN dephosphorylation reactions were performed in cortical homogenates 
isolated from control (white circles) and SE (black circles) animals. Basal (A) and 
maximal (B) CaN reactions were allowed to continue for specific time intervals, 
and the corresponding activities plotted to determine reaction rate. The portion of 
the reaction shown is during the linear (pre-steady state) portion of the reaction 
A) Under basal conditions, the reaction rate (as indicated by linear regression 
analysis of the data with time as the independent variable and µg pNP produced 
as the dependent variable. r2 = 0.992) was 0.257µg/min in control homogenates 
(white circles). CaN-mediated dephosphorylation in SE cortical homogenates 
(black circles) occurred at a rate of 0.355µg/min. This represents an increase of 
36.72 ± 7.6% when compared to the control rate. B) Maximal dephosphorylation 
occurred at a rate of 0.684µg/min in control homogenates, as indicated by linear 
regression analysis (r2 = 0.991). The maximal reaction rate in SE homogenates 
was 0.804µg/min, an increase of 17.55 ± 4.74% over the control rate. Data 
represents an average of three experiments. 
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Figure 3. SE alters CaN substrate affinity in rat cortical homogenates.  
Substrate affinity (Km) and maximal pNPP dephosphorylation (Vmax) for CaN 
were determined under basal and maximal conditions for SE and control 
cortical homogenates. A) SE increased both Km and Vmax for pNPP 
dephosphorylation by CaN under basal conditions.  A substrate concentration 
isotherm was generated under basal dephosphorylation conditions in cortical 
homogenates isolated from control animals (white circles) and SE animals 
(black circles). Both Vmax and substrate affinity were increased in SE 
homogenates when compared to control. Inset: Linweaver-Burk plots of data 
from control and SE homogenates. SE resulted in an increase in maximal 
dephosphorylation (Vmax) under basal conditions. Vmax for SE homogenates 
(black circles) was higher than that of control homogenates (white circles) (p 
< 0.05, n=3, student’s t-test). Km was increased after SE. (p < 0.05, n=3). B) 
SE increased Vmax for pNPP dephosphorylation under conditions for maximal 
CaN activity.  Substrate concentration isotherms under maximal 
dephosphorylation conditions were generated in cortical homogenates 
isolated from control (white circles) and SE (black circles) animals. Maximal 
dephosphorylation was increased in SE homogenates when compared to 
control. However, substrate affinity in SE and control homogenates was not 
significantly different under maximal conditions. Inset: Linweaver-Burk plot of 
substrate isotherms from control and SE homogenates. Vmax was increased in 
SE homogenates (p < 0.05, n=3). Substrate affinity appeared to increase, 
however the change was small and not statistically significant (p > 0.05, n=3). 
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Figure 4.  The SE-induced increase in pNPP dephosphorylation was not 
due to tyrosine phosphatase activity. 
Cortical homogenates were isolated from control and SE rats and subjected to 
basal (white bars) and maximal (black bars) reaction conditions. The reactions 
were performed in the absence (-) or presence (+) or 100µM NaVO4. This level of 
NaVO4 is sufficient to inhibit tyrosine phosphatases and Mn2+-stimulated CaN 
activity. The inclusion of NaVO4 did not significantly affect basal pNPP 
dephosphorylation, but resulted in complete inhibition of Mn2+-stimulated pNPP 
dephosphorylation (*** p < 0.001, n=4, Student’s t-test)  
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Figure 5. The SE-induced increase CaN activity was inhibited by okadaic 
acid in a concentration-dependent manner. 
A) Low concentration OA has no significant effect on pNPP dephosphorylation in 
cortical homogenate. The addition of 150nM okadaic acid did not affect pNPP 
dephosphorylation under either basal or maximal activity in homogenates 
isolated from either SE or control animals (p > 0.05, n=4). This suggests that 
neither PP1 (IC50 for OA: 10-15nM) nor PP2A (IC50: 100pM) is responsible for the 
measured activity.  B) High concentration of OA results in significant inhibition of 
pNPP dephosphorylation. 50µM okadaic acid inhibited maximal activity in both 
control and SE cortical homogenates (** p<0.01, n=6, two-tailed paired student’s 
t-test). Maximal activity was inhibited by 10.65% in SE homogenates, and by 
6.61% in homogenate isolated from control animals. High concentration OA also 
inhibited basal activity by 11.17% in SE homogenates (** p<0.01, n=6, two-tailed 
paired student’s t-test), but did not inhibit pNPP dephosphorylation in control 
homogenates (p>0.05, n=6, two-tailed paired student’s t-test). The data suggests 
that SE results in an OA-sensitive increase in pNPP dephosphorylation, 
measured under both basal and maximal conditions for CaN activity.  
54 
 
 
55 
 
 
 
 
 
 
Figure 6. The post-SE increase in CaN activity was not due to a SE-induced 
increase in CaN protein expression.  
To determine if SE results in increased CaN enzyme levels, homogenates from 
control and SE rats were subjected to western analysis. Cortical (A) and 
hippocampal (B) homogenates were resolved on SDS-PAGE and blotted to 
nitrocellulose (see methods). The resulting blots were reacted a monoclonal 
antibody against the A subunit of CaN. SE did not result in a significant alteration 
of CaN immunoreactivity in any brain region studied. A) Immunoreactivity was 
93.62 ± 3.01% of control enzyme levels in cortical homogenates isolated from SE 
animals. B) CaN immunoreactivity in hippocampal homogenates isolated from 
SE animals was 104.17 ± 14.57% of the control enzyme level.  
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Figure 7. MK-801 pretreatment prevented the SE-dependent increase in 
CaN activity in cortical homogenates. A) Preinjection of animals with MK-801 
(a non-competitive NMDA antagonist) completely prevented the SE-dependent 
increase in CaN activity in cortical homogenates. CaN activity in MK-801 cortical 
homogenates was not significantly different from that of control homogenates for 
both basal (white) and maximal (black) activities (p > 0.05, n=4, one-way ANOVA 
with Tukey post-hoc analysis). SE homogenates had significantly higher activity 
than both MK-801 and control homogenates under both basal and maximal 
conditions (*p < 0.05, n=4). B) MK-801 pre-treatment reduced, but did not 
completely prevent, the SE-dependent increase in CaN activity in hippocampal 
homogenates. MK-801 treated animals had significantly lower CaN activity than 
SE animals under both basal (white) and maximal (black) conditions (p < 0.05, 
n=4). However, both basal and maximal hippocampal CaN activity in MK-801 
animals was significantly higher than that of control animals (p < 0.05).  
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CHAPTER II 
STATUS EPILEPTICUS-INDUCED CHANGES IN THE 
SUBCELLULAR DISTRIBUTION AND ACTIVITY OF 
CALCINEURIN IN RAT FOREBRAIN 
 
INTRODUCTION: 
Status epilepticus (SE) is a severe medical emergency affecting more 
than 100,000 people per year in the United States [100, 103]. Victims of SE are 
at risk for both immediate mortality and long-term neurological pathologies 
associated with the disorder [105, 111, 124]. Previous research has shown many 
of these pathological consequences to be associated with calcium and calcium-
regulated systems [115, 126]. Calcium’s central role in the pathology of SE has 
made characterization of calcium-regulated systems an important area for further 
study in SE. 
One calcium-regulated enzyme of particular interest is the calcium-
stimulated phosphatase, calcineurin (CaN). CaN’s enrichment in forebrain 
neurons and its key role in the modulation of many neuronal processes make it 
an intriguing enzyme for study. For example, CaN regulates gene transcription 
through the NFAT family of molecules [6, 162], modulates the function of both the 
GABA and NMDA receptors [63, 67, 68, 163, 164], affects cytoskeletal 
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architecture through dephosphorylation of microtubules and associated proteins 
[70-72], regulates neurotransmitter release [165], and may be involved in the 
initiation of apoptosis [91, 166]. All of these processes may play a role in the 
pathology of SE, warranting a closer look into any association between CaN and 
SE.  
Several recent studies have, in fact, suggested an association between 
CaN and seizure activity. For instance, Kurz et al. [167] described an SE-
dependent increase in CaN activity in the forebrain, while Moia et al. [122] 
suggested that CaN activity may be essential for the development of seizures in 
a kindling model. While these findings suggest the involvement of CaN in the 
development of seizure activity, more research is needed to elucidate the 
physiological role of this enzyme in SE. For example, the ability to localize SE-
induced changes in enzyme activity and concentration to specific subcellular 
compartments would provide valuable clues to the role of CaN in the pathology of 
SE.  
The present study examined the effects of SE on enzyme activity and the 
sub-cellular distribution of CaN in the cortex and hippocampus. CaN activity was 
assayed in sub-cellular fractions isolated from both of these regions, and CaN 
concentration in each fraction was determined by western analysis. Additionally, 
immunohistochemical studies were conducted on hippocampal tissue from SE 
and control animals. A significant SE-dependent increase in CaN activity was 
observed in synaptosomal and crude nuclear fractions. This increase was 
accompanied by a significant increase in CaN concentration in these fractions as 
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demonstrated by western analysis. In addition, immunohistochemical studies 
revealed an apparent increase in CaN levels in the apical dendrites of CA1 
neurons in the hippocampus following SE.  
 
METHODS AND MATERIALS: 
  
Materials: 
 All materials were reagent grade and were purchased from Sigma 
Chemical Co. (St. Louis, MO) unless otherwise noted. Bio-Rad protein assay 
concentrate, sodium dodecyl sulfate (SDS), 2-mercaptoethanol, blotting grade 
dry milk, and Mini-Protean II SDS-PAGE apparatus and power supplies were 
purchased from Bio-Rad Laboratories (Richmond, CA). ABC reagents were 
obtained from Vector Laboratories (Burlingame, CA). Absolute ethyl alcohol was 
purchased from AAPER Alcohol and Chemical Co. (Shelbyville, KY). Adult male 
Sprague-Dawley rats were obtained from Harlan Laboratories (Indianapolis, IN).  
 
Pilocarpine model of status epilepticus: 
 All animal use procedures were in strict accordance with the Guide for the 
Care and Use of Laboratory Animals described by the National Institutes of 
Health and were approved by the Virginia Commonwealth University Animal Use 
Committee. SE was induced in adult male Sprague-Dawley rats by the method 
described in Mello et al [141]. Rats were handled regularly for approximately one 
week to acclimate them to handling prior to drug administration. Adult rats 
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weighing 175-230g were injected intraperitoneally (i.p.) with 350mg/kg 
pilocarpine HCl, a potent muscarinic agonist. 30 minutes prior to the pilocarpine 
injection, all rats were treated i.p. with 1mg/kg methylscopolamine. 
Methylscopolamine is a peripheral muscarinic antagonist; administering it prior to 
pilocarpine injection minimizes adverse peripheral effects. Control rats received 
all injections, except that pilocarpine was administered at 1/10th its seizure-
inducing dose. Control animals did not exhibit any behavioral seizure activity. All 
drugs were dissolved in 0.9% saline. 
 Behavioral seizures typically began 20 minutes following pilocarpine 
injection. Seizures were rated according to the scale described by Racine [142]. 
Only animals reaching stage 5 seizures were included in this study. Stage 5 was 
classified as the most severe level of seizure activity, characterized by rearing 
and falling. Rats not responding to the initial pilocarpine injection received a 
second injection at on half of the initial dose (175 mg/kg). Rats that still did not 
display stage 5 seizure activity following a second pilocarpine injection were 
excluded from the SE group. 
 
Isolation and homogenization of brain regions: 
Rats were rapidly decapitated after 1 hour of SE. Brains were dissected 
on a petri dish on ice to preserve post-mortem enzyme activity. Cortical, 
hippocampal, and cerebellar brain regions were quickly isolated and immediately 
homogenized with 10 strokes (up and down) at 12,000 rpm, using a motorized 
homogenizer (TRI-R Instruments, Inc. Rockville Center, NY). Brain regions were 
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homogenized into ice-cold homogenization buffer containing 5mM HEPES (pH 
7.0), 7mM EGTA, 5mM EDTA, 1mM dithiothreitol (DTT), 0.3mM PMSF, and 
300mM sucrose. Cortical regions were homogenized into 7ml of buffer, 
hippocampal regions into 3ml of buffer, and cerebellar regions into 5ml. All brain 
homogenates were either separated into aliquots and stored for later use, or 
subjected to the differential centrifugation procedure described below. 
 
Isolation of sub-cellular fractions:  
Sub-cellular fractions were isolated by a differential centrifugation 
procedure as modified from Edelman et al [168]. Brain region homogenate was 
first centrifuged at 5000g for 10 minutes, to produce a crude nuclear pellet (P1) 
and a supernatant (S1). The P1 pellet was resuspended in homogenization 
buffer, separated into aliquots, and stored at -80°C until used. The S1 was 
centrifuged for 30 minutes at 18,000g to produce the crude synaptoplasmic 
membrane/mitochondiral pellet (P2) and a supernatant (S2). The P2 pellet was 
resuspended in ½ the original volume of the homogenate (3.5mL for cortex, 
2.5mL for cerebellum, 1.5mL for hippocampus), then separated into aliquots and 
stored at -80°C until used. The S2 was subjected to another centrifugation, at 
100,000g for 60 minutes. The resulting supernatant (S3) was separated into 
aliquots and stored for later use. The P3 pellet was resuspended in 
homogenization buffer (700µL for cortex, 500µL for cerebellum, 300µL for 
hippocampus), and likewise separated into aliquots and stored at -80°C for later 
use. 
63 
 
pNPP assay of phosphatase activity: 
 Calcineurin activity was assayed using the procedure detailed by Pallen 
and Wang [143] as modified by Kurz et al. [167]. All reaction tubes were 
prepared on ice and contained the following: 25mM MOPS (pH 7.0), 1mM DTT, 
2mM p-nitrophenol phosphate (pNPP). Some basal tubes also contained 2mM 
EGTA and 2mM EDTA. Maximal tubes contained the same reagents as basal 
reactions, with the addition of 2mM MnCl2. Where appropriate, 120µM gossypol, 
50µM okadaic acid (sodium salt), or 100µM sodium orthovanadate was added to 
the reaction mixture. Final reaction volumes were 1ml. Both Mn2+ and 
Ca2+/calmodulin activate calcineurin in this assay; however, Mn2+ activates 
calcineurin more strongly than calcium [21]. Therefore, Mn2+ was used instead of 
calcium in maximal reactions to better visualize the cation-stimulated activity of 
the enzyme. Prior to use, the protein concentration of all homogenates was 
determined using the method of Bradford et al. [144]. Reactions were initiated by 
the addition of 200 µg/ml of homogenate or the appropriate subcellular fraction. 
Reactions were incubated at 37°C for 15 minutes in a shaking water bath. Tubes 
were then removed from the water bath and placed in ice to stop the reaction. 
Absorbance of the reaction mixture was immediately measured at 405nm in a 
spectrophotometer (UV-2101, Shimadzu Scientific Instruments, Inc. Columbia, 
MD). Absorbance units were converted to nmol of pNP produced by comparison 
to a pNP concentration standard absorption curve. 
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CaN immunoblotting procedure: 
 Western analysis was performed essentially as described previously [145]. 
Briefly, homogenates were resolved on SDS-PAGE and transferred to a 
nitrocellulose membrane using the Geni blot system (Idea Scientific, Minneapolis, 
MN). Nitrocellulose was then immersed for one hour in blocking solution 
containing phosphate buffered saline (PBS, pH 7.4), 0.05% (v/v) polyoxyethylene 
sorbitan monolaurate (tween-20), 50 g/L Bio-Rad blotting grade dry milk, and 
horse serum (Vector Laboratories Inc., diluted 50 µl/10ml). The nitrocellulose 
membrane was then incubated with primary antibody in blocking solution for one 
hour. Anti-CaN A antibody (clone CN-A1, mouse monoclonal IgG, Sigma 
Chemical Co.) was diluted 1:10,000 for western analysis. Membranes were then 
washed three times in a wash solution containing PBS, tween-20, and dry milk. 
Nitrocellulose was then reacted with a secondary antibody in blocking solution for 
45 minutes. The membrane was then washed three times and incubated with an 
avidin-biotinylated horseradish peroxidase complex for 30 minutes. Nitrocellulose 
was then washed three times in PBS for 10 minutes per wash. Blots were 
developed with a solution containing 10 ml PBS, 0.025% (v/v) H2O2, and 8 mg 4-
chloro-1-napthol dissolved in 2ml of methanol. Specific immunoreactive bands 
were quantified by computer-assisted densitometry (Inquiry, Loats Associates, 
Westminster, MD).    
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Immunohistochemical analysis: 
 SE was induced in male Sprague-Dawley rats as described above. After 
one hour of SE, rats were anesthetized with halothane and transcardially 
perfused with a solution containing 4% paraformaldehyde and 0.1% 
glutaraldehyde. Brains were then removed and allowed to post-fix in the 
perfusion fixative for 24hr. Brains were then blocked to allow sectioning of the 
dorsal hippocampus, embedded in agar and coronally sectioned into serial 40 µm 
sections on a Leica VT1000S vibratome (Leica Microsystems, Bannockburn, IL). 
Sections were stored in 12 well culture plates until used.  
For immunohistochemical staining, sections were incubated for 30 
minutes in normal serum at 37°C. Sections were then incubated overnight with a 
polyclonal anti-CaN A antibody at a dilution of 1:50,000. Following incubation 
with the primary antibody, sections were then washed 4X with phosphate-
buffered saline (PBS, pH 7.4) for 15 minutes per wash. The tissue was then 
incubated in secondary antibody for 1 hour at 37°C. Sections were washed 3X in 
PBS, then placed in Vectastain ABC reagent for 2 hours. The first hour of 
incubation in ABC was performed at 37°C, the second hour at room temperature. 
Sections were then washed 2X in PBS for 10 minutes per wash, and 1X in Tris-
Base (pH 7.6) It was essential to wash in Tris-Base at this step because the 
staining procedure requires most of the phosphate to be washed out of the tissue 
to work properly. The tissue was then stained with a glucose oxidase-DAB-nickel 
preparation.   
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Statistical analysis: 
 All statistical analysis of data was performed using GraphPad Prism 3.0 
(GraphPad Software, San Diego, CA). Levels of phosphatase activity or 
concentration were compared to control using the Student’s t-test (two-tailed 
distribution, unpaired or paired where appropriate), or using one-way ANOVA 
with Tukey post-test to control for type one errors in multiple comparisons. 
Computer assisted densitometric analysis was performed using Inquiry (Loats 
Associates Inc, Westminster, MD). 
 
RESULTS: 
  
CaN-mediated dephosphorylation of pNPP: 
 Fractions were isolated from the cortex and hippocampus of control and 
SE animals. In both the hippocampal and cortical homogenates, overall post-SE 
CaN activity was significantly increased. In hippocampal homogenates, SE 
resulted in a 21.2 ± 4.7% increase in basal CaN activity, and a 20.8 ± 5.0% 
increase in maximal activity when compared to control animals. Similarly, in 
cortical homogenates isolated from SE animals, basal CaN activity was 49.3 ± 
13.6% of control, and maximal activity was elevated 34.3 ± 13.9% above control 
values. This overall increase in CaN activity in the homogenate is consistent with 
the findings of previous studies [167] and establishes a baseline to which the 
activities of individual fractions may be compared. 
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The effects of several inhibitors were tested to confirm that the observed 
increase in pNPP dephosphorylation was due to an increase in CaN activity and 
not due to contamination from other phosphatases (Figure 8). The results 
obtained are consistent with a previous characterization of the pNPP assay [167]. 
The addition of okadaic acid (a potent inhibitor of PP1 and PP2A) did not effect 
either basal or maximal pNPP dephosphorylation, suggesting PP1 and PP2A are 
not responsible for the observed increase in activity. The effects of sodium 
orthovanadate (NaVO4) on pNPP dephosphorylation were also tested. NaVO4 is 
a potent inhibitor of tyrosine phosphatases; however, it also inhibits the Mn2+ 
stimulated activity of CaN. In this study, sodium orthovanadate did not affect the 
SE-induced increase in basal activity; however, under maximal reaction 
conditions, NaVO4 blocked pNPP dephosphorylation down to basal levels in 
homogenates isolated from both control and SE animals. These results are 
consistent with CaN activity, and suggest that tyrosine phosphatases are not 
involved in the SE-dependent increase in enzyme activity. Finally, gossypol (120 
µM), a specific CaN inhibitor [169], was tested. Co-incubation with gossypol 
blocked the SE-induced increase in both basal and maximal CaN activity  
(p<0.05, n=3), suggesting CaN is responsible for the increase. The data 
demonstrate that the SE-induced increase in pNPP dephosphorylation is due to 
CaN and not due to another phosphatase. 
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Selective modulation of CaN by SE in specific subcellular fractions: 
An SE-dependent increase in CaN activity was observed in the P1 pellet 
from both cortical and hippocampal tissue. The P1, or crude nuclear pellet, 
contains nuclei and other large molecular weight fractions. In hippocampal P1 
isolated from control animals, basal CaN activity was 3.8 ± 0.01 µg pNP/min/mg. 
Following SE, this value increased by 13.1 ± 4.7%, to 4.3 ± 0.2 µg pNP/min/mg 
(p < 0.05, n=3). Under maximal conditions, CaN activity in control hippocampal 
P1 was 6.1 ± 0.1 µg pNP/min/mg. SE induced a 10.6 ± 2.9% increase in the 
maximal CaN activity, to a value of 6.8 ± 0.2 µg pNP/min/mg (p < 0.05, n=3).  
SE also induced a significant increase in basal and maximal enzyme 
activity in cortical P1 fractions (Figure 9). Under basal reaction conditions, CaN 
activity in control P1 was 3.1 ± 0.9 µg pNP/min/mg. Following SE, basal activity 
increased 29.4 ± 11.9 % to 4.1 ± 0.6 µg pNP/min/mg (p < 0.05, n = 9). Maximal 
activity in cortical P1 isolated from control animals was 6.2 ± 0.1 µg pNP/min/mg. 
Following SE, maximal CaN activity increased by 14.88 ± 3.3 % to a value of 7.1 
± 0.2 µg pNP/min/mg (p < 0.001, n = 9). The increase in activity in both the 
hippocampus and cortical P1 was similar to that observed in homogenate. 
In crude synaptoplasmic membrane (P2) fractions isolated from forebrain 
homogenates, SE resulted in a significant increase in both basal and maximal 
CaN activity (Figure 9). Average basal CaN activity measured in control 
hippocampal P2 was 2.7 ± 0.7 µg pNP/min/mg. Following SE, this value was 
elevated to 4.8 ± 0.3 µg pNP/min/mg, an increase of 77.8 ± 25.9% (p < 0.05, n=3, 
Student’s t-test). Control maximal activity in hippocampal P2 was 7.0 ± 0.8 µg 
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pNP/min/mg. After SE, activity increased 56.4 ± 16.3% over control, to a value of 
10.9 ± 0.8 µg pNP/min/mg (p < 0.05, n=3). This increase is more than double the 
overall increase observed in hippocampal homogenate.  
 In cortical P2, a large, SE-dependent increase in CaN activity was 
observed under both basal and maximal reaction conditions (Figure 9). Average 
basal CaN activity in control samples was 2.7 ± 0.4 µg pNP produced/ min/ mg of 
protein. Following SE, this value increased to 5.6 ± 0.7 µg pNP/min/mg, an 
increase of 107.4 ± 29.6% (p < 0.01, n=6).  Maximal activity in cortical P2 
isolated from control animals was 7.4 ± 0.6 µg pNP/min/mg. In SE animals, this 
value was increased by 54.0 ± 10.7%, to a value of 11.4 ± 0.6 µg pNP/min/mg (p 
< 0.01, n=6). This increase was also more than twice the overall increase 
observed in cortical homogenates in this study. 
Unlike the other membrane-rich fractions, cortical P3 did not display any 
significant, SE-dependent change in CaN activity (Figure 9). In cortical P3 
isolated from control animals, basal activity was 1.8 ± 0.2 µg PNP/min/mg. After 
SE, activity in the P3 decreased to 1.7 ± 0.1 µg PNP/min/mg, an increase of 5.5 
± 4.1% which was not statistically significant (p > 0.05, n=3). Maximal activity in 
control cortical P3 was 3.4 ± 0.1 µg PNP/min/mg, while in SE P3 this value was 
3.1 ± 0.1 µg PNP/min/mg. This difference was also not statistically significant (p 
> 0.05, n=3). It was not possible to test hippocampal P3 due to the extremely low 
protein yield present in this fraction. The lack of an SE-dependent increase in 
activity in this fraction indicated that the post-SE increase in activity observed in 
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the P1 and P2 fractions was not due to a nonselective precipitation of CaN during 
SE. 
No significant SE-induced change in CaN activity was observed in the 
cytosolic (S3) fraction isolated from either hippocampus or cortex. However, it is 
interesting to note that under both basal and maximal conditions, CaN activity 
appeared to decrease slightly (Figure 9). This is particularly interesting 
considering that overall CaN activity increased by 35-50% in the cortical 
homogenate. In S3 isolated from control hippocampi, basal CaN activity was 1.3 
± 0.1 µg PNP/min/mg. Following SE, this value decreased by 10.8 ± 18.5% to 1.1 
± 0.2 µg PNP/min/mg (p > 0.05, n=4). Under maximal reaction conditions, CaN 
activity in S3 isolated from control animals was 4.4 ± 0.4 µg PNP/min/mg. In S3 
from SE animals, CaN activity was 3.8 ± 0.1 µg PNP/min/mg, a decrease of 13.6 
± 13.4% from control (p > 0.05, n=4). Similarly, in cortical S3, control CaN activity 
was 2.3 ± 0.2 µg PNP/min/mg under basal conditions. Following SE, this value 
decreased by 8.6 ± 8.8% to a value of 2.1 ± 0.1 µg PNP/min/mg (p > 0.05, n=8). 
Under maximal conditions, control CaN activity was 9.1 ± 0.3 µg PNP/min/mg in 
the cytosol. In cytosolic fractions isolated from SE animals, this value decreased 
14.4 ± 9.8% to 7.8 ± 0.9 µg PNP/min/mg (p > 0.05, n=8).   
 
SE resulted in increased synaptoplasmic CaN in both the hippocampus and 
cortex. 
 The increase in activity observed in the P2 fraction in both the 
hippocampus and cortex was far larger than that observed in any other fraction 
71 
 
or the homogenate. This increase in activity could be accounted for by an 
increase in the amount of enzyme present in this fraction, either through new 
synthesis of CaN or by translocation from other areas of the cell. To examine this 
hypothesis, western analysis of homogenate from all fractions and brain regions 
was performed, using an antibody directed against the catalytic A-subunit of the 
enzyme (CN-1, Sigma, St. Louis, MO). In all fractions, a band with molecular 
weight of approximately 61kDa was resolved. This corresponds with the size of 
the CaN A subunit [8].  In P2 isolated from cortical homogenates, two other 
bands were sometimes observed. Both of these bands were determined to be 
due to non-specific binding of the secondary antibody (anti-mouse IgG), as they 
were also observed when the primary antibody was omitted from the reactions. 
 In the P2 fraction, a large increase in CaN A immunoreactivity was 
observed in both the hippocampus and cortex (Figure 10). Optical density of the 
61kDa band in fractions from SE animals was 194.9 ± 31.04% of control in the 
hippocampus (p < 0.05, n=5), and 207.2 ± 22.3% of control in the cortex (p < 
0.001, n=6).  No significant difference in immunoreactivity was detected in any 
other sub-cellular fraction.  
 
SE results in increased CaN A immunoreactivity in apical dendrites of 
hippocampal CA1 neurons. 
 To further characterize the SE-dependent increase in CaN activity and 
concentration observed in the P2 fraction, immunohistochemical studies were 
performed on paraformaldehyde-fixed coronal sections from SE and control 
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animals. Hippocampal sections from control animals demonstrated diffuse 
staining throughout the pyramidal cell layer, with the exception of the pyramidal 
cell nuclei (Fig. 11A, C). Faint CaN immunoreactivity was observed in the 
surrounding cortex (data not shown). This diffuse staining remained unchanged 
following SE. Therefore, the intensity of cortical staining was used as a 
background value to compare control and SE images. When viewed under 400X 
magnification, individual pyramidal neurons could be visualized (Fig. 11E). The 
cytoplasm of these cells demonstrated very diffuse CaN-reactive staining. The 
darkest staining was seen around the plasma membrane of these neurons. 
Occasional dendritic processes demonstrated CaN immunoreactivity; however, 
many apical dendrites could not be individually visualized in control sections. 
These histological findings were in agreement with previous studies 
demonstrating the presence of CaN in the hippocampal formation, particularly in 
the plasma membrane and in neurites [170, 171]. 
 Hippocampal sections from SE animals demonstrated several qualitative 
changes when compared to control sections (Fig. 11B). Similar to the control 
sections, diffuse CaN-reactive staining was present throughout CA1-3. However, 
this staining was noticeably more intense in the SE sections. Staining was still 
relatively poor in the surrounding cortex in the SE sections. In addition to the 
increased level of staining in the pyramidal neurons, an intensely stained band 
could be seen near the pyramidal cell layer of the hippocampus in SE sections. 
At 400X magnification this intense staining was found to be present around the 
plasma membranes and throughout the apical dendrites of pyramidal neurons 
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(Fig. 11F). Unlike the control sections, CaN immunoreactivity was absent from 
the nuclei of pyramidal neurons from SE animals as well as those from control 
animals. It was not possible to visualize any axonal processes leading from the 
pyramidal cells, nor were any darkly stained processes observed in axonal layers 
of the hippocampus, suggesting that the increased CaN immunoreactivity was 
post- rather than presynaptic. Finally, no interneurons were detected in control or 
SE sections, suggesting an absence of CaN in these neurons which is in 
agreement with previous research [172].  
 
DISCUSSION: 
 Recent research suggests a physiological role for CaN in the pathology of 
seizure disorders [122, 167]. However, much remains to be discovered about the 
effects of SE on CaN and the physiological ramifications of these effects. Since 
CaN regulates many neuronal processes [67, 70, 164-166], understanding how 
SE effects the activity of specific subcellular pools of CaN is warranted. The 
present study demonstrated a significant, SE-dependent increase in CaN activity 
in the synaptosomal (P2) and nuclear (P1) fractions isolated from rat cortex and 
hippocampus. Additionally, a significant, SE-dependent increase in CaN 
concentration was observed in P2 fractions isolated from hippocampal and 
cortical tissue. No significant increase in CaN activity or concentration was 
observed in the cortical P3 fraction, confirming that the observed increase was 
not due to nonspecific precipitation of CaN protein during SE. Can activity in the 
hippocampal P3 was not assessed due to low protein yield in this fraction. 
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Immunohistochemical staining of hippocampal tissue revealed increased CaN 
staining in apical dendrites of the CA1 region. These data suggest that SE 
induces a translocation of CaN into specific subcellular compartments, where it 
may play an important role in the pathophysiology of SE. 
A significant increase in CaN activity was observed in the nuclear (P1) 
pellet fraction. While this is a relatively crude fraction, the observed increase in 
activity may represent translocation of enzyme into the nucleus or cell 
membrane. There are precedents for nuclear translocation of calcineurin. For 
example, CaN is capable of dephosphorylating the NFAT family of molecules. 
Although originally described in the immune system [6], several members of the 
NFAT family have been identified in neuronal tissue [173, 174]. Following 
dephosphorylation by CaN, both the enzyme and NFAT move to the nucleus of 
the cell, where the NFAT molecule regulates gene transcription. Previous studies 
have shown alteration of gene transcription to be an important pathological 
mechanism in SE and epileptogenesis [175-177]. CaN-regulated mechanisms, 
similar to the NFAT mechanism described above, may play an important role in 
this modulation of gene expression. 
A large, significant increase in both CaN activity and enzyme 
concentration was observed in the P2 fraction. The P2 fraction is highly enriched 
in both crude synaptoplasmic membrane and mitochondria [168]. Previous 
studies have not detected significant amounts of CaN in purified mitochondrial 
preparations [171]; however, it is possible that SE induces a translocation of 
enzyme to these organelles. CaN plays an essential role in several apoptotic 
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pathways [91, 166]. Movement of the enzyme to the mitochondria would likely 
facilitate these apoptotic mechanisms, resulting in increased cell death.  
An alternative hypothesis on the apparent increase in enzyme 
concentration observed in both western and immunohistochemical studies is that 
prolonged SE modulates the immunoreactivity of CaN. Pathological changes in 
protein immunoreactivity have been observed before [146]. The changes in 
enzyme immunoreactivity would have to be a primary structural change, since it 
is observed in both western and immunohistochemical analyses. The altered 
immunoreactivity would also explain why a significant increase in CaN 
concentration is observed in the P1 and P2 fractions without a significant loss of 
enzyme in the other subcellular fractions studied. 
On the other hand, the increase in CaN concentration in the P2 fraction 
may represent a true increase of enzyme at the synaptoplasmic membrane. 
Immunohistochemical data demonstrated a significant increase in CaN staining 
in the pyramidal cell layers, particularly the CA1 region, of hippocampus isolated 
from SE animals. The observation that the increased staining is confined to 
hippocampal pyramidal neurons suggests that SE may induce a unique 
mechanism in these cells that is not present in other hippocampal neurons. The 
histochemical data also suggest that the increase in CaN concentration is 
occurring primarily post-synaptically, in the dendrites of affected cells. This 
increase in enzyme concentration places approximately double the control 
amount of enzyme in the post-synaptic region of neurons, where it may modulate 
neurotransmitter receptors. 
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The GABAA receptor is a particularly important CaN-regulated system in 
the study of SE. GABA receptors are the primary receptor responsible for the fast 
inhibitory response in neuronal tissue [65], and play a major role in preventing 
the neuronal hyperexcitability associated with epilepsy and SE [124]. Several 
recent studies have demonstrated an inhibitory modulation of GABAA receptor 
function by CaN [66-68, 159, 160]. This modulation of GABAA receptor function 
may occur through direct dephosphorylation of receptor subunits. GABAA 
receptors have a critical phosphorylation level required for optimal function. A 
post-SE elevation in CaN concentration in the dendrites could result in highly 
increased dephosphorylation of GABAA receptors, producing a net disinhibition of 
cellular excitability. An increase in CaN activity during and immediately after SE, 
such as the one described in this study, could lead to short-term loss of GABAA 
receptor function. This acute loss of inhibitory tone could lead to increased 
seizure propagation, failure of seizure termination, or resistance to antiepileptic 
drug treatment. 
Additionally, high levels of CaN in the synaptic region of neurons may 
have several other pathological effects. CaN indirectly modulates the activities of 
the serine/ threonine phosphatases PP1 and PP2A through dephosphorylation of 
their respective inhibitors [178-180]. Thus, an increase in CaN activity could 
result in an accompanying increase in the activity of PP1 and 2A in neurons, with 
numerous downstream effects. CaN also is capable of dephosphorylating 
microtubules [70, 181], altering dendritic stability [79] and affecting the outgrowth 
of developing neurites [78].  
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The observed SE-dependent change in CaN concentration and activity 
could result from either increased synthesis of CaN or translocation of the 
enzyme from other cellular compartments. Several previous studies have 
observed that there is no significant, post-SE increase in the concentration of 
CaN in whole cell homogenate [167, 182], nor has any post-seizure increase in 
CaN mRNA been detected [182]. The lack of a SE-dependent net increase in 
CaN protein concentration or mRNA expression strongly suggests that SE does 
not induce synthesis of the enzyme. Indeed, it seems unlikely that animals 
undergoing the high physiological stress of SE, and studied at an acute post-SE 
time point, would have the necessary time and capacity to synthesize the amount 
of CaN represented by the increase. 
 Translocation of the enzyme may account for the increased levels of CaN 
detected in the P2 fraction. Movement of CaN to the synaptosomal fraction from 
other cellular compartments would suggest that a concurrent decrease in CaN 
concentration should be detected in other sub-cellular fractions. However, no 
significant decrease in CaN concentration was detected in any of the fractions 
isolated in this study, although the slight decrease in CaN activity observed in the 
cortical cytosol may suggest some loss of enzyme. This discrepancy may be due 
to the relatively small volume of the P2 fraction when compared to the cytosol; 
the effect of the translocation to the synaptosomes may simply be diluted by the 
large volume of the cytosolic compartment.  
This study is the first to demonstrate a post-SE increase in CaN 
concentration and activity in specific subcellular compartments. The increase in 
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CaN activity in the nuclear-enriched P1 fraction suggests that CaN may alter 
gene expression. Alterations in gene expression may be responsible for many of 
the long-term effects of SE, such as the post-SE development of spontaneous 
seizure activity (epileptogenesis). On the other hand, the large increase in CaN 
activity and concentration in the synaptosomal P2 fraction suggests a CaN-
modulated alteration in neurotransmitter receptor function. This mechanism could 
be responsible for many of the acute effects of SE, as well as playing a role in 
the resistance to anti-epileptic drugs seen in some instances of SE. Further 
research into these topics may help to clarify the pathological mechanisms of SE, 
and may help to develop more effective anti-epileptic drugs, ultimately leading to 
more effective treatment of this life-threatening and debilitating condition. 
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Figure 8. Prolonged SE resulted in increased CaN activity in cortical 
homogenates.  
SE induced a significant increase in both basal and maximal pNPP 
dephosphorylation. (A) Basal (white) and maximal (black) CaN activity was 
determined in cortical homogenates isolated from both control and SE animals. 
SE resulted in an approximately 50% increase in basal activity and a 34% 
increase in maximal pNPP deposphorylation when compared to homogenate 
protein isolated from control animals. (B) The prolonged SE-induced increase in 
pNPP dephosphorylation was due to CaN activity. Basal (white) and maximal 
CaN reactions were performed in the presence of okadaic acid (OA; 50 µM), 
sodium orthovanadate (NaVO4; 100 µM) and the CaN-selective inhibitor, 
gossypol (Goss.; 120 µM). OA did not affect either basal or maximal pNPP 
dephosphorylation, suggesting that PP1 and PP2A did not significantly contribute 
to the observed dephosphorylation of pNPP. As expected, the tyrosine and 
activated CaN inhibitor NaVO4 blocked maximal pNPP dephosphorylation. 
However, NaVO4 did not affect the SE-induced increase in basal 
dephosphorylation of pNPP. In addition, the CaN-selective inhibitor, gossypol, 
blocked both basal and maximal increased pNPP dephosphorylation. *P < 0.05 
different from no drug homogenate; **P < 0.01 different from no drug 
homogenate; ***P < 0.001, paired Student's t test, n = 3 each group. 
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Figure 9. The SE-induced increase in CaN activity was observed in specific 
subcellular fractions.  
SE-induced a significant increase in hippocampal CaN activity. Basal (A) 
and maximal (B) CaN activity was determined in specific subcellular fractions 
isolated from hippocampal homogenates. Significant increases in CaN activity 
were observed in the nuclear-enriched P1 fraction, as well as the mitochondrial 
and SPM-enriched P2 fractions. No significant change in CaN activity was 
observed in the cytosolic fraction (S3). Additionally, no change was observed in 
the endoplasmic reticulum-enriched P3 fraction isolated from cortical tissue. The 
lack of increase in the P3 fraction suggests that the increased CaN activity in the 
nuclear and SPM fractions was not due to nonspecific precipitation of the 
enzyme subunits. CaN activity was not assessed in hippocampal P3 due to low 
protein yield in this fraction. SE also resulted in increased CaN activity in specific 
subcellular fractions isolated from cortical homogenates. Basal (C) and maximal 
(D) CaN activity was determined in specific subcellular fractions isolated from 
cortical homogenate. SE resulted in a significant increase in nuclear and 
synaptoplasmic membrane fractions but not in endoplasmic reticulum or cytosolic 
fractions when compared to control fractions. No changes were observed in any 
fraction isolated from the cerebellum (data not shown). *P < 0.05 different from 
control, Student's t t test. **P < 0.01 different from control, Student's t test. See 
text for specific n values. 
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Figure 10. SE resulted in a significant increase in CaN protein levels in the 
SPM-enriched P2 fraction. (A) SPM-enriched hippocampal protein isolated from 
control (C) and SE (SE) rats was subjected to Western analysis and tested with a 
specific antibody directed against the A subunit of CaN. There was a selective 
increase in immunoreactivity toward CaN observed in the SPM-enriched fraction. 
(B) SE resulted in an almost 2-fold increase in CaN immunoreactivity in the SPM-
enriched P2 subfraction. Immunoreactivity was quantified by computer-assisted 
densitometry (see Materials and methods). SE resulted in a significant, 95% 
increase in CaN immunoreactivity. *P < 0.05, n = 5, Student's t test. (C) SPM-
enriched cortical protein isolated from control (C) and SE (SE) rats was subjected 
to Western analysis and tested with a specific antibody directed against the A 
subunit of CaN. There was a selective increase in immunoreactivity toward CaN 
observed in the SPM-enriched fraction. (D) SE resulted in a significant, 107% 
increase in CaN immunoreactivity (n = 6) in the SPM-enriched P2 subfraction. *P 
< 0.05, Student's t test. ***P < 0.001, Student's t test. 
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Figure 11. SE resulted in increased immunoreactivity of CaN in the 
dendritic processes of hippocampal CA1 neurons. Animals were subjected to 
prolonged SE or sham protocols, perfused, and studied for CaN immunoreactivity 
(see Materials and methods). (A) low magnification (40× original magnification) of 
dorsal hippocampus from control animal. Hippocampi from control animals 
displayed a nondescript, evenly distributed CaN immunoreactivity. (B) Low 
magnification of dorsal hippocampi isolated from an animal subjected to 
prolonged SE. Overall, an increase in immunoreactivity is observed in the 
hippocampal pyramidal region (both A and B are balanced for CaN 
immunoreactivity observed in nearby entorhinal cortex). (C) 100x original 
magnifaction and (E) 400x magnification, of CA1 pyramidal neurons in A. The 
CaN immunoreactivity appeared evenly distributed with the only substantial 
staining being cytosolic. (D) and (F) Higher magnification of CA1 pyramidal 
neurons isolated from animals subjected to prolonged SE displayed increased 
immunoreactivity, especially in the apical dendritic areas. Together with the data 
in Fig 2.3 the data suggest that SE induced a translocation of CaN into 
postsynaptic processes in CA1 pyramidal neurons. 
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CHAPTER III 
A SIGNIFICANT INCREASE IN BOTH BASAL AND MAXIMAL 
CALCINEURIN ACTIVITY FOLLOWING FLUID PERCUSSION 
INJURY IN THE RAT 
 
INTRODUCTION: 
 Traumatic brain injury is one of the major causes of death and disability in 
the United States today [183]. The initial traumatic insult to neuronal tissue can 
lead to significant pathology; however, much of the pathology associated with 
TBI also involves secondary damage to the tissue surrounding the primary injury 
site [183, 184]. Multiple cellular signals and mechanisms trigger significant 
physiological changes in neuronal tissue in the hours and days after TBI. These 
events occur in tissue not directly damaged by the primary insult, and result in 
such diverse effects as the formation of reactive astrocytes, alterations in 
neuronal excitability and receptor function, and induction of apoptosis [184]. It is 
this secondary phase of TBI that offers the most promise for treatment in the 
clinical setting; presumably a window exists following the initial injury during 
which much of this secondary damage could be prevented by pharmacological 
agents. Prevention of this later and more widespread stage of injury would 
drastically reduce the long-term consequences of severe TBI. Unfortunately, 
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clinical and laboratory testing of many neuroprotective agents up to this point has 
proven disappointing [90]. Clearly, more research into the cellular mechanisms 
occurring following TBI is needed to further our understanding of secondary 
neuronal damage and death. 
 Calcium and calcium-regulated systems play a central role in the spread 
of neuronal damage after TBI [132]. Therefore, calcium-modulated systems are 
an intriguing area for study when attempting to understand the cellular changes 
taking place after brain injury. One calcium-modulated enzyme that may prove 
important in studies of neuronal injury is the neuronally-enriched phosphatase, 
calcineurin. 
 Calcineurin is a calcium/calmodulin-stimulated serine/ threonine 
phosphatase that is highly enriched in neuronal tissue [137]. As the only 
identified calcium-regulated phosphatase, calcineurin has an important 
physiological role. CaN regulates neuronal excitability through modulation of both 
the GABA and NMDA receptors [64, 67, 68], plays a key role in the development 
of learning and memory [138], and is an important modulator of neuronal 
apoptosis [140, 185]. CaN also regulates the synthesis of nitric oxide, a free 
radical potentially important in TBI [186], and an isoform of CaN may modulate 
the formation of reactive astrocytes [187, 188]. In spite of the relevance of CaN to 
many of the pathological consequences of TBI, little research has been done 
detailing the effects of brain injury on calcineurin activity. 
 The present study investigates the effect of moderate central fluid 
percussion injury on CaN activity in rat brain homogenate from the cortex, 
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hippocampus and cerebellum. Both basal and maximal (cation-stimulated) CaN 
activity were assayed in all three brain regions. A TBI-dependent increase in CaN 
activity was observed in both the cortex and hippocampus, and this increase in 
CaN activity was found to persist two to three weeks post-injury. 
 
MATERIALS: 
 All materials were reagent grade and were purchased from Sigma 
Chemical Co. (St. Louis, MO) unless otherwise noted. Bio-Rad protein assay 
concentrate, sodium dodecyl sulfate (SDS), 2-mercaptoethanol, blotting grade 
dry milk, and Mini-Protean II SDS-PAGE apparatus and power supplies were 
purchased from Bio-Rad Laboratories (Richmond, CA). ABC reagents were 
obtained from Vector Laboratories (Burlingame, CA). Adult male Sprague-
Dawley rats were obtained from Harlan Laboratories (Indianapolis, IN). 
 
METHODS: 
 
Surgical preparation and fluid percussion injury: 
All animal use procedures were in strict accordance with the Guide for the 
Care and Use of Laboratory Animals described by the National Institutes of 
Health and were approved by the Virginia Commonwealth University Animal Use 
Committee. Adult male Sprague-Dawley rats weighing between 300 and 350g 
were surgically prepared under sodium pentobarbital anesthesia (54 mg/kg 
intraperitoneally). Animals were placed in a stereotactic frame and the scalp 
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sagitally incised. A 4.8 mm hole was then trephined into the skull over the sagittal 
suture midway between bregma and lambda. A nickel-plated screw was placed 
1mm rostral to bregma, and a second screw was inserted 1mm caudal to 
lambda. A modified female Luer-Loc syringe hub (2.6 mm inside diameter) was 
placed over the exposed dura and bonded in place with a cyanoacrylate 
adhesive. Dental acrylic was then poured around the syringe hub and screws. 
The scalp was then sutured, bacitracin was applied to the wound, and the animal 
was returned to its home cage. 
 Twenty-four hours following the surgical procedure, the rats were again 
anesthetized (4% isoflurane in a carrier gas mixture of 70% N2O and 30% O2). 
Rats in the sham-injury (control) group were anesthetized and connected to the 
injury device, but the pendulum was not released. Rats in the injured group were 
anesthetized and subjected to a moderate (2.1 ± 0.1 atm) level of fluid 
percussion injury. The Luer-Loc fitting, screws, and dental cement were then 
removed from the skull. Following recovery, rats were returned to their home 
cages and allowed to survive for 24 hours, one week, two weeks, three weeks or 
four weeks prior to being sacrificed. 
 
Fluid percussion injury device: 
 The fluid percussion injury device used in these experiments is identical to 
that described by Dixon et al. [189]. Briefly, the device consisted of a Plexiglas 
cylinder reservoir 60cm long and 4.5cm in diameter. At one end of the cylinder 
was a rubber-covered Plexiglas piston mounted on O-rings. The opposite end of 
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the cylinder had a metal housing 2cm long, containing a transducer. A 5mm tube 
with a 2mm inner diameter was fitted at the end of the metal housing. The tube 
terminated with a male Luer-Loc fitting. This fitting was connected to a female 
Luer-Loc fitting that had been chronically implanted over the exposed dura of the 
rat. The entire system was filled with isotonic saline. The injury was produced by 
a metal pendulum that struck the piston of the injury device. The injury device 
injected a small volume of saline into the closed cranial cavity and produced brief 
displacement of brain tissue. The magnitude of injury was controlled by varying 
the height from which the pendulum was released. The resulting pressure pulse 
was measured externally by a pressure transducer (model EPN-0300A*-100A, 
Entran Devices, Fairfield, NJ) and recorded on a storage oscilloscope (model 
5111, Tektronix, Beaverton, OR). 
 
Isolation and homogenization of brain regions: 
Rats were anesthetized and decapitated 24 hours, one week, two weeks, 
three weeks, and four weeks after injury. Brains were dissected on a petri dish on 
ice to reduce post-mortem alteration of enzyme activity. Cortical, hippocampal, 
and cerebellar brain regions were quickly isolated and immediately homogenized 
with 10 strokes (up and down) at 12,000 rpm, using a motorized homogenizer 
(TRI-R Instruments, Inc. Rockville Center, NY). Brain regions were homogenized 
into ice-cold homogenization buffer containing 5mM HEPES (pH 7.0), 7mM 
EGTA, 5mM EDTA, 1mM dithiothreitol (DTT), 0.3mM PMSF, and 300mM 
sucrose. Cortical regions were homogenized into 7ml of buffer, hippocampal 
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regions into 3ml of buffer, and cerebellar regions into 5ml. All brain homogenates 
were normalized for protein, separated into aliquots and stored at -80°C until 
used. 
 
PNPP assay of calcineurin activity: 
 CaN activity was quantified using the procedure described in detail by 
Kurz et al. [167]. Briefly, the reactions were performed as follows. All reaction 
tubes were prepared on ice and contained the following: 25mM MOPS (pH 7.0), 
1mM DTT, 2mM p-nitrophenol phosphate (pNPP). Maximal tubes contained the 
same reagents as basal reactions, with the addition of 2mM MnCl2. Final reaction 
volumes were 1ml. Prior to use, the protein concentration of all homogenates 
was determined using the method of Bradford [144]. Reactions were initiated by 
the addition of 200 µg/ml brain region homogenate. Reactions were incubated at 
37°C for 15 minutes in a shaking water bath. Tubes were then removed from the 
water bath and placed in ice to stop the reaction. Absorbance of the reaction 
mixture was immediately measured at 405nm in a spectrophotometer. 
Absorbance units were converted to nmol of pNP produced by comparison to a 
pNP concentration standard absorption curve. 
 
RII phosphopeptide assay: 
Each fraction was subjected to 1% triton X-100 for 1h at 4° C. Samples 
were then spun at 100,000 g in a tabletop centrifuge. The resulting supernatant 
will be passed through a centrifugal filter device with a 10,000 MW cutoff 
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(MicroCon filters, Amicon). These steps are necessary to remove endogenous 
phosphate from the assay, otherwise background phosphate would overwhelm 
the detection protocol. The final, phosphate-free solution was then balanced for 
protein as above. Reaction tubes contained the following: 50 mM Tris-HCl, 6 mM 
MgCl2, 0.5 mM CaCl2, 15 µM RII phosphopeptide and 5 µg of protein. Reaction 
tubes were incubated for 15 min at 37°C in a shaking water bath. Reactions were 
terminated by the addition of 2X the reaction volume of a malachite green-based 
agent (Calbiochem). Reactions were read at 620 nm in a UV-Vis 
spectrophotometer (Cary 50). Increased absorbance in this system indicates 
increased phosphate release from the CaN substrate. Absorbances were 
compared to a phosphate standard curve. 
 
pNPP substrate kinetics: 
Basal reaction tubes were prepared containing 25mM MOPS, 1mM DTT, 
2mM EGTA, 2mM EDTA, and 150nM okadaic acid to minimize the influence of 
other phosphatases on the results of the assay [167].  Maximal reaction tubes 
contained 25mM MOPS, 1mM DTT, 2mM MnCl2, and 150nM okadaic acid. All 
reaction tubes were prepared on ice. pNPP was added to the tubes for final 
concentrations of 0, 0.1, 0.2, 0.5, 1, 2, 4, 8, 16 and 24mM. CaN reactions were 
initiated by the addition of homogenate and assayed as described above. Values 
for Km and Vmax were obtained via a non-linear regression analysis of the 
substrate isotherm. 
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Western blot analysis: 
 Western analysis was performed essentially as described previously [167]. 
Briefly, homogenates were resolved on SDS-PAGE and transferred to a 
nitrocellulose membrane using the Geni blot system (Idea Scientific, Minneapolis, 
MN). Nitrocellulose was then immersed for one hour in blocking solution 
containing phosphate buffered saline (PBS, pH 7.4), 0.05% (v/v) polyoxyethylene 
sorbitan monolaurate (tween-20), 50 g/L Bio-Rad blotting grade dry milk, and the 
appropriate normal serum (Vector Laboratories Inc., diluted 50 µl/10ml). The 
nitrocellulose membrane was then incubated with primary antibody in blocking 
solution for one hour. Anti-CaN A antibody (clone CN-A1, mouse monoclonal 
IgG, Sigma Chemical Co.) was diluted 1:10,000 for western analysis, and anti β-
tubulin antibody was diluted 1:1,000. Membranes were then washed three times 
in a wash solution containing PBS, tween-20, and dry milk. Nitrocellulose was 
then reacted with a secondary antibody in blocking solution for 45 minutes. The 
membrane was then washed three times and incubated with an avidin-biotin 
horseradish peroxidase complex for 30 minutes. Nitrocellulose was then washed 
three times in PBS for 10 minutes per wash. Blots were developed with a solution 
containing 10 ml PBS, 0.025% (v/v) H2O2, and 8 mg 4-chloro-1-napthol dissolved 
in 2ml of methanol. Specific immunoreactive bands were quantified by computer-
assisted densitometry (Inquiry, Loats Associates, Westminster, MD). 
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Statistical analysis: 
 All statistical analysis of data was performed using GraphPad Prism 3.0 
(GraphPad Software, San Diego, CA), or Sigma Stat 2.03 (SPSS Inc, Richmond, 
CA). Levels of phosphatase activity were compared to control using the Student's 
t-test (two-tailed distribution, unpaired) or one-way ANOVA with Tukey post 
analysis to control for type 1 errors in multiple comparisons. Values for Vmax and 
Km were determined by a non-linear regression curve for single-site substrate 
binding, included with the Prism software. Computer assisted densitometric 
analysis was performed using Inquiry (Loats Associates Inc, Westminster, MD). 
 
RESULTS: 
 
Central fluid percussion injury results in an increase in calcineurin activity 
in specific brain regions: 
 CaN activity was quantified in homogenates from the cortex, hippocampus 
and cerebellum under both basal and maximal reaction conditions. In both the 
cortex and hippocampus CaN activity was significantly elevated after TBI. In 
hippocampal homogenates, TBI induced a significant increase in phosphatase 
activity above control levels under both basal and maximal conditions (Figure 
12A). Average basal CaN activity measured in sham hippocampal homogenates 
was 3.63 µg pNP produced/min/mg of protein. Following TBI, this value was 
elevated to 5.01 µg pNP/min/mg, an increase of 38.2% (p <0.001, n=10, 
Student’s t-test). Control maximal activity in hippocampal homogenates was 7.36 
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µg pNP/min/mg. After injury, activity increased 28.6% over control, to a value of 
9.47 µg pNP/min/mg (p < 0.05, n=10). 
 TBI induced a significant increase in both basal and maximal CaN activity 
in cortical homogenates. However, the increase in CaN activity was substantially 
smaller than that observed in hippocampal homogentates (Figure 12B). Average 
basal CaN activity in control samples was 3.49 µg pNP/min/mg. Following TBI, 
this value increased to 4.11 µg pNP/min/mg, and increase of 17.8% (p<0.05, 
n=6). Maximal activity in cortical homogenates isolated from sham animals was 
6.99 µg pNP/min/mg. In injured animals, this value was increased by 14.6%, to a 
value of 8.01 µg pNP/min/mg (p < 0.05, n=6). The increase in both the cortical 
and hippocampal homogenates was present despite the addition of ion chelators 
to the reaction mix (see methods). 
 
Changes in pNPP dephosphorylation were caused by CaN: 
 Previous studies [167] have demonstrated a high degree of CaN-
specificity in the pNPP assay. For the present study, these results were futher 
confirmed by the use of gossypol, a specific CaN inhibitor (Figure 13). Under 
basal reaction conditions, the addition of gossypol decreased pNPP 
dephosphorylation in cortical homogenates isolated from control animals from 
3.49 µg pNP produced/min/mg of protein to 1.38 µg pNP produced/min/mg, a 
decrease of 60.4%. Likewise, in cortical homogenates isolated from injured 
animals, pNPP dephosphorylation was reduced by 65.9% in the presence of 
gossypol, from 4.11 µg pNP produced/min/mg to 1.40 µg pNP produced/min/mg. 
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Under maximal reaction conditions, the addition of gossypol resulted in a 74.2% 
decrease in pNPP dephosphorylation in control homogenates, from 7.36 µg pNP 
produced/min/mg to 1.89 µg pNP produced/min/mg. pNPP dephosporylation was 
similarly decreased in cortical homogenates isolated from injured animals, from 
9.47 µg pNP produced/min/mg to 1.94 µg pNP produced/min/mg in the presence 
of gossypol, a decrease of 79.5%. In the presence of gossypol, there was no 
significant difference between control and injured values for pNPP 
dephosporylation (p <0.01, n = 10) suggesting that any TBI-dependent 
alterations in pNPP dephosphorylation were due to CaN. 
 
 
The TBI-dependent increase in CaN activity persists several weeks post-
injury:  
 CaN activity was assayed in both the cortex and hippocampus to 
determine the duration of the TBI-dependent increase in enzyme activity. In 
addition to the acute time-point discussed above, both basal and maximal CaN 
activity were measured at one week, two weeks, three weeks, and four weeks 
post-injury. The post-injury increase in CaN activity persisted two to three weeks 
after the TBI event; however, the magnitude of the increase in activity decreased 
with time in both hippocampal and cortical homogenates. 
 In cortical homogenates isolated from injured animals, basal CaN activity 
was 124% of control activity at the one week time point (p <0.01, n=3). Two 
weeks post-injury, basal CaN activity was 121% of control basal activity (p < 
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0.01, n=6), and three weeks post-injury, basal CaN activity was 108.6% of control 
values (p < 0.05, n=3). At the four week post-TBI time point, basal CaN activity in 
homogenates isolated from TBI animals was 97.6% of control basal activity, a 
difference that was not significant (Figure 14A).  
Similarly, at the one week time point, maximal CaN activity in cortical 
homogenates from injured animals was increased to 120.4% of control activity (p 
< 0.01, n=3). Two weeks post-injury, CaN activity was increased to 115.6% of 
control in cortical homogenates isolated from injured animals (p < 0.05, n=6). No 
significant increase in maximal CaN activity was observed at either the three or 
four week time point (Figure 14B).  
The time-course of increased CaN activity in hippocampal homogenates 
demonstrated a pattern similar to that of cortical homogenates. Basal activity in 
homogenates isolated from injured animals was 132.3% of control one week 
post-injury (p < 0.01, n=3). At two weeks post-injury, basal CaN activity was 
128.4% of control activity (p < 0.01, n= 6), and at three weeks post-injury, basal 
CaN activity was 114.4% of control activity in hippocampal homogenates (p < 
0.05, n=3). At four weeks post-injury, there was no longer a statistically 
significant TBI-dependent increase in basal CaN activity (Figure 14C).  
Maximal CaN activity remained elevated for two weeks post-injury in 
hippocampal homogenates. One week post-injury, maximal CaN activity was 
126.2% of control activity in hippocampal homogenates isolated from injured 
animals (p < 0.01, n = 3). Two weeks post-injury, maximal CaN activity was 
124.1% of control activity (p < 0.01, n=6). By three weeks post-injury, maximal 
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CaN activity had receeded to 104% of control activity, a difference which was not 
statistically significant (p > 0.05, n=3). At four weeks post injury, maximal CaN 
activity in hippocampal homogenates isolated from injured animals was 
indistinguishable from that of control animals (Figure 14D). 
 
TBI induces an alteration in CaN enzyme kinetics in both the cortex and 
hippocampus: 
 Other models of cerebral trauma have been shown to alter apparent 
substrate affinity of CaN [167]. Therefore, to further characterize the effect of TBI 
on CaN activity, substrate affinity (Km) and maximal dephosphorylation rate 
(Vmax) were examined (see Materials and Methods). Substrate concentration 
isotherms of the pNPP dephosphorylation reaction were examined in both 
cortical and hippocampal homogenates, and under both basal and maximal 
reaction conditions. In hippocampal homogenates, the maximal rate of pNPP 
dephosphorylation was increased approximately 22% under basal reaction 
conditions (Figure 15A). In homogenates from control animals, Vmax was 4.17 µg 
pNP/min/mg. In TBI homogenates, this value was elevated to 5.09 µg 
pNP/min/mg (p < 0.001, n=3). The apparent Km was not significantly affected by 
TBI under basal conditions in the hippocampus. In control homogenates, the 
apparent Km was 0.94 mM. Following TBI, the substrate affinity increased 
(decreased Km) by 5.3% to 0.89 mM. However, the TBI-induced increase in 
substrate affinity was not statistically significant (p>0.05, n=3). 
100 
 
 Under maximal CaN reaction conditions in hippocampal homogenates, the 
apparent Vmax was significantly increased, while substrate affinity was not 
significantly altered by TBI (Figure 15B). In hippocampal homogenates isolated 
from control animals, Vmax was 8.64 µg pNP/min/mg. Following TBI, this value 
increased by 14.4% to 9.88 µg pNP/min/mg (p<0.001, n=3). Substrate affinity 
was not altered under maximal dephosphorylation conditions in the 
hippocampus. In homogenates from both control and injured animals, the 
apparent Km was approximately 0.20 mM (p>0.05, n=3). 
 Under both basal and maximal conditions in the cortex, Vmax, but not Km, 
was significantly increased following brain injury (Figure 16A). Under basal 
conditions, the apparent Vmax in homogenates isolated from control animals was 
6.88 µg pNP/min/mg. In animals subjected to TBI, this value increased 11.5% to 
7.67 µg pNP/min/mg (p<0.01, n=3). In control homogenates, the Km for basal 
reaction conditions was 0.95 mM pNPP. Following TBI, this value decreased 
slightly to 0.90 mM pNPP, a decrease of 5.3% that was not statistically 
significant. (p>0.05, n=3). Under maximal conditions in the cortex (Figure 16B), 
the apparent Vmax was 10.82 µg pNP/min/mg. After injury, this value was 
significantly increased by 9.8% to 11.88 µg pNP/min/mg (p<0.01, n=3). Km was 
not significantly altered under maximal reaction conditions in cortical 
homogenates. The control value for Km was 0.68 mM, following TBI, this value 
decreased by 7.3% to 0.63 mM. This difference was not statistically significant 
(p>0.05, n=3). 
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TBI did not affect CaN activity in the cerebellum: 
 While significant increases in CaN activity were found in both the cortex 
and hippocampus following TBI, no increase was found in cerebellar 
homogenates. In fact, values for CaN activity appeared to decrease slightly 
(Figure 17). Under basal reaction conditions, the average control CaN activity in 
cerebellar homogenates was 3.84 µg pNP/min/mg. Following TBI, basal activity 
was 3.51 µg pNP/min/mg, a decrease of 8.6% that was not statistically significant 
(p>0.05, n=6). Maximal activity in sham cerebellar homogenates was 9.15 µg 
pNP/min/mg. Following TBI, this value decreased by 4.1%, to 8.78 µg 
pNP/min/mg (p>0.05, n=6). Although the decrease in neither basal nor maximal 
activity was statistically significant, the response of the cerebellum was 
remarkable due to the obvious difference from the significant increases in activity 
found in the other brain regions. To determine if significant post-TBI neuronal cell 
loss in the cerebellum contributed to the lack of increase and lower activities 
observed in this study, homogenates were assayed for the presence of a neuron-
specific marker. Western analysis of cerebellar homogenates from control and 
TBI animals was performed using an antibody directed against β-tubulin (Clone 
TUJ1, Covance, Richmond, CA). This method has been shown to be an accurate 
assay for neuronal concentration [190, 191]. No significant difference in β-tubulin 
immunoreactivity was found between cerebellar homogenates from sham injured 
animals (Figure 18). This suggests that a roughly similar amount of neuronal 
tissue remained in the cerebellar homogenate 24 hours post-TBI, and that 
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neuronal cell loss was likely not responsible for the lower CaN activities observed 
in the cerebellum. 
 
The observed increase in CaN activity was not due to an increase in the 
amount of CaN present: 
 A possible explanation for the increase in CaN activity observed in the 
hippocampus and cortex is the increased synthesis of enzyme following TBI. To 
examine this hypothesis, western analyses of homogenate from all brain regions 
were performed, using an antibody directed against the catalytic A-subunit of the 
enzyme (CN-1, Sigma, St. Louis, MO). In all three brain regions, a single band 
with molecular weight of approximately 61 kDa was resolved. This corresponds 
with the size of the CaN A subunit [8]. Computer-assisted densitometric analysis 
was performed on TBI and control fractions (see Materials and Methods). Optical 
density of the immunoreactive band in cortical TBI homogenate was found to be 
94.8% of control density (Figure 19A). In the hippocampus, CaN 
immunoreactivity in TBI homogenate was 103.4% of control (Figure 19B) and in 
the cerebellum, immunoreactivity was 107.1% of control (Figure 19C). The 
density of the immunoreactive bands was not significantly different in any region 
tested (p>0.05, n=3 for all regions). The data suggest that an increase in CaN 
synthesis was not responsible for the increase observed in the cortex and 
hippocampus, nor was a decrease in the amount of CaN present responsible for 
the slight decrease in CaN activity in the cerebellum. 
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DISCUSSION: 
 The present study is the first to demonstrate a significant increase in CaN 
activity following fluid percussion brain injury. TBI induced a significant increase 
in both basal and maximal CaN activity in both the hippocampus and cortex, 
which persisted two to three weeks after injury. No increase in CaN activity was 
observed in the cerebellum. TBI-dependent increases in both substrate affinity 
and maximal reaction rate were demonstrated in the hippocampus and cortex. 
The significant increase in CaN activity was not due to an increase in the amount 
of CaN present in the homogenate. An increase in the activity of this important 
neuronal phosphatase has broad physiological implications, and may be an 
important step in the development of the pathological consequences of TBI. 
 Several possible mechanisms exist to explain the TBI-induced elevation in 
CaN activity. Significant increases in intracellular calcium concentrations have 
been demonstrated following TBI in several model systems, including the fluid 
percussion model used in this study [192, 193] and in hippocampal neurons in 
culture [194, 195].  Calcineurin is a calcium/calmodulin-stimulated enzyme, and 
would be highly sensitive to an increase in intracellular free calcium 
concentrations. Therefore, it is reasonable to suspect altered intracellular calcium 
levels were responsible for increased CaN activation following TBI. There is 
precedent to assume that increased intracellular calcium could account for 
altered enzyme activity lasting well after the event, as was the case in this study. 
The study of intracellular calcium described by Fineman et al. [193] detected 
increased intracellular calcium up to 4 days post TBI (the longest time-point 
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used), while studies in culture have detected persistent alterations in calcium 
entry and homeostatic mechanisms [194, 195].  However, under the reaction 
conditions employed in the present study, any increased Ca2+ should have been 
adequately buffered. In addition, increasing ion-chelator concentrations in the 
reaction mix did not significantly effect calcineurin activity in this assay (Data not 
shown). Therefore, increased intracellular Ca2+ alone cannot account for the 
observed increase in CaN activity.  
 It is possible that TBI alters the expression of CaN, resulting in a greater 
amount of the enzyme being present in neuronal cells after injury. An increase in 
the amount of CaN would explain both the increase in the apparent pNPP 
dephosphorylation rate without the alteration in substrate affinity following TBI. 
However, western analyses of cortical and hippocampal homogenates did not 
detect a significant change in the amount of CaN present in the tissue. This 
suggests that increased synthesis of CaN is not responsible for the results 
demonstrated in this study. 
 CaN activity may be increased after TBI due to post-translational 
modification of the enzyme. There are several intriguing possible modifications of 
the enzyme that could result in alterations in CaN activity similar to those 
observed in this study. For example, limited proteolysis of the CaN A subunit by 
the calcium-stimulated protease calpain I produces a highly active, calcium-
independent form of CaN [12, 14]. Interestingly, several studies have 
demonstrated a TBI-dependent increase in calpain I activity, possibly due to 
increased intracellular calcium levels [154, 196]. Increased calpain activity could 
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result in higher levels of the partially digested, highly active form of CaN. 
However, the 43 kDa activated CaN fragment was not detected by the western 
analysis performed in this study, nor was a significant reduction in CaN A 
immunoreactivity detected, indicating that a large amount of the enzyme was not 
broken down by calpain. This does not completely discount proteolysis as a 
possible mechanism for the TBI-induced increase in CaN activity. Partially 
digested CaN is reported to have a basal activity 1100% higher than that of the 
holoenzyme [14]. An increase of this magnitude suggests that, if the activated 43 
kDa fragment is present after TBI, it constitutes only a small amount (less than 
5%) of total enzyme. A difference in protein levels of this magnitude would be 
difficult to detect through western blot analysis. It is also possible that the epitope 
recognized by the antibody was no longer present following proteolysis, 
explaining why no small fragments appeared on the western blot. 
 Other post-translational regulatory mechanisms also affect CaN activity. 
Phosphorylation of CaN by both PKC and CaM Kinase II has been shown to 
inactivate the enzyme [197]. Additionally, the membrane-associated protein 
AKAP79 binds CaN, also inactivating the enzyme [56]. A TBI-induced alteration 
in any of these mechanisms could result in the observed increase in CaN activity. 
 The TBI-dependent increase in CaN activity described in this study was 
not observed in the cerebellum. In fact, a small decrease in CaN activity was 
observed in all samples. Although, this decrease was not significant, it is 
interesting when considered in context of the significant increases observed in 
the other tow brain regions. Central fluid percussion injury produces a large 
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amount of strain on the brainstem and nearby structures, with death often 
resulting from brainstem injury in severe FPI [198, 199]. Therefore, it was 
possible that physical damage and death of neurons in this region may have 
contributed to the lower CaN activity. Western analysis for β-tubulin, a neuron-
specific marker, did not detect a significant difference between TBI and sham 
homogenates. Additionally, western analysis of CaN did not detect a significant 
difference in CaN A immunoreactivity. Therefore, loss of CaN protein was not a 
contributing factor confounding a potential TBI-induced increase in enzyme 
activity. The data suggest that TBI modulated different mechanisms in the cortex 
and hippocampus than in the cerebellum. 
 The moderate fluid percussion injury used in this study results in 
numerous cognitive deficits, including memory dysfunction [200], loss of spatial 
navigation skills [201], and sensorimotor deficits [202]. These deficits are often 
worst in the days and weeks immediately following TBI. Increased CaN activity 
may play a role in this cognitive dysfunction. CaN plays a modulatory role in both 
LTP and LTD of neurons. CaN also modulates major inhibitory receptors, such 
as the GABAA receptor, and major excitatory receptors, such as the NDMA 
receptor. Additionally, recent research suggests a major role for CaN in the 
process of learning and memory. An increase in CaN activity could disrupt any of 
these processes, playing a role in the cognitive deficits that follow TBI. 
Interestingly, recent studies have shown cyclosporin A (CsA), a potent CaN 
inhibitor, to be beneficial in preserving cognitive and motor function following TBI 
[203, 204]. CsA has other functions as well, most notably blocking the formation 
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of the mitochondrial transition pore [205], and thus it is impossible to clearly 
attribute its neuroprotective function to the inhibition of CaN. However, these 
results, in combination with those of the present study, clearly identify CaN as an 
important area for further TBI-related research. 
Among the physiological roles of CaN, modulation of the GABAA receptor 
is of particular interest. The GABAA receptor is the primary inhibitory receptor in 
the brain, and is essential for the control of neuronal excitability [65]. Several 
recent studies have demonstrated a down modulation of GABAA receptor 
function by CaN [66-68, 159]. A post-TBI elevation in CaN activity may result in 
increased dephosphorylation of GABAA receptors, resulting in a net disinhibition 
of cellular excitability. A loss of GABA function could produce cognitive and motor 
deficits, as well as possibly being epileptogenic. It is interesting to note that a 
recent study found antagonism of the GABAA receptor to be detrimental to 
recovery of cognitive function after TBI [206]. 
Another major cellular mechanism modulated by calcineurin is apoptosis. 
Several studies have shown CaN to be an essential link in apoptotic pathways 
[140, 185]. Additionally, artificially high levels of CaN activity predisposes 
neuronal cells to apoptosis [207]. When a truncated, highly active form of the 
enzyme was overexpressed in neuronal cells, even normally sub-lethal stimuli 
were capable of inducing apoptotic cell death. The increased CaN activity 
demonstrated in the present study, particularly the larger increases in the 
hippocampus, may make neurons in these regions more likely to undergo 
apoptosis. Recent literature suggests that apoptotic cell death may play an 
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important role in the pathology of TBI, making this mechanism an intriguing area 
for further study [208-210]. 
 The results presented in this study describe a TBI-induced increase in 
CaN activity that persists up to three weeks post-injury. The relatively persistent 
nature of this increase suggests a major role for CaN in TBI-related pathologies, 
with the enzyme playing a role in both immediate neuronal dysfunction and 
possibly inducing chronic neurological changes. Further research into the role of 
CaN in TBI may provide a new avenue for clinical treatment of brain injury. For 
example, the calcineurin inhibitors cyclosporin A and FK506 have both shown 
promise as neuroprotective agents in several models of TBI, although debate 
exists about their mechanism of action [93, 94, 211]. Future research is needed 
to detail the physiological role of calcineurin in TBI and the mechanism 
responsible for the observed increase in CaN activity. This research will offer 
useful insight into the biochemical mechanisms occurring during traumatic brain 
injury. 
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Figure 12. TBI resulted in a significant increase in basal and maximal CaN 
activity. Basal (white) and maximal (black) calcineurin activity were assayed in 
hippocampal and cortical homogenates isolated 24 h after moderate fluid-
percussion injury. (A) Hippocampal homogenates isolated from injured animals 
displayed a significant increase in both basal (52.2%) and maximal (34.3%) CaN 
activity. (B) A TBI-dependent increase in CaN activity was also observed in 
cortical homogenates, although this increase was smaller than that observed in 
the hippocampus. Basal CaN activity was elevated by 44.9% and maximal CaN 
activity was increased by 39.1% when compared to control homogenates (***p < 
0.001, *p < 0.05, n =10, Student’s t-test). 
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Figure 13. The observed increase in pNPP dephosphorylation is CaN-
specific. Cortical homogenates from injured and control animals 24 h post-injury 
were subjected to basal (white bars) and maximal (black bars) reaction 
conditions in the presence and absence of gossypol, a CaN-specific inhibitor. In 
the presence of gossypol, both basal and maximal pNPP dephosphorylation 
were significantly reduced in control and injured homogenates (***p < 0.001, n = 
10, Student’s t-test). When gossypol was added to the reaction, basal pNPP 
dephosphorylation was not significantly different from maximal pNPP 
dephosphorylation in either control or TBI homogenates (p > 0.05, n = 10). 
Finally, control and TBI pNPP dephosphorylation were not significantly different 
in the presence of gossypol (p  > 0.05, n = 10), indicating that the observed 
injury-dependent increase in pNPP dephosphorylation was due to CaN activity. 
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Figure 14. The TBI-induced increase in CaN activity lasts several weeks 
post-injury. Cortical and hippocampal homogenates from injured and control 
animals were isolated at 1, 2, 3, and 4 weeks post-injury. Under basal reaction 
conditions, CaN activity remained significantly elevated in cortical homogenates 
(A) at 1 and 2 weeks post-injury. At 3 and 4 weeks post-injury, basal CaN activity 
was not significantly different from control values. Under maximal conditions, 
CaN activity in cortical homogenates (B) was significantly elevated at 1 and 2 
weeks post-injury. At 3 and 4 weeks post-injury, maximal CaN activity was not 
significantly different from control. In hippocampal homogenates, CaN activity 
was significantly elevated under basal conditions (C) post-injury at 1, 2, and 3 
weeks post-injury. At 4 weeks post-injury, basal CaN activity was not significantly 
different from control. Under maximal reaction conditions, CaN activity was 
elevated in hippocampal homogenates (D) at 1, 2, and 3 weeks postinjury. At 4 
weeks post-injury, maximal CaN activity was not significantly different from 
control (**p < 0.01, *p < 0.05, n = 8 for all groups, one-way ANOVA with Tukey 
post-hoc analysis). 
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Figure 15. TBI modulated CaN enzyme kinetics in hippocampal 
homogenates. Substrate concentration isotherms were constructed in 
hippocampal homogenates isolated from control and TBI animals. (A) Basal CaN 
reactions were performed in control (open circles) and TBI (closed circles) 
homogenates. TBI resulted in a 27.4% increase in apparent Vmax (p <  0.001, n 
=  3). However, substrate affinity was not significantly affected (5.0% decrease in 
Km, p  > 0.05, n = 3). (B) Maximal CaN reactions were performed in 
homogenates isolated from control (open circles) and TBI (closed circles) 
animals. Like basal CaN reactions, TBI resulted in a significant (20.2%, p < 
0.001, n = 3) increase in apparent Vmax, without a significant increase in 
substrate affinity (Km not changed). 
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Figure 16. TBI modulated CaN enzyme kinetics in cortical homogenates. 
Substrate concentration isotherms were constructed in cortical homogenates 
isolated from control and TBI animals. Cortical homogenates displayed a 
significant increase in CaN activity. (A) Basal CaN reactions were performed in 
control (closed circles) and TBI (open circles) homogenates. TBI resulted in a 
22.3% increase in apparent Vmax (p < 0.01, n = 3). However, substrate affinity 
was not significantly affected (5.3% difference in Km, p > 0.05, n = 3). (B) 
Maximal CaN reactions were performed in homogenates isolated from control 
(open circles) and TBI (closed circles) animals. Like basal CaN reactions, TBI 
resulted in a significant (15.2%, p < 0.01, n = 3) increase in apparent Vmax, 
without a significant increase in substrate affinity (6.7%, p > 0.05, n = 3). 
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Figure 17. TBI did not affect CaN activity in the cerebellum. 
Basal (white) and maximal (black) CaN activity was assayed in cerebellar 
homogenates 24 h post-TBI. Both basal and maximal activity appeared to 
decrease slightly; however values were not found to be significantly different from 
those observed in control homogenates (p < 0.05, n =10, Student’s t-test). 
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Figure 18. TBI did not induce significant neuronal loss in the cerebellum at 
the acute time-point.  
(A) Western analysis for the neuron-specific protein β-tubulin was used to 
determine relative concentrations of neuronal tissue in TBI and control cerebellar 
homogenates. (B) Computer-assisted densitometry demonstrated that β-tubulin 
immunoreactivity was not significantly different between TBI homogenate and 
control, suggesting a roughly similar amount of neuronal tissue was present in 
the homogenate before and after injury. β-Tubulin immunoreactivity in TBI 
cerebellum was 106. ± 9.4% of control (p > 0.05, n > 6, Student’s t-test). 
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Figure 19. The post-TBI alteration in CaN activity was not due to a TBI-
induced increase in CaN protein expression.  
To determine if TBI resulted in increased CaN enzyme levels, homogenates from 
all brain regions were subjected to western analysis for the catalytic CaN A 
subunit. Immunoreactivity in the hippocampus (A), cortex (B), and cerebellum (C) 
was quantified with computer-assisted densitometry (D), and found not 
significantly different from control (p < 0.05, n = 3 for all brain regions, Student’s 
t-test). Blots shown are representative from samples utilized for biochemical 
characterization. 
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CHAPTER IV 
A PERSISTENT CHANGE IN SUBCELLULAR DISTRIBUTION OF 
CALCINEURIN FOLLOWING FLUID PERCUSSION INJURY IN 
THE RAT. 
 
INTRODUCTION: 
 
Traumatic brain injury (TBI) remains a major cause of death and disability 
in the United States today [183]. Although the initial injury often involves 
irreversible destruction of tissue, secondary, potentially preventable injury 
processes take place in the days and weeks after injury. This secondary damage 
causes pathological change in cells over a much greater area than the primary 
injury, and is often responsible for many of the lasting neurological deficits 
associated with TBI [183, 184] The delayed nature of this secondary injury offers 
a potential window for treatment, making it an exciting area for both basic 
research and clinical trials. Fluid percussion brain injury provides an excellent 
model for this type of secondary, generalized injury; moderate fluid percussion 
does very little immediate damage to the brain tissue, but animals are left with 
pathologically altered neuronal cells and lasting neurological deficits [212]. 
Central fluid percussion, in particular, is associated with reduced cell death when 
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compared with lateral fluid percussion [213]. 
Many of the mechanisms associated with secondary neuronal injury in TBI 
are associated with calcium and calcium-modulated systems [132]. A calcium-
regulated enzyme of current interest is the neuronally enriched phosphatase, 
calcineurin (CaN). Expression of CaN mRNA is elevated after injury in at least 
one model [214]. Additionally, the CaN inhibitors cyclosporin A and FK-506 have 
both shown promise as neuroprotective agents in several models of TBI [93, 94, 
215, 216], although only cyclosporin A has been evaluated in the specific model 
used in this study [94]. In the case of cyclosporin A, the neuroprotective effect 
may be due to CaN inhibition, but most studies suggest neuroprotection is due to 
the drug's effects on mitochondria. On the other hand, for FK-506, the 
neuroprotective action is more likely due to CaN inhibition [93, 216]. Finally, 
recent research has characterized a TBI-dependent increase in CaN activity in 
the fluid percussion model, further implicating CaN in brain trauma-induced 
pathology [217]. 
The present study expands on our previous study of CaN in TBI, further 
characterizing the effects of fluid percussion TBI on CaN in rat forebrain. CaN 
immunoreactivity was increased in synaptoplasmic membrane-enriched fractions 
from both the cortex and hippocampus. This elevation in CaN immunoreactivity 
persisted for 2 weeks in the cortex, and up to 4 weeks in the hippocampus. 
Additionally, immunohistochemical studies of the hippocampus demonstrated a 
TBI-dependent elevation in CaN immunoreactivity in dendritic processes of the 
CA1 region. The data suggest a long-lasting post-injury translocation of CaN to 
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the post-synaptic region of neurons, where it may play a role in pathologically 
altering synaptic activity. 
 
METHODS: 
 
Surgical preparation and fluid percussion injury: 
All animal use procedures were in strict accordance with the Guide for the 
Care and Use of Laboratory Animals described by the National Institutes of 
Health and were approved by the Virginia Commonwealth University Institutional 
Animal Care and Use Committee. Adult male Sprague–Dawley rats weighing 
between 300 and 350 g were surgically prepared under sodium pentobarbital 
anesthesia (54 mg/kg intraperitoneally). Animals were placed in a stereotactic 
frame and the scalp was sagitally incised. A 4.8-mm hole was then trephined into 
the skull over the sagittal suture midway between bregma and lambda. A nickel-
plated screw was placed 1 mm rostral to bregma, and a second screw was 
inserted 1 mm caudal to lambda. A modified female Luer-Loc syringe hub (2.6 
mm inside diameter) was placed over the exposed dura and bonded in place with 
a cyanoacrylate adhesive. Dental acrylic was then poured around the syringe 
hub and screws. The scalp was then sutured, bacitracin was applied to the 
wound, and the animal was returned to its home cage. 
Twenty-four hours following the surgical procedure, the rats were again 
anesthetized (4% isoflurane in a carrier gas mixture of 70% N2O and 30% O2). 
Rats in the sham-injury (control) group were anesthetized and connected to the 
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injury device, but the pendulum was not released. Rats in the injured group were 
anesthetized and subjected to a moderate (2.1 ± 0.1 atm) level of fluid 
percussion injury. The Luer-Loc fitting, screws, and dental cement were then 
removed from the skull. Following recovery, rats were returned to their home 
cages and allowed to survive for 24 h, 1 week, 2 weeks, 3 weeks, or 4 weeks 
prior to being sacrificed. Six injured and six sham-injured animals were obtained 
for each post-injury time point for Western analysis. An additional three injured 
and three sham-injured animals were obtained for immunohistochemical studies 
from the 24-h and 4-week time points. 
 
Fluid percussion injury device: 
The fluid percussion injury device used in these experiments is identical to 
that described by Dixon et al. [189]. Briefly, the device consisted of a Plexiglas 
cylinder reservoir 60 cm long and 4.5 cm in diameter. At one end of the cylinder 
was a rubber-covered Plexiglas piston mounted on O-rings. The opposite end of 
the cylinder had a metal housing 2 cm long, containing a transducer. A 5-mm-
long tube with a 2-mm inner diameter was fitted at the end of the metal housing. 
The tube terminated with a male Luer-Loc fitting. This fitting was connected to a 
female Luer-Loc fitting that had been chronically implanted over the exposed 
dura of the rat. The entire system was filled with isotonic saline. The injury was 
produced by a metal pendulum that struck the piston of the injury device. The 
injury device injected a small volume of saline into the closed cranial cavity and 
produced brief displacement of brain tissue. The magnitude of injury was 
126 
 
controlled by varying the height from which the pendulum was released. The 
resulting pressure pulse was measured externally by a pressure transducer 
(model EPN-0300A*-100A, Entran Devices, Fairfield, NJ) and recorded on a 
storage oscilloscope (model 5111, Tektronix, Beaverton, OR). 
 
Isolation and homogenization of brain regions: 
Rats were anesthetized and decapitated 24 h, 1 week, 2 weeks, 3 weeks, 
and 4 weeks after injury or sham-injury. No obvious contusion or gross signs of 
injury were noted. Brains were dissected on a petri dish on ice to reduce 
postmortem alteration of enzyme activity. Cortical and hippocampal brain regions 
were quickly isolated and immediately homogenized with 10 strokes (up and 
down) at 12,000 rpm using a motorized homogenizer (TRI-R Instruments, Inc., 
Rockville Center, NY). Brain regions were homogenized into ice-cold 
homogenization buffer containing 5 mM HEPES (pH 7.0), 7 mM EGTA, 5 mM 
EDTA, 1 mM dithiothreitol, 0.3 mM phenylmethylsulfonylfloride, and 300 mM 
sucrose. Cortical regions were homogenized into 7 ml of buffer and hippocampal 
regions into 3 ml of buffer. Cortical homogenates consisted of both left and right 
hemispheres, while hippocampal homogenates consisted of both the left and 
right hippocampus. Subcellular fractions were then isolated by a differential 
centrifugation procedure [168] with modifications described previously [217]. 
Brain region homogenate was first centrifuged at 5000 × g for 10 min to produce 
a crude nuclear pellet (P1) and a supernatant (S1). The P1 pellet was 
resuspended in homogenization buffer, separated into aliquots, and stored at −80 
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°C until used. The S1 was centrifuged for 30 min at 18,000 × g to produce the 
crude synaptoplasmic membrane/mitochondiral pellet (P2) and a supernatant 
(S2). The S2 was separated into aliquots and stored at −80 °C. The P2 pellet 
was resuspended in homogenization buffer (1 ml for cortex, 500 µl for 
hippocampus), then separated into aliquots and stored at −80 °C until used. 
 
CaN immunoblotting procedure: 
Western analysis was performed essentially as described previously [146]. 
Briefly, homogenate protein concentrations were measured and balanced. 
Homogenates were then resolved on SDS-PAGE (5 µg/lane, 5 well, 1.5 mm thick 
gels, Mini-Protean II system, Bio-Rad, Hercules, CA) and transferred to a 
nitrocellulose membrane using the Geni blot system (Idea Scientific, Minneapolis, 
MN). Anti-CaN A antibody (clone CN-A1, mouse monoclonal IgG, Sigma 
Chemical Co.) was diluted 1:10,000 for Western analysis, and stained using the 
Vectastain Elite anti-mouse IgG kit (Vector Laboratories Inc., Burlingame, CA). 
Blots were developed with a solution containing 10 ml PBS, 0.025% (v/v) H2O2, 
and 8 mg 4-chloro-1-napthol dissolved in 2 ml of methanol. Specific 
immunoreactive bands were quantified by computer-assisted densitometry (GS-
800 Calibrated Densitometer, BioRad). 
 
Immunohistochemical analysis: 
Immunohistochemical studies were carried out as described previously 
[146, 217]. At 24 h and 4 weeks post-injury, rats were anesthetized with 
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halothane and transcardially perfused with a solution containing 4% 
paraformaldehyde and 0.1% glutaraldehyde. Brains were then removed and 
allowed to post-fix in the perfusion fixative for 24 h. Brains were then blocked to 
allow sectioning of the dorsal hippocampus, embedded in agar and coronally 
sectioned into serial 40-µm sections on a Leica VT1000S vibratome (Leica 
Microsystems, Bannockburn, IL). Sections were stored in 12-well culture plates 
until used. 
For immunohistochemical staining, sections were incubated for 30 min in 
normal serum at 37 °C. Sections were then incubated overnight with a polyclonal 
anti-CaN A antibody at a dilution of 1:50,000. Following incubation with the 
primary antibody, sections were then washed 4× with phosphate-buffered saline 
(PBS, pH 7.4) for 15 min per wash. The tissue was then incubated in secondary 
antibody for 1 h at 37 °C. Sections were washed 3× in PBS, then placed in 
Vectastain ABC reagent for 2 h. The first hour of incubation in ABC was 
performed at 37 °C, the second hour at room temperature. Sections were then 
washed 2× in PBS for 10 min per wash, and 1× in Tris–Base (pH 7.6). The tissue 
was then stained with a glucose oxidase-DAB-nickel preparation. 
 
RESULTS: 
 
TBI resulted in a long-lasting increase of CaN immunoreactivity in both the 
cortex and hippocampus 
Western analysis was performed for homogenate and subcellular fractions 
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for both cortex and hippocampus. No significant post-TBI difference in CaN 
immunoreactivity was found in homogenate from either cortical or hippocampal 
tissues, indicating that there was no overall increase in the amount of CaN 
present in this tissue (Fig 20). Additionally, no difference in CaN immunoreactivity 
was detected in the P1 (nuclear-enriched) or S2 fractions (data not shown). 
Crude synaptoplasmic membrane (SPM) fractions were isolated from the 
cortex and hippocampus at several time points post-injury to assess the duration 
of the increase in CaN immunoreactivity. All SPM fractions were compared with 
fractions isolated from sham-operated controls at identical time points post-
sham-injury. At 24 h post-injury, a significant increase in CaN immunoreactivity 
was observed (257.9 ± 32.0% of control, Fig. 21 and Fig. 22) in the P2 (crude 
SPM) fraction isolated from post-TBI cortical tissue. CaN immunoreactivity 
remained increased to 218.1 ± 25.4% of control 1 week post-TBI (Figs. 21 and 
22), and 202.1 ± 23.1% of control 2 weeks post TBI (Fig. 21C). At 3 weeks post-
injury, CaN immunoreactivity had returned to baseline, and was indistinguishable 
from that of sham-operated animals (Figs. 21 and 22). 
  Similarly, a TBI-dependent increase in CaN immunoreactivity to 
261.3 ± 24.8% of control was observed 24 h post-injury in hippocampal crude 
SPM (Figs. 23 and 24). CaN immunoreactivity remained elevated to 
261.6 ± 26.2% of control 1 week post-TBI (Figs. 23 and 24), 259.2 ± 20.1% of 
control 2 weeks post-TBI (Figs. 23 and 24), and 138.7 ± 10.3% of control 3 
weeks post-TBI (Figs 23 and 24). At 4 weeks post-injury, CaN immunoreactivity 
in hippocampal SPM-enriched fractions was 130.4 ± 12.5% of control (Figs. 23 
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and 24). Although the elevation in CaN immunoreactivity decreased over time in 
the hippocampus, it remained significantly higher than that of sham-operated 
control animals for the entire 4 weeks of this study, suggesting a persistent 
alteration in the CaN content of the SPM fraction. 
 
TBI resulted in a long-lasting increase in CaN A immunoreactivity in apical 
dendrites of hippocampal CA1 neurons 
To further characterize the TBI-dependent increase in CaN 
immunoreactivity observed in the crude SPM fraction, immunohistochemical 
studies were performed on paraformaldehyde-fixed coronal sections from TBI 
and control animals, both at 24 h (Fig. 25A, B) and 4 weeks (Fig. 25C, D) post-
injury. Hippocampal sections from sham-control animals demonstrated no 
noticeable histological differences between 24-h and 4-week post-sham 
treatment (Fig. 25A, C). Hippocampal sections from control animals 
demonstrated diffuse staining throughout the pyramidal cell layer, with the 
exception of the pyramidal cell nuclei. Faint CaN immunoreactivity was observed 
in the surrounding cortex (data not shown). This diffuse cortical staining 
remained unchanged following TBI. Therefore, the intensity of cortical staining 
was used as a background value to compare control and TBI images. Individual 
hippocampal pyramidal neurons could be visualized in sham animals; the 
cytoplasm of these cells demonstrated very diffuse CaN-reactive staining. The 
darkest staining was seen around the plasma membrane of these neurons. 
Occasional dendritic processes demonstrated CaN immunoreactivity; however, 
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many apical dendrites could not be individually visualized in control sections. 
These histological findings were in agreement with previous studies 
demonstrating the presence of CaN in the hippocampal formation, particularly in 
the plasma membrane and in neurites [217]. 
Hippocampal sections from TBI animals demonstrated several qualitative 
changes when compared to sham-control sections (Fig. 25B, D). Similar to the 
control sections, diffuse CaN-reactive staining was present throughout the 
hippocampus. However, this staining was noticeably more intense in the 24-h 
post-injury sections. Staining was still relatively poor in the surrounding cortex in 
the TBI sections. Intense staining was found to be present around the plasma 
membranes and throughout the apical dendrites of pyramidal neurons. Unlike the 
control sections, where few processes could be seen, many apical dendrites 
were easily visualized and intensely stained in the TBI sections. It was not 
possible to visualize any axonal processes leading from the pyramidal cells, nor 
were any darkly stained processes observed in axonal layers of the 
hippocampus, suggesting that the increased CaN immunoreactivity was post- 
rather than presynaptic. Finally, no interneurons were detected in control or SE 
sections, suggesting an absence of CaN in these neurons that is in agreement 
with previous research. Although these changes were most intense in the 24-h 
post-injury sections, they remained noticeably different from control in the 4-week 
post-injury samples, a finding which corresponds well with the subcellular fraction 
data presented above. 
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DISCUSSION: 
 
The present study identified an increase in CaN immunoreactivity in the 
P2 fraction isolated from hippocampal and cortical tissue that lasted for a 
significant amount of time post-injury. This study did not identify any significant 
increase in CaN immunoreactivity in homogenate from these tissues. This 
suggests that the increase in CaN content in the crude SPM fraction was due to 
translocation, rather than new protein synthesis. Additionally, 
immunohistochemical staining of hippocampal tissue revealed increased CaN 
staining in the apical dendrites of the CA1 region that persisted at least 4 weeks 
post-injury. These data suggest a TBI-induced translocation of CaN into specific 
synaptic membrane-rich compartments, and also indicate that this translocation 
remains in effect during the critical weeks immediately following brain injury. 
Recent studies have suggested that CaN participates in the biochemical 
mechanisms leading to neuronal pathology following traumatic brain injury. 
Additionally, inhibitors of CaN, including cyclosporin A and FK506, can be 
neuroprotective if administered within a short time of the injury event. However, it 
is important to note that FK506 has not been specifically studied in the fluid 
percussion model of TBI, and caution should be used when applying results from 
these inhibitor studies across injury models. A great deal remains to be 
understood about the exact physiological role played by CaN in these 
pathological processes, and a better understanding of CaN activity post-TBI may 
allow more effective targeting of these treatments. Previous studies in our 
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laboratory described an increase in CaN activity beginning acutely post-injury 
and persisting for several weeks post-injury [218]. Since CaN regulates a diverse 
group of neuronal processes, understanding how this increase in activity relates 
to specific subcellular compartments is important in determining the role of CaN 
in TBI-induced pathology. 
The P2 fraction described in this study is highly enriched in both crude 
synaptoplasmic membrane and mitochondria [168]. Previous studies have not 
detected significant amounts of CaN in purified mitochondrial preparations [171]; 
however, it is possible that TBI induces a translocation of the enzyme to these 
organelles. CaN plays an essential role in several apoptotic pathways [91, 166], 
and movement of the enzyme to the mitochondria would likely facilitate these 
apoptotic mechanisms, resulting in increased cell death. While this is an 
intriguing hypothesis, the lack of significant amounts of CaN in mitochondrial 
preparations from other studies, coupled with the immunohistochemical data in 
this study, makes mitochondrial translocation of CaN an unlikely explanation for 
the data presented. 
CaN has been detected in purified synaptoplasmic membranes by several 
researchers [171, 219]. The increased immunoreactivity of CaN in the P2 fraction 
observed in this experiment could be due to a translocation of enzyme to the 
synaptic membrane. Immunohistochemical data presented in this study 
described a significant increase in CaN immunoreactivity in the pyramidal cell 
layers of the hippocampus, especially in the CA1 region. The fact that this 
increase in immunoreactivity was confined primarily to the apical dendrites 
134 
 
supports the hypothesis that TBI leads to a translocation of the enzyme to the 
post-synaptic membrane. This would place double the control amount of CaN in 
a region rich in substrates highly relevant to the pathology of TBI. This 
translocation is an especially intriguing possibility when considered along with 
prior observations that TBI induces an increase in CaN activity. 
The fluid percussion model of TBI used in this study has been shown to 
lead to numerous cognitive deficits in the animals studied, including poor 
performance in tasks known to rely on new memory formation and hippocampal 
processing [202, 220-222]. Interestingly, the duration of some of the major 
deficits in learning and memory in the fluid percussion model correlates well with 
the duration of increased CaN immunoreactivity [221-223]. CaN plays an 
important role in learning and memory through its regulation of LTP and LTD [41, 
224]. Through its actions leading to dephosphorylation of NMDA receptors, CaN 
activity is generally thought to be associated with weakening synaptic strength, 
i.e., LTD [69, 180, 225]. The translocation of CaN noted in this study would 
greatly increase the amount of CaN in the vicinity of these receptors, possibly 
increasing LTD of neurons important in memory formation and decreasing overall 
cognitive function. Additionally, CaN has been shown to cause depotentiation of 
neurons that have undergone LTP, also weakening relative synaptic strength 
[226]. A recent study has shown that fluid percussion TBI leads to an inability to 
maintain LTP in hippocampal CA1 neurons [227]. Interestingly, both the post-TBI 
translocation of CaN and the increase in its activity are present long after the 
initial injury in the hippocampus, a structure essential for memory formation and 
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highly vulnerable to TBI-induced damage. 
Conversely, CaN has also been shown to decrease GABAergic 
neurotransmission by dephosphorylating an essential phosphorylation site on the 
GABA receptor [66, 68]. Additionally, CaN-mediated dephosphorylation is the 
rate-limiting step in dynamin-mediated vesicle endocytosis [228] such as occurs 
in GABAA receptor internalization [229]. Thus, an increase of CaN concentration 
in the vicinity of GABAA receptors could decrease inhibitory neurotransmission 
both by decreasing receptor function and decreasing the number of available 
receptors. A decrease in inhibitory neurotransmission could lead to pathologically 
hyperexcitable neuronal tissue, such as occurs in the epileptic activity and 
hippocampal hyperexcitability associated with the fluid percussion injury model 
[230-232]. Understanding the exact physiological role of CaN in TBI clearly 
depends on discovering which elements of the post-synaptic membrane CaN 
associates with after the injury, providing an intriguing area for future research. 
This study is the first to describe a TBI-dependent increase in CaN 
concentration in the post-synaptic region of neurons. This increase persists well 
after the acute injury, suggesting that it may play a role in the development of 
TBI-associated pathologies. Discovery of TBI-associated effects on this important 
enzyme is especially relevant in light of the recent interest in the neuroprotective 
effects of CaN inhibitors. Further research into the effects of TBI on CaN will help 
lead to a better understanding of the biochemical processes occurring in the days 
and weeks post-injury, and will hopefully lead to more effective treatment options 
for these devastating injuries. 
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Figure 20: TBI did not alter total CaN A expression in hippocampal and 
cortical homogenates 
Western analysis of cortical (A) and hippocampal (C) homogenates did not 
demonstrate a TBI-dependent change in CaN A immunoreactivity 24h post-injury 
when compared to sham animals. In cortical homogenates (B) from injured 
animals, CaN immunoreactivity was 98.7 % of control as determined by 
calibrated densitometry (p > 0.05, n = 6, Student’s t-test). In hippocampal 
homogenates (D), CaN immunoreactivity was 103.2 % of control (p > 0.05, n=6). 
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Figure 21: CaN immunoreactivity in crude SPM isolated from cortical tissue 
was elevated for 2 weeks post-TBI 
In crude SPM isolated from the cortex of injured animals, a marked increase in 
CaN immunoreactivity was present 24h (A), one week (B), and two weeks post 
injury (C). CaN A immunoreactivity returned to baseline at three weeks postinjury 
(D) and remained similar to control values at four weeks post-injury (not shown). 
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Figure 22: Calibrated densitometry of cortical crude SPM westerns reveals 
a significant increase in CaN A immunoreactivity 
Optical density was calculated using a calibrated densitometer. CaN 
immunoreactivity was significantly increased over sham-control values at 24h (p 
< 0.01, n=6, Student’s t-test), one week (p < 0.01, n = 6), and two weeks post-
injury (p < 0.01, n=6). At both three and four weeks post-TBI, CaN 
immunoreactivity was indistinguishable from sham-control values (p > 0.05, n=6). 
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Figure 23: CaN immunoreactivity in crude SPM isolated from hippocampal 
tissue was elevated up to 4 weeks post-injury 
In crude SPM isolated from hippocampal tissue, increased CaN A 
immunoreactivity was observed in injured animals 24h (A), one week (B), two 
weeks (C), three weeks (D) and four weeks (E) post-injury. Although the 
alteration in CaN A immunoreactivity decreased with time, CaN A levels in the 
hippocampus did not return to control values during the span of this study. 
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Figure 24: Calibrated densitometry of hippocampal crude SPM westerns 
demonstrates a significant increase in CaN A immunoreactivity 
Optical density was calculated using a calibrated densitometer. CaN 
immunoreactivity was significantly increased over their respective sham-control 
values at 24h (p < 0.001, n = 6, Student’s t-test), one week (p < 0.01, n = 6), two 
weeks (p < 0.01, n=6), three weeks (p < 0.05, n = 6), and four weeks post-injury 
(p < 0.05, n = 6). The increase in hippocampal CaN A immunoreactivity trended 
toward control values over time. 
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Figure 25: TBI induced an increase in CaN A immunoreactivity in apical 
dendrites of hippocampal CA1 neurons 
Immunohistochemistry of sham-operated animals revealed diffuse CaN A 
immunoreactivity around the cell bodies of CA1 neurons at both 24h (A) and four 
weeks (C). In injured animals, CaN A immunoreactivity was far more intense than 
control in the apical dendrites of these neurons 24h post-injury, allowing 
numerous dendritic processes to be visualized (B). The injury-induced alteration 
in CaN A staining remained present four weeks post-injury, although qualitatively 
less intense (D). (representative slices shown, n=3). 
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CHAPTER V 
A CELLULAR MECHANISM FOR DENDRITIC SPINE LOSS IN THE 
PILOCARPINE MODEL OF STATUS EPILEPTICUS 
 
INTRODUCTION: 
Status epilepticus (SE) is a severe neurological emergency characterized 
by persistent, continuous seizure activity [233]. In addition to an immediate risk of 
mortality, patients experiencing SE are at risk for a number of chronic 
neurological pathologies as a consequence of the seizure episode, including 
cognitive impairment, focal neurological deficits, and the development of chronic 
epilepsy [105, 116, 124]. A number of SE-induced biochemical and 
morphological changes in the brain have been investigated as possible causes of 
this long-term pathology. One recent finding that may have relevance to this 
subject is the SE-induced loss of dendritic spines [234]. 
 Dendritic spines are small, dynamic protuberances from the dendritic shaft 
that are critical for synaptic transmission throughout the CNS, representing the 
primary location of excitatory glutamatergic neurotransmission [235]. The 
presence of dendritic spines is thought to aid neurotransmission in several ways, 
both by increasing the surface area for synaptic contact and by providing a 
specialized compartment for the excitatory postsynaptic machinery [236]. The 
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importance of these spines to excitatory neurotransmisson, and the apparent 
ability of neurons to alter spine density, size and shape in response to synaptic 
input, makes them an ideal location for regulation of synaptic strength. In fact, 
spine plasticity has been noted as a possible mechanism of long-term 
potentiation/depression [80] and has been implicated in several models of 
learning and memory [237-239]. 
  Interestingly, profound decreases in dendritic spine density, as well as 
alterations in spine shape and size, have been detected in both SE and several 
models of chronic epilepsy [234, 240-242]. Although the precise physiological 
consequence of this pathological spine plasticity has not yet been elucidated, 
several possible theories have been proposed. SE and epilepsy have both been 
associated with long-term cognitive deficiencies [116], and a widespread and 
chronic loss of dendritic spine density could certainly play a major role in this 
pathology, especially considering the importance of spines in learning and 
memory models [237]. On the other hand, SE-induced spine plasticity may also 
represent a potential mechanism of epileptogenesis, in which the loss of dendritic 
spines is part of a pathological reorganization of synaptic networks leading to an 
overall increase in neuronal excitability [243]. In spite of the uncertainty about the 
pathological consequences of SE-induced spine plasticity, such a widespread 
alteration in the structure of excitatory synapses remains an important and highly 
interesting consequence of SE and certainly merits continued investigation.  
 Unfortunately, the biological mechanisms responsible for this SE-induced 
spine plasticity remain poorly understood as well. One potential mechanism 
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involves the calcium-regulated phosphatase, calcineurin (CaN). The cytoskeleton 
of spines is composed primarily of actin filaments, and CaN has been shown to 
regulate actin stability in a number of neuronal settings, including axonal growth 
cones and dendrites. Additionally, activation of CaN by NMDA-receptor 
associated calcium influx has been shown to destabilize F-actin in dendritic 
spines, and CaN and F-actin are co-localized in dendritic spines under these 
conditions [79]. Finally, recent research has demonstrated an SE-induced 
increase in CaN activity and enzyme concentration in post-synaptic regions of 
neurons [167, 217]. Thus an enzyme capable of regulating the structure of 
dendritic spines is both activated and localized into the vicinity of the spines in 
SE, placing CaN in an ideal position to play a role in SE-induced spine plasticity. 
 The present study investigated the CaN-dependent regulation of actin 
stability in the context of SE-induced dendritic spine loss. We demonstrate an 
SE-dependent dephosphorylation of cofilin, an actin-depolymerizing factor that is 
activated by dephosphorylation. We also show a subsequent increase in cofilin-
actin binding and actin depolymerization. All of these SE-induced cytoskeletal 
events are shown to be blocked by pre-administration of the CaN inhibitors, 
FK506 (tacrolimus) and cyclosporin A, strongly suggesting a CaN-dependent 
mechanism. Finally, SE-induced dendritic spine loss was demonstrated 
histologically in several brain regions, this spine loss was also blocked by the 
administration of CaN inhibitors. These findings implicate CaN in a widespread, 
SE-induced alteration in the structure of synaptic contacts, potentially furthering 
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our understanding of the cellular mechanisms underlying chronic SE-induced 
neurological pathology.  
 
METHODS: 
 
Pilocarpine model of status epilepticus: 
 All animal-use procedures were in strict accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and were 
approved by the Virginia Commonwealth University Institutional Animal Care 
and Use Committee. Adult Sprague-Dawley rats were handled after arrival from 
Harlan Laboratories, for acclimation to handling before drug treatment. One 
week before the induction of SE, four surface electrodes were implanted into 
the skulls of rats under ketamine anesthesia, as described previously [244]. 
Two frontal electrodes were implanted over frontal cortex [3.5 mm anterior to 
bregma, ±2.5 mm L/R (F1/F2)]. Two posterior electrodes were implanted over 
parietal cortex and hippocampus [2.0 mm posterior to bregma, ±2.5 mm L/R 
(P1/P2)]. A fifth electrode was fixed onto the surface of the skull as a ground. 
The electrodes were secured in place with dental acrylate, and the animals 
were allowed ≥5 days to recover from surgery before experiments were 
performed. 
Twenty minutes before the injection of pilocarpine, methylscopolamine, 
a muscarinic antagonist, was administered i.p. (1 mg/kg) to reduce adverse 
peripheral affects of the pilocarpine. Where appropriate, 10 mg/kg cyclosporin A 
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(Sigma) or 5 mg/kg FK506 (Fujisawa) was administered i.v. (tail vein) 3 hours 
prior to the induction of SE. Control and sham-surgery animals were attached 
to video-EEG machines (BMSI 5000; Nicolet, Madison, WI), and baseline EEG 
recordings were obtained for ≥10 min after scopolamine injection. SE was 
induced in experimental animals by i.p. injection of 375 mg/kg pilocarpine HCl, 
a muscarinic agonist. Behavioral and encephalographic activities were 
recorded throughout the procedure [244]. Once initial seizure activity was 
observed, the time was noted, and rats were allowed to seize for specific 
amounts of time before the animals were processed. These time points 
consisted of 10, 15, 20, 30, 40, 50, 60, and 70 min after the first discrete 
seizure. Since our laboratory has previously characterized SE onset as being 
10 min after the first discrete seizure [244], these times approximate 0, 5, 10, 
20, 30, 40, 50, and 60 min of SE, respectively. Behavioral seizures were 
assessed according to the scale of Racine [142]. 
 
Brain region isolation and subcellular fractionation:  
 Rats were rapidly decapitated after specific durations of SE. Brains were 
rapidly dissected on a petri dish on ice to preserve postmortem enzyme activity. 
Cortical and hippocampal brain regions were quickly isolated and immediately 
homogenized with 10 strokes (up and down) at 12,000 rpm, using a motorized 
homogenizer (TRI-R Instruments, Inc., Rockville Center, NY). Brain regions were 
homogenized into an ice-cold isotonic homogenization buffer containing 10 mM 
Tris-HCl (pH 7.0), 7 mM EGTA, 5 mM EDTA, 1 mM dithiothreitol (DTT), 0.3 mM 
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PMSF, and 187 mM sucrose. Cortical regions were homogenized into 7 ml of 
buffer and hippocampal regions into 3 ml. All brain homogenates were then 
subjected to the differential centrifugation procedure described below. 
Isolation of crude synaptoplasmic membrane fractions was achieved using 
a differential centrifugation procedure [168] modified as described previously 
[217, 245]. Briefly, brain region homogenates were centrifuged at 5000g for 10 
min to produce a crude nuclear pellet (P1) and a supernatant (S1). The P1 pellet 
was resuspended in homogenization buffer, separated into aliquots, and stored 
at -80°C. The S1 was centrifuged for 30 min at 18,000g to produce the crude 
synaptoplasmic membrane/ mitochondrial pellet (P2) and a supernatant (S2). 
The P2 pellet was resuspended in 1/10 the original volume of the homogenate 
(700 µl for cortex, 300 µl for hippocampus), separated into aliquots, and stored at 
-80°C until used. 
 
Western analysis: 
Western analysis was performed in a manner similar to that described 
previously [217]. Briefly, fractions were balanced for protein using the Bradford 
method [144], resolved on SDS-PAGE, and transferred to a nitrocellulose 
membrane using the Trans-blot system with the plates in the high-intensity field 
configuration (BioRad, Richmond, CA). Nitrocellulose was then immersed for 1 h 
in blocking solution, containing phosphate buffered saline (PBS, pH 7.4), 0.05% 
(v/v) polyoxyethylene sorbitan monolaurate (Tween 20), and 2.5% Bio-Rad 
blotting grade dry milk. The nitrocellulose membrane was then incubated with the 
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appropriate primary antibody in blocking solution for 1 h. Anti-CaN A antibody 
(clone CN-A1, mouse monoclonal IgG, Sigma Chemical Co.) was diluted 
1:10,000, anti-actin antibody was diluted 1:5000, DARRP-32 antibody was 
diluted 1:1000, and anti-cofilin (Chemicon) and anti-phosphocofilin (Chemicon) 
were diluted 1:500 for western analysis. Membranes were then washed three 
times in a wash solution containing PBS, Tween 20, and dry milk. Next, 
nitrocellulose was reacted with the appropriate HRP-conjugated secondary 
antibody in blocking solution for 30 min, then washed 3X in PBS/Tween for 10 
minutes each wash. Finally, blots were reacted with a luminol reagent for 5 
minutes (Pierce Pico-sensitive reagent for CaN A and actin studies, Pierce 
Femto-sensitive reagent for cofilin and phospho-cofilin staining). Blots were 
immediately exposed to x-ray film (Kodak X-OMAT). Films were developed using 
a Kodak X-OMAT developer. Specific immunoreactive bands were quantified by 
computer-assisted densitometry (GS-800 calibrated densitometer and Quantity 
One software, BioRad) and compared to a linear concentration curve as 
described previously [146].  
 
Immunoprecipitation: 
Homogenates were spun at 5000 x g for 5 min to clear large insoluble 
material. All samples were balanced to ensure equivalent protein content, 500 µg 
of protein was incubated on a rotating rack with anti-cofilin antibody diluted 1:50 
(Chemicon) overnight at 4º C. 30 µL of protein-A agarose beads were then 
added to the sample and incubated (rotating) for 3h at 4º C. The beads were then 
150 
 
precipitated by spinning the samples at 2000 x g for 2 minutes. The resulting 
pellet was washed 3X in phosphate buffered saline with 1% triton X-100. The 
pellet was then suspended in SDS sample buffer, placed in a boiling water bath 
for 5 minutes, and subjected to SDS-PAGE.  
 
Actin polymerization assay: 
 Actin polymerization was assayed using the differential solubility of F-actin 
and G-actin in 1% triton. Samples were incubated in 1% triton for 1h at 4° C, then 
subjected to a 1h centrifugation at 100,000 x g. The resulting supernatant and 
pellet were balanced for protein concentration, then run on a 10% SDS-PAGE 
gel and subjected to western analysis as described previously. The ratio of the 
amounts of actin present in these two fractions was used to provide an estimate 
of the actin polymerization state in different brain region isolates. 
 
Rapid Golgi impregnation: 
 Visualization of dendritic spines was accomplished via a modification of 
the single-section rapid Golgi procedure described previously [246]. After 1h of 
SE, animals were anesthetized with an overdose of sodium pentobarbital and 
transcardially perfused with 10% neutral buffered formalin. Brains were removed 
and postfixed overnight in 10% neutral buffered formalin, then sectioned into 
deionized water at 100 µm on a vibratome (Leica VT-1000S). Sections were then 
incubated 30 min at room temperature in a solution containing 0.5% osmium 
tetroxide, followed by a 2h incubation in a solution of 3.5% potassium 
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dichromate. Sections were removed from the dichromate solution and placed on 
a glass slide with a few drops of dichromate surrounding the section. A second 
slide was placed on top of the section, and the two slides were spaced apart from 
one another by a glass coverslip. The entire assembly was held together with 
cyanoacrylate-based glue. This assembly was placed in a solution of 1% silver 
nitrate and kept in the dark on a shaker for 6-12h. The slide/coverslip assembly 
was then disassembled and the slides rinsed in deionized water. Sections were 
then dehydrated through a series of increasing ethanol concentrations, cleared 
with xylene, and mounted on slides with glass coverslips using Permount. Slides 
were examined under 40X and 100X oil immersion objectives (400X and 1000X 
final magnification). A minimum of 3 neurons were studied per slide, and at least 
3 slides were examined per animal. Photographic images were obtained with an 
Olympus Q-fire camera and processed with Adobe Photoshop CS.   
  
Statistical analysis: 
 EEG review and analysis was performed using Insight II software 
(Persyst, Prescott, AZ). All statistical analysis was performed using GraphPad 
Prism 4.0 (GraphPad Software, San Diego, CA). For multiple group comparisons, 
ANOVA with Tukey post-hoc analysis was used with a minimum significance 
level of p < 0.05. All data is presented as mean ± SEM unless otherwise noted. 
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RESULTS: 
SE induces a rapid increase in CaN activity and concentration in post-
synaptic regions: 
 Previous studies in our laboratory described a dramatic increase in CaN 
immunoreactivity in post-synaptic neuronal regions after 1 hour of SE [217]. This 
places highly elevated amounts of CaN in an ideal location to regulate synaptic 
transmission through a number of post-synaptic mechanisms, including alteration 
of the dendritic cytoskeleton. The present study expands upon these results 
through the use of video-EEG monitoring, which allowed us to obtain tissue at 
highly precise time-points during SE, thus providing a temporal profile of SE-
induced alterations in CaN activity and distribution.  
 Crude SPM fractions were isolated at specific times after the first discrete 
seizure as described previously [244], and western analysis for CaN was carried 
out to determine the CaN content of SPM isolated from both control and SE 
animals at several time-points. Fractions were analyzed from both cortical and 
hippocampal tissues, as these were the brain regions previously shown to 
demonstrate an increase in SPM CaN immunoreactivity. In both cortical and 
hippocampal samples, SPM CaN immunoreactivity was not significantly different 
from control at 10 minutes post-first discrete seizure (a time-point corresponding 
to the onset of status epilepticus). However, at 15 minutes post-first discrete 
seizure and all subsequent time points, CaN immunoreactivity was significantly 
increased over control values in both cortical and hippocampal SPM (Fig 26).  
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Using a pNPP-based phosphatase assay as described previously [167], 
we also examined CaN phosphatase activity at the above time-points in cortical 
and hippocampal crude SPM fractions (Fig 27). Similar to the increase in CaN 
concentration, CaN activity approximately doubled shortly after the onset of 
continuous seizure activity in both cortical and hippocampal crude SPM. This 
increase in activity is of roughly the same magnitude as the increase in CaN 
concentration described above, and is likely due to the increased quantity of the 
enzyme present in this fraction after the onset of SE. Interestingly, an additional 
increase in CaN activity – beyond the 2-fold increase observed at 10 minutes –
was observed in cortical and hippocampal SPM fractions 30 minutes after the 
first discrete seizure. This increase in activity did not correspond to a further 
increase in CaN immunoreactivity in the crude SPM fraction. A similar increase in 
CaN activity is also observed in homogenates at this later time point [247]; we 
have previously hypothesized that this further increase in CaN activity represents 
a post-translational modification of the enzyme brought on by SE [167]. 
To further characterize the SE-induced increase in synaptic CaN 
concentration and activity, we examined the phosphorylation state of a known 
neuronal CaN substrate, DARRP-32 (Fig 28). In both cortical and hippocampal 
fractions, SE induced a profound dephosphorylation of DARRP-32. This 
dephosphorylation could be blocked by administration of FK506 or cyclosporin A 
prior to the induction of SE, indicating that SE-induced dephosphorylation of 
these substrates was CaN-dependent.  In cortical SPM, phospho-DARRP-32 
immunoreactivity was 12.3 ± 10.2% of control after SE, while immunoreactivity 
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was 62.1 ± 7.3% of control in animals that were treated with FK506 and 45.8 ± 
9.1% of control in animals that were treated with cyclosporin A. Similar results 
were achieved in hippocampal tissue (data not shown). The CaN-dependent, SE-
induced dephosphorylation of this substrate further demonstrates the dramatic 
increase in synaptic CaN activity that is present in SE, and confirms the efficacy 
of the CaN inhibitors used in this study.  
Finally, the SE-induced increase in CaN enzyme activity in crude SPM 
was examined using an RII phosphopeptide-based assay. This assay allows the 
detection of phosphate released from a CaN-specific peptide substrate. 
Increases in CaN activity similar to those described with the pNPP assay were 
present in this assay as well. CaN activity increased after 1 hour of SE in both 
cortical (Fig 29A) and hippocampal (Fig 29B) crude SPM fractions. 
 The above results, taken together with our previous studies, demonstrate 
a significant increase in CaN activity and concentration in the post-synaptic 
regions of neurons shortly after the onset of continuous seizure activity.  
 
CaN-dependent cofilin dephosphorylation in SE: 
 To determine the cellular consequences of the SE-induced increase in 
post-synaptic CaN activity, we examined the effect of SE on the stability of the 
dendritic cytoskeleton, and consequently on dendritic spine plasticity. CaN may 
regulate the stability of dendritc actin via cofilin, a CaN-regulated actin 
depolymerization factor. Through the use of a phospho-specific cofilin antibody 
we were able to assess the phosphorylation state of cofilin after SE, both with 
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and without the administration of CaN inhibitors. In both homogenates and crude 
SPM fractions isolated from SE animals, we found a significant 
dephosphorylation of cofilin in cortical and hippocampal samples. In cortical 
SPM, phospho-cofilin immunoreactivity was decreased 54.2 ± 12.3 % from 
control after 1h of SE (Fig 30A), while in hippocampal SPM phospho-cofilin levels 
decreased 74.1 ± 13.2 % from control (Fig 30B). A similar SE-induced decrease 
in cofilin phosphorylation was observed in homogenates from these brain 
regions, indicating that the effect was not an artifact of the SPM isolation 
procedure (data not shown). Overall cofilin immunoreactivity was not significantly 
affected by SE in any fraction tested (Fig 30 C, D), indicating that the observed 
decrease in phospho-cofilin was likely due to dephosphorylation of the protein 
rather than a decrease in the amount of cofilin present in the neuron. 
 To determine if the SE-induced dephosphorylation of cofilin was CaN-
dependent, we administered CaN inhibitors, FK506 or cyclosporin A, to animals 
prior to induction of SE. In FK506-treated animals, SE decreased phospho-cofilin 
immunoreactivity by 18.2 ± 13.0% in cortical SPM (Fig 30A), and 37.1 ± 14.6% in 
hippocampal SPM (Fig 30B). While SE still induced some cofilin 
dephosphorylation in these FK506-treated animals, phospho-cofilin 
immunoreactivity was significantly greater in SPM samples from FK506-treated 
animals than in untreated SE animals, indicating that SE-induced cofilin 
dephosphorylation was at least partially CaN-dependent. Similar results were 
achieved by treating animals with cyclosporin A prior to SE. Phosphocofilin 
immunoreactivity was decreased 32.9 ± 9.7% in cortical SPM and 38.6 ± 11.7% 
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in hippocampal SPM isolated from cyclosporin A animals when compared to 
control (Fig 30 A, B). These values were significantly greater than the cofilin 
phosphorylation levels in untreated SE animals. The fact that two different CaN 
inhibitors (with different mechanisms of action) were effective in preventing SE-
induced cofilin dephosphorylation provides a strong argument that CaN inhibition 
was indeed the important factor in preventing cofilin dephosphorylation, rather 
than some side-effect of the inhibitors. This data suggests that increased 
dendritic CaN activity leads to cofilin dephosphorylation after SE. While this study 
is the first to present such a finding, the data corresponds well with previous 
research detailing CaN’s effects on cofilin and actin stability. 
  
Time-course of cofilin dephosphorylation: 
 Western blot analysis was used to determine the phosphocofilin 
immunoreactivity by western blot at specific time-points post-first discrete 
seizure. Both cortical and hippocampal crude SPM isolates were examined, 
using control and pilocarpine-treated animals. In both cortical and hippocampal 
samples, cofilin phosphorylation levels decreased significantly from control levels 
after just 10 minutes of seizures, a time point which generally corresponded with 
the onset of continuous seizure activity. At 10 minutes post-first discrete seizure, 
phosphocofilin immunoreactivity was decreased 40.2 ± 6.7% from control in 
cortical samples (Fig 31A) and 60.1 ± 8.3% in hippocampal samples (Fig 31B). 
At the 20 and 40 minute time points, phosphocofilin immunoreactivity was 
indistinguishable from the 70 minute time point presented earlier. It is interesting 
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to note the speed with which cofilin phosphorylation responds to seizure activity, 
suggesting that even a few minutes of continuous seizure activity may be 
sufficient to induce widespread activation of this protein. We also noted that the 
temporal profile of cofilin dephosphorylation correlates with the timing of the 
increase in dendritic CaN activity, providing further support for the idea that CaN 
is partially responsible for SE-induced cofilin activation.  
 
SE increases cofilin-actin binding: 
 Upon activation by dephosphorylation, cofilin binds tightly to F-actin at 
specific sites, leading to actin depolymerization. To study this binding, we utilized 
a co-immunoprecipitation protocol. Cofilin-associated actin was then measured 
via western analysis of the precipitate. 
  After one hour of SE, there was a profound increase in cofilin-actin co-
immunoprecipitation. In cortical samples, actin immunoreactivity was 167.0 ± 
20.1% of control values in the precipitate (Fig 32A, B), suggesting an 
approximately 1.5-fold increase in cofilin-actin binding. Similar results were 
achieved in hippocampal samples, with actin immunoreactivity increased by 
201.3 ±17.6% in cofilin immunoprecipitates from SE animals (Fig 32C, D). When 
the precipitation procedure was carried out in the absence of anti-cofilin antibody, 
a minimal amount of actin was present in the precipitate, indicating that the 
primary source of actin immunoreactivity was actin that was bound to cofilin and 
co-precipitated with it.  
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 Both FK506 and cyclosporin A significantly reduced cofilin-actin co-
immunoprecipitation. Pretreatment of animals with FK506 resulted in a SE-
induced cofilin-actin co-immunoprecipitation that was 102.9 ± 3% of control in 
cortical samples (Fig 32A, B) and 121.3 ± 8.2% of control in hippocampal 
samples (Fig 32C, D). Both of these values are significantly lower than those of 
untreated SE animals, suggesting that CaN inhibition prevents cofilin-actin 
binding. Similar results were achieved with cyclosporin A. This data complements 
our finding that CaN inhibition prevents SE-induced cofilin dephosphorylation, 
since dephosphorylation of cofilin is required for the protein to bind to actin.  
  
SE induced actin depolymerization is CaN-dependent: 
 Following dephosphorylation and actin binding, cofilin induces 
depolymerization of F-actin to G-actin. To study this next step in our 
hypothesized pathway of SE-induced, CaN-mediated spine loss, we quantified 
the relative amounts of F and G-actin present in cortical and hippocampal SPM 
after SE. To accomplish this, we made use of the fact that F-actin is insoluble in 
1% Triton X-100, while G-actin remains soluble. SPM fractions were treated with 
Triton and centrifuged to precipitate insoluble material, thus separating F-actin 
from G-actin. Both the pellet and supernatant were subjected to SDS-PAGE and 
western analysis to quantify the amount of actin present.  
 In crude SPM isolated from SE cortex, Triton-soluble actin 
immunoreactivity was 123.2 ± 8.1 % of control (Fig 33A), while Triton-insoluble 
actin immunoreactivity was 79.3 ± 6.7 % of control (Fig 33B), indicating an SE-
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induced shift from F-actin to G-actin in the crude SPM. A similar change was 
noted in hippocampal samples, with Triton-soluble actin immunoreactivity 121.9 ± 
7.4% of control (Fig 33C), while insoluble actin immunoreactivity was 71.3 ± 
5.4% of control (Fig 33D), again demonstrating a decrease in F-actin and an 
increase in G-actin. Overall actin immunoreactivity in this fraction was unchanged 
by SE. In both cortical and hippocampal homogenates, FK506 significantly 
reduced this actin depolymerization, partially preventing the SE-induced 
increases in Triton-soluble actin immunoreactivity (G-actin) and the decreases in 
Triton-insoluble actin immunoreactivity (F-actin). Thus, by blocking the first step 
in this pathway – the CaN-induced dephosphorylation of cofilin – we prevented 
the final biochemical step of actin depolymerization.   
 
CaN inhibitors prevent dendritic spine loss in SE: 
 The preceding results demonstrate that CaN-mediated cofilin 
dephosphorylation leads to actin depolymerization in SE. Actin is the primary 
component of the dendritic spine cytoskeleton, and spine morphogenesis and 
retraction require actin depolymerization. CaN-mediated actin depolymerization, 
therefore, may likely lead to dendritic spine loss in SE. We studied dendritic spine 
density in SE via a modification of the rapid Golgi impregnation procedure (Fig 
34). This procedure has the advantage of staining neuronal processes in their 
entirety, allowing excellent visualization of dendritic arbors and spines. We 
examined neurons in frontal cortex, parietal cortex, and several hippocampal 
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subfields, including CA1, CA3 and dentate gyrus in sections from control 
animals, SE animals, and FK506-treated SE animals.  
 Previous studies have demonstrated a significant SE-induced loss of 
dendritic spines in the granule cells of the dentate gyrus. These results were 
confirmed in the present study with the Golgi technique. In control animals, 
numerous spines could be observed on all dendritic branches of the DG granule 
cells (Fig 34B). Following SE, spine density decreased remarkably, with few 
spines observed on any dendrites in the DG, a result consistent with previous 
studies (Fig 34C). Administration of the CaN inhibitor FK506 prevented SE-
induced spine loss (Fig 34D). In dentate gyrus granule cells, FK506-treated 
animals had an observed spine density that was qualitatively far greater than that 
of untreated SE animals, and appeared similar to control. This data strongly 
suggests a CaN-dependent mechanism of spine loss in SE, such as the CaN-
dependent activation of cofilin described above.  
 
DISCUSSION: 
The results presented in this study demonstrate a CaN-dependent 
mechanism of dendritic spine loss in the pilocarpine model of SE. A dramatic 
increase in CaN activity and concentration occurs in the crude SPM fraction of 
hippocampal and cortical tissues at or near the onset of continuous seizure 
activity. Coupled with our previous histochemical results [217], this demonstrates 
an increase in the effective amount of CaN phosphatase activity in dendritic 
regions of neurons. This study elucidated one pathological consequence of this 
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increased post-synaptic CaN activity by examining CaN’s effects on dendritic 
actin stability. First, we have shown a CaN-dependent dephosphorylation of the 
actin-depolymerizing factor, cofilin. Like the increase in CaN concentration and 
activity, this dephosphorylation develops shortly after the onset of SE. The 
expected biochemical consequences of an SE-induced activation of cofilin were 
also found to occur in a CaN-mediated manner, with a SE-dependent increase in 
cofilin-actin binding and a subsequent SE-induced depolymerization of dendritic 
actin. Finally, the CaN-dependent depolymerization of dendritic actin led to SE-
induced dendritic spine loss, which was demonstrated histologically in several 
brain regions and was blocked with the CaN inhibitor FK506. These findings 
implicate CaN in a widespread, SE-induced alteration in the structure of synaptic 
contacts, proving our hypothesis that SE-induced dendritic spine loss is CaN-
dependent via cofilin. These findings also potentially further our understanding of 
the cellular mechanisms underlying chronic SE-induced neurological pathology. 
 
SE, Epilepsy and Spine Loss: 
The observed SE-induced reduction in dendritic spine density may be part 
of the long-term neurological pathology that is associated with SE. As the primary 
site of excitatory neuronal synapses, and given their importance in models of 
learning and memory, spines appear to be critical for normal cognition. Studies in 
animal models have documented cognitive difficulties associated with SE, both in 
adult and developing animals [116]. While SE-induced neuronal death 
undoubtedly accounts for some of this loss of cognitive function, other, more 
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subtle, mechanisms – such as spine loss – are likely responsible as well. 
Depending on the duration of the SE-induced decrease in dendritic spine density, 
the mechanism described in this study could be a mechanism underlying SE-
induced cognitive dysfunction. In one previous study, dendritic spine density 
rebounded in the weeks following SE, although with significant alterations in 
spine morphology and location. Spine density then decreased again – possibly 
through a different mechanism – once chronic seizure activity ensued 
(spontaneous recurrent seizures are a common consequence of the pilocarpine 
model of SE) [240]. These findings tend to argue against the acute mechanism of 
spine loss described in this study as the cause of long-term cognitive dysfunction 
(although it may cause short-term deficits); however, they do suggest that it may 
be part of another chronic SE-associated pathology, epileptogenesis. 
In the pilocarpine model of SE, spontaneous recurrent seizures typically 
begin approximately 2 weeks after the prolonged seizure episode. No epileptic 
activity is seen during this quiescent period, but there is a great deal happening 
on a cellular level. It is thought that the biochemical and structural changes that 
lead to recurrent seizure activity are being completed during this time. While the 
exact mechanisms responsible for epileptogenesis remain the subject of intense 
study and debate, dendritic spine plasticity certainly is a promising candidate for 
this role. The loss and subsequent regrowth of dendritic spines could represent a 
pathological reorganization of synaptic networks leading to the formation of 
epileptic foci in the brain. It is especially interesting that spine loss has been 
documented in the dentate gyrus of the hippocampus. Network reorganization 
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and neuronal hyperexcitability in this region are frequently proposed as possible 
mechanisms of epileptogenesis. Furthermore, after the SE-associated loss of 
spines, it has been shown that their regrowth in this region is colocalized with 
sites of mossy fiber sprouting [242]. Thus an outgrowth of axonal structures that 
has been previously implicated in epileptogenesis seems to coincide with a 
reorganization of post-synaptic structures, all of which is occurring in a region 
that seems to be critical in the development of temporal lobe epilepsy. 
Considered in the context of epileptogenesis, the CaN-mediated mechanism of 
spine loss presented in this paper may help explain the results of several other 
studies. FK506 ameliorated spine loss in the present study, while other 
researchers have documented that CaN inhibitors can prevent epileptogenesis in 
both a kainic acid model of SE [121] and a kindling model of epilepsy [122, 248]. 
Further research may determine if these two effects are related.  
 
Cellular Mechanism of Spine Plasticity 
 Spine plasticity has long been observed in both chronic epilepsy and 
acute SE models [234], although the mechanisms that underlie this spine loss 
have not yet been determined. Like the increase in SPM CaN observed in this 
study, dendritic spine loss does not seem to occur with isolated, discrete seizure 
activity. Instead, spine loss only occurs in models that involve continuous seizure 
activity or chronic recurrent seizures, a characteristic that certainly fits with the 
observed behavior of CaN. Additionally, a great deal of research suggests that 
CaN modulates neuronal spine density and morphology under normal conditions, 
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with the enzyme having been previously shown to cause calcium-stimulated 
spine plasticity in several non-pathological model systems. Halpain et al. 
demonstrated a loss of spines in cultured hippocampal neurons in response to 
NMDA application. CaN was shown to co-localize with F-actin at synapses, and 
CaN inhibitors blocked NMDA-mediated spine loss in these neurons, strongly 
suggesting a CaN-mediated spine loss [79]. Simlarly, Zhou et al. described an 
LTD-associated spine shrinkage that required both NMDA and CaN to occur [80]. 
Under physiological conditions, it is highly probable that CaN-mediated spine 
plasticity is part of a learning and memory mechanism, considering the 
importance of both CaN and spines to learning models. However, with the 
profound increase in CaN levels at the synapse that we have observed in SE, 
this regulation of spine plasticity may become pathologically active, resulting in a 
detrimental reorganization of synaptic contacts.  
The present study documented a profound increase in CaN concentration 
and activity in the crude SPM fraction of neuronal tissue of animals that had 
undergone as little as 5-10 minutes of continuous seizure activity. As we have 
described previously, continuous seizure activity typically began approximately 
10 minutes after the first discrete seizure in this model [244]. No detectable 
increase was seen, however, in animals that experienced discrete, but not 
continuous, seizure activity, indicating that the onset of SE was essential for 
significant changes in CaN to occur. Such a translocation of CaN to the synapse 
may initially be a physiological defense mechanism for the neuron in the face of 
excessive excitation, as CaN is known to negatively modulate neurotransmission 
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through the AMPA and NMDA subtypes of glutamate receptor. Perhaps such a 
mechanism, occurring near the onset of continuous seizures, represents a 
pathway by which seizure activity can be terminated in brains that are not prone 
to SE. However, as SE progresses and worsens, this sustained increase in 
synaptic CaN activity also could play a pathological role in neurons. A number of 
recent studies support such a hypothesis. For example, it has long been known 
that administration of CaN inhibitors prior to SE prevents chronic SE-related 
behavioral pathologies, such as a SE-induced loss of cognitive abilities and the 
development of spontaneous continuous seizures [121]. Several mechanisms 
have been proposed as pathological roles for CaN in seizure disorders, including 
negative modulation of the GABA receptor [123, 249] and – the focus of the 
current study – modulation of dendritic spines. 
CaN may perform this pathological modulation of spine morphology via its 
regulation of the actin-depolymerizing factor, cofilin. Cofilin is a small peptide 
that, when dephosphorylated, binds to F-actin and causes its depolymerization 
[250, 251]. Cofilin has been shown to regulate the structure of dendritic spines by 
inducing the depolymerization of their actin cytoskeleton [80, 82, 252]. Recent 
studies have shown that CaN induces cofilin dephosphorylation (and thus 
subsequent actin depolymerization) either directly [253], or, more likely, indirectly 
via an intermediary phosphatase known as slingshot [81], thus making a 
mechanism involving CaN activation of cofilin and subsequent spine loss quite 
plausible. In fact, one recent study has already shown spine loss in long-term 
depression through a mechanism dependent on both CaN and cofilin [80]. 
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 The data described in this study clearly indicate a CaN-dependent 
regulation of cofilin in SE. First, the SE-induced dephosphorylation of cofilin 
required the onset of continuous seizure activity, a requirement shared with the 
increase in SPM CaN and SE-induced dendritic spine loss. In fact, the timing of 
this loss of SPM cofilin phosphorylation coincides perfectly with the increase in 
SPM CaN concentration and activity. Furthermore, both of the CaN inhibitors 
cyclosporin A and FK506 blocked SE-induced cofilin dephosphorylation. The fact 
that two different CaN inhibitors blocked SE-induced cofilin dephosphorylation 
strongly argues in favor of a CaN-dependent mechanism, although some modest 
SE-induced dephosphorylation did occur in the presence of effective doses of 
each inhibitor. This is not in itself surprising, as a number of other mechanisms 
exist for the regulation of cofilin phosphorylation. Activation of these pathways in 
SE is certainly possible, and merits future study. However, CaN-mediated 
dephosphorylation represented a major portion of the observed decrease in 
phosphocofilin immunoreactivity. This CaN-dependent dephosphorylation of 
cofilin did indeed activate the molecule, as SE was also shown to lead to a CaN-
dependent increase in cofilin-actin binding and a CaN-dependent 
depolymerization of actin. While the observed change in the F/G actin ratio was 
relatively modest, when one considers the prevalence of actin in all cell types 
and cellular structures in the brain, even a 20% difference in the relative amounts 
of F- and G- actually represents a quite profound structural change. This 
structural change manifested itself in a CaN-dependent loss of dendritic spines. 
As other researchers have previously, we observed a SE-dependent loss of 
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dendritic spines after 1 hour of SE. Considering the timing of the CaN-induced 
cofilin dephosphorylation, this loss of spines may, in fact, have occurred even 
earlier in SE, and future studies should certainly explore synaptic changes at 
these earlier time-points. 
The novel findings presented in this study describe a cellular mechanism 
for actin depolymerization and dendritic spine loss in the pilocarpine model of SE. 
This spine loss is widespread throughout the forebrain after SE, and is CaN-
dependent, involving the actin depolymerizing factor, cofilin. Further research in 
this area may help elucidate the role of dendritic spine plasticity in SE-associated 
neuronal pathologies, potentially provide insight into some of the mechanisms 
underlying epileptogenesis and providing the basis for future treatment options.
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Figure 26: The seizure-induced increase in crude SPM CaN 
immunoreactivity occurs near the onset of SE.  CaN immunoreactivity was 
measured in crude SPM fractions isolated from cortex (A) and hippocampus (B). 
In both fractions, CaN immunoreactivity was found to be increased significantly 
above control values at 15 minutes post-first discrete seizure, or approximately 5 
minutes after the onset of continuous seizure activity.  CaN immunoreactivity 
doubled at this time-point in both cortical and hippocampal SPM, and remained 
similarly elevated at all subsequent time-points. (** p < 0.01,  n = 3 per time-
point, student’s t-test).  
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Figure 27: Temporal profile of basal and cation-stimulated CaN activity in 
cortical and hippocampal crude SPM. In both cortex (A, B) and hippocampus 
(C, D) CaN activity (as measured by the pNPP assay) in the SPM increased with 
a temporal profile similar to the SE-induced increase in CaN immunoreactivity 
noted above. Both basal (A, C) and cation-stimulated (B, D) activity increased 
significantly by 20 minutes post-first discrete seizure, with the magnitude of the 
increase being roughly similar to the magnitude of the increase in CaN 
immunoreactivity via western blot. As SE continued, a further increase in CaN 
activity was observed in all fractions and in all reaction conditions (although this 
increase is most noticeable in under the basal reaction conditions). The timing of 
this later increase corresponds to an increase in CaN activity that is observed in 
the overall homogenate and is discussed previously (* p < 0.05, ** p < 0.01, *** p 
<0.001).  
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Figure 28: SE leads to increased CaN-dependent dephosphorylation of 
DARRP-32. Phospho-DARRP-32 immunoreactivity was determined via western 
analysis. SE was found to induce a significant dephosphorylation of the protein (p 
<0.05, n=3), a finding that is consistent with increased CaN activity. Pretreatment 
of animals with either CaN inhibitor reduced DARRP dephosphorylation 
significantly (p < 0.05 compared to SE, n=3), indicating that the inhibitors were 
reaching the brain in sufficient concentrations to inhibit CaN activity. 
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Figure 29: RII phosphopeptide assay for CaN activity. To further expand 
upon our previous results, we examined CaN activity in the crude SPM of cortex 
and hippocampus using an additional enzyme assay procedure. Phosphate 
released from RII phosphopeptide, a specific CaN substrate, was assayed using 
a malachite-green based reaction and read in a spectrophotometer at 620nm. In 
both cortex (A) and hippocampus (B) a significant increase in CaN activity was 
observed after 1h of SE. This increase was of similar magnitude to that observed 
with the pNPP assay. (p < 0.05, n=3).  
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Figure 30: SE induces a CaN-dependent dephosphorylation of cofilin. In 
both cortical (A) and hippocampal (B) crude SPM, SE induced a significant (p < 
0.01, n=10 in both regions) dephosphorylation of cofilin, as measured by 
immunoreactivity on western analysis using a phosphocofilin antibody. 
Administration of one of the immunosuppressant CaN inhibitors (FK506 or 
cyclosporin A) prior to SE partially blocked this dephosphorylation (p < 0.05 when 
compared to SE, n = 6 in both cortex and hippocampus). Changes in 
phosphocofilin immunoreactivity were not due to changes in overall cofilin 
concentration, as western analysis with a cofilin antibody revealed no change in 
overall levels of the protein in either cortical (C) or hippocampal (D) SPM. 
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Figure 31: Temporal profile of cofilin dephosphorylation in the pilocarpine 
model of SE. (A) Western analysis for phosphocofilin in cortical (left) and 
hippocampal (right) crude SPM at 10, 20 and 40 minutes post-first discrete 
seizure. Cofilin phosphorylation was detected as early as 10 minutes post-first 
discrete seizure in both brain regions. This time point corresponds approximately 
to the onset of continuous seizure activity in this model. (B) Calibrated 
densitometry of phosphocofilin western blots in cortical (left) and hippocampal 
(right) crude SPM fractions. Cofilin phosphorylation was significantly decreased 
at 10 minutes and all subsequent time points (* p < 0.05, ** p < 0.01, *** p 
<0.001) 
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Figure 32: SE induces a CaN-dependent binding of cofilin to actin as 
detected by coimmunoprecipitation. Cofilin was immunoprecipitated from 
cortical (A, B) and hippocampal (C,D) homogenates, then the actin content of the 
precipitate was determined by western analysis. Very little actin was precipitated 
in the absence of cofilin primary antibody (A, far left), confirming the specificity of 
the assay procedure. In both cortical (A, B) and hippocampal (C,D) samples, SE 
led to a significant (p < 0.05) increase in cofilin-actin coprecipitation. This 
association of the two proteins was significantly blocked by calcineurin inhibitors 
(p < 0.05 when compared to SE value).    
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Figure 33: SE induces CaN dependent actin depolymerization. F-actin and 
G-actin were separated by solubility in 1% triton, then assayed by western 
analysis in cortical (A, B) and hippocampal (C,D) crude SPM. In cortical SPM, SE 
caused a significant (p < 0.05) increase in the amount of actin present in the 
triton-soluble fraction (A). G-actin is soluble in triton while F-actin is not, and thus 
this increase in soluble actin likely represents an SE-induced depolymerization of 
actin. A similar decrease in triton-insoluble actin (F-actin) was observed in 
cortical homogenates following SE (B). The CaN inhibitor FK506 blocked the shift 
of actin from the soluble to insoluble fraction, suggesting that the observed actin 
depolymerization was CaN-dependent. Similar effects were observed in 
hippocampal triton-soluble (C) and triton-insoluble (D) fractions isolated from 
crude SPM (n = 3 for all groups). 
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Figure 34: FK506 blocks SE-induced dendritic spine loss in granule cells of 
the dentate gyrus. Coronal sections were blocked for dorsal hippocampus and 
sectioned at 150 microns on a vibratome, then stained using a single-section 
variant of the rapid Golgi method. Granule cells with numerous processes were 
easily visualized in control sections (A). Under higher magnification, numerous 
dendritic spines were visualized in control dendrites (B), while relatively few 
spines were observed in dendrites of SE animals (C). In SE animals pre-treated 
with FK506, spine density appeared qualitatively to be preserved. (representative 
sections shown, n = 3 animals per group) 
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DISCUSSION 
 
The present study examined the effects of two different models of 
neuronal injury on the activity and distribution of CaN. In chapter one, we 
demonstrated an SE-dependent increase in both basal and maximal CaN activity 
and a corresponding change in CaN substrate kinetics. This change was 
dependent on NMDA-mediated calcium influx, and not due to an increase in the 
overall amount of CaN present in the cell after SE. In chapter two, through the 
use of western and immunohistochemical analysis, we showed an SE-dependent 
increase in the amount of CaN present in the post-synaptic region of neurons. 
This SE-induced increase in synaptoplasmic CaN concentration was 
accompanied by a dramatic increase in CaN activity in this fraction. We suspect 
that the SE-induced increase in synaptic CaN is due to a translocation of the 
enzyme, as the results of chapter one indicated that no new CaN synthesis had 
taken place. Taken together, the results presented in the first two chapters of this 
study describe a profound increase in post-synaptic CaN concentration and 
activity after one hour of SE, changes that could have major implications in the 
pathology of SE. In chapters three and four we demonstrated a similar increase 
in CaN activity and post-synaptic increase in CaN concentration in the moderate 
fluid percussion model of traumatic brain injury. These changes in CaN activity 
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and subcellular distribution persisted for several weeks post-injury, a time-course 
which corresponds to a number of TBI-associated pathologies Finally, in chapter 
five, we examined one potential physiological consequence of SE-induced 
increases in post-synaptic CaN activity and concentration. CaN was shown to be 
part of a cellular mechanism of SE-induced dendritic spine loss, possibly 
implicating the enzyme in SE-induced chronic neurological pathology. Altogether, 
the results presented in this study provide compelling evidence that CaN is 
involved in neuronal damage in two disparate models of injury, and provide at 
least one cellular mechanism for this damage in the pilocarpine model of SE. 
Ideally, further research in this topic will provide a basis for future neuroprotective 
and therapeutic treatments. 
The presence of injury-dependent changes in CaN activity in both models 
may be explained by the importance of glutamate-mediated excitotoxic 
mechanisms to the pathology of both conditions. In fact, this alteration in CaN 
activity and distribution would not be the first pathologic mechanism shared 
between TBI and SE. For example, MK801, a non-competitive NMDA channel 
blocker, is neuroprotective in animal models of both conditions [254, 255]. Both 
TBI and SE lead to neuronal hyperexcitability, particularly in the hippocampus. 
Additionally, both TBI and SE are epileptogenic in animal models and clinical 
studies (in fact, TBI represents one of the major causes of epilepsy in the United 
States). Thus, while TBI and SE are clearly different types of neuronal injury, it is 
just as clear that they share some pathological mechanisms and long-term 
consequences. The identification of these common pathological  pathways, such 
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as CaN activation and redistribution, may allow for the development of multi-use 
treatment modalities. 
 
Increased forebrain homogenate CaN activity in SE and TBI: 
 In both SE and TBI, a significant increase in basal and Mn-stimulated CaN 
activity was observed. Western analysis in homogenates from both models 
revealed no significant increase in CaN concentration, suggesting that this 
increase in activity was not due to injury-stimulated synthesis of new enzyme. A 
number of other possibilities exist to explain this increase in activity. First of all, 
glutamate-induced calcium influx could directly stimulate the enzyme, resulting in 
the observed increase in activity. This explanation is unlikely for several reasons. 
First, the levels of free calcium achieved inside neurons during toxic glutamate 
stimulation are well above the concentration range commonly associated with 
CaN activation. In fact, high calcium concentrations have actually been shown to 
inactivate the enzyme, rather than activating it. Second, the timing of the 
increase in CaN activity in homogenate correlates poorly with calcium entry as a 
mechanism. In SE, homogenate CaN activity increased after approximately 30 
minutes of continuous seizure activity, although cellular free calcium levels rise 
much sooner. Finally, addition of excess chelator to the reaction mix did not 
eliminate the observed increase in activity. On the other hand, local calcium 
concentrations in some portions of the neuron could certainly be within the 
appropriate range, due to the separation of specialized compartments within the 
cell. When CaN activity is considered on a finer scale than that provided by 
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tissue homogenization, direct activation by glutamate-induced calcium influx is 
certainly possible, however we belive it is not likely to explain the wholesale 
increase in activity observed in the homogenates after both injuries. 
 While direct activation of the enzyme by glutamate-induced calcium influx 
does not seem to explain the increase in CaN activity, NMDA-receptor 
associated calcium influx still was essential for the enzyme activation to occur. 
This tends to implicate other calcium-regulated systems in the activation of the 
enzyme in homogenate. Phosphorylation of the enzyme by a calcium-stimulated 
kinase is one such explanation, although significant regulation of the enzyme 
through such a mechanism has not been conclusively demonstrated. Another 
possible mechanism involves partial proteolysis of the enzyme by calcium 
stimulated proteases. Such proteolysis has been shown to activate the enzyme 
via removal of the autoinhibitory domain. Interestingly, the calcium stimulated 
protease, calpain, has been shown to be activated in both SE and TBI, and this 
mechanism of CaN activation has been demonstrated in an in vitro model of 
glutamate excitotoxicity. Further research is needed to determine if calpain-
mediated activation of CaN is responsible for the delayed increase in CaN 
activity observed in SE, and the similar increase in homogenate CaN activity 
observed in TBI. Interestingly, the increase in CaN activity persisted for several 
weeks in TBI, and it is possible that this sustained increase is due to some 
combination of post-translational modification and increased resting calcium 
levels.  
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Increased synaptoplasmic CaN concentration in SE and TBI: 
 In both model systems, a profound increase in the amount of CaN present 
in the crude synaptoplasmic membrane fraction was noted in hippocampal and 
cortical isolates. Additionally, immunohistochemistry confirmed this increase in 
post-synaptic CaN immunoreactivity in hippocampal slices from both SE and TBI 
animals. Two possible explanations exist for this increased CaN 
immunoreactivity in SPM fractions and on IHC; either new CaN has been 
synthesized or existing CaN has been translocated to the membrane.  
 Regardless of the cause of the increased CaN immunoreactivity, the result 
is functionally the same. Both injury processes result in a dramatic increase in 
the amount of CaN present at the synapse. In SE, this increase was determined 
to be very rapid, occurring shortly after the onset of continuous seizure activity (in 
contrast to the increase in homogenate activity, which was delayed until 20-30 
minutes of continuous seizures had occurred). A proportional increase in activity 
accompanied this increase in CaN concentration in both models. At least in the 
SE model, this increase in activity was determined to be mechanistically distinct 
from the increase in homogenate activity discussed above. A careful analysis of 
the temporal profile of SE-induced CaN activity changes in SPM reveals an 
immediate increase in CaN activity that corresponds in timing and magnitude 
with the increase in SPM CaN concentration, and a separate, later increase in 
activity that corresponds temporally with the increase in homogenate activity. 
Thus two events appear to be taking place: increased CaN concentration post-
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synaptically shortly after the onset of continuous seizure activity, and a later 
increase in CaN activity caused by post-translational modification of the enzyme.  
 There are numerous possible implications of this increased post-synaptic 
CaN activity and concentration for the observed pathologies of both models. As 
described previously, CaN regulates a number of neurotransmitter receptors. 
Disregulation of the GABAA receptor has been observed as a pathological 
mechanism in both TBI and SE [161, 256-258]. A number of studies have 
demonstrated negative modulation of GABAA function by CaN [66, 67], and at 
least one study has shown a direct CaN-mediated dephosphorylation of a GABAA 
subunit [69]. Additionally, an injury-induced modulation of the receptor by CaN 
has already been observed in a model of hypoxic injury in immature rats [123]. 
The dramatically increased SPM CaN activity observed in the two model systems 
in this study could result in increased GABAA receptor dephosphorylation (or 
increased receptor internalization), decreased GABAergic neurotransmission, 
and increased neuronal excitability. Post-injury hyperexcitability and eventual 
epileptogenesis are hallmarks of both TBI and SE [230], pathologies that could 
be explained by a negative modulation of GABAA receptors by the increased 
post-synaptic CaN. Futhermore, one study has demonstrated a loss of 
GABAergic inhibition that was NMDA-dependent, like the increase in CaN activity 
described in this study [259]. This mechanism of neuronal disinhibition merits 
future research in both of these conditions.  
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CaN and cognitive function: 
 A second potential implication of increased post-synaptic CaN is 
decreased cognitive function. This is of particular interest in TBI, where cognitive 
deficits are a common and unfortunate consequence of the injury. A great deal of 
evidence suggests that CaN exerts a negative modulation on learning and 
memory. Studies in rats have revealed that CaN inhibition increases performance 
in associative memory-related tasks. For example, Ikegami et al. demonstrated 
an increase in conditioned fear memory in rats treated with CaN antisense 
oligonucleotides or FK506 [260]. Similarly Lin et al. demonstrated that application 
of CaN inhibitors to the amygdala in vivo prevented the extinction of fear memory 
[261, 262]. A number of studies have examined the effects of genetically reduced 
CaN activity on learning and memory, either via overexpression of a calcineurin 
autoinhibitory peptide or by CaN knockout. Conditional (doxycycline-dependent) 
overexpression of the CaN autoinhibitory peptide in adult mouse brain resulted in 
enhanced short- and long-term memory in an object recognition task [5]. 
Additionally, overexpression of the autoinhibitory peptide enhanced performance 
in the Morris water maze (MWM) task. Mutant mice treated with doxycycline 
learned the position of the platform in the maze more rapidly and retained this 
information longer (the platform was removed and the number of times the 
mouse crossed the prior location on successive days measured), indicating a 
positive effect of CaN inhibition on learning and memory [5]. Finally, several 
studies have investigated the effects of conditional overexpression of calcineurin, 
often using a doxycycline-sensitive mutant mouse that overexpresses a 
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truncated, active form of calcineurin (see calpain proteolysis, above). Mansuy 
and colleagues demonstrated that calcineurin overexpressing mice had deficient 
long-term memory and deficient spatial learning as tested by the Barnes maze 
task, but normal short term memory. These deficits could be entirely rescued by 
“turning off” the calcineurin overexpression. Additionally, the mice in this study 
had difficulty with an object-recognition task when tested at long (but not short) 
intervals [224]. The researchers theorized that CaN was essential for the 
transition from short-term to long term memory; on a cellular level, they 
hypothesized that this was due to CaN’s negative effects on an intermediate-
length form of LTP [224, 263, 264]. In a later study by the same laboratory, the 
mutant mice also exhibited impaired spatial learning on the MWM task. When 
conditional mutants were allowed to train on the MWM task with CaN 
overexpression suppressed (normal CaN levels) their performance was the same 
as control mice; however, if CaN overexpression was then induced after the 
training phase, the performance of the mice declined and they could no longer 
remember the position of the platform. This seems to indicate that CaN 
overexpression also interferes with memory retrieval. Interestingly, if CaN levels 
were subsequently restored to normal, memory of platform position was 
recovered [264]. The results of these CaN overexpression studies correspond 
well with the inhibitor and autoinhibitory peptide-based studies, suggesting that 
within a certain range, CaN activity generally acts to prevent memory formation 
and retrieval while promoting memory extinction. Thus a dramatic increase in 
post-synaptic CaN, such as that observed in SE and TBI in this study, could be 
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responsible for decreased cognition after the injury event. Interestingly, the 
duration of increased CaN activity and post-synaptic concentration correlates 
with previous results documenting the duration of cognitive deficits after TBI. 
Future research into this cellular mechanism may provide clinical options for 
preserving cognitive abilities after brain injury. 
 
SE, epilepsy and spine loss: 
 Finally, injury-induced increases in post-synaptic CaN may lead to 
negative modulation of dendritic spines. Decreased spine density has been 
previously observed in SE [240], and is postulated to be involved in chronic post-
seizure pathology. As discussed above, CaN negatively modulates spine density 
in several model systems [79, 80]. Thus, an SE (or TBI)-mediated increase in 
CaN activity and concentration in the immediate vicinity of dendritic spines could 
account for decreased spine density in these conditions. We investigated this 
intriguing cellular mechanism in the pilocarpine model of SE, and discovered a 
profound CaN-dependent loss of dendritic spines. 
There are several potential physiological roles of the CaN-dependent loss 
of spines described in this study. In the pilocarpine model of SE, spontaneous 
recurrent seizures typically begin approximately 2 weeks after the prolonged 
seizure episode [265]. No epileptic activity is seen during this quiescent period, 
but there is a great deal happening on a cellular level. It is thought that the 
biochemical and structural changes that lead to recurrent seizure activity are 
being completed during this time. While the exact mechanisms responsible for 
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epileptogenesis remain the subject of intense study and debate, dendritic spine 
plasticity certainly is a promising candidate for this role. The loss and subsequent 
regrowth of dendritic spines could represent a pathological reorganization of 
synaptic networks leading to the formation of epileptic foci in the brain. It is 
especially interesting that spine loss has been documented in the dentate gyrus 
of the hippocampus [242]. Network reorganization and neuronal hyperexcitability 
in this region are frequently proposed as possible mechanisms of 
epileptogenesis. Furthermore, after the SE-associated loss of spines, it has been 
shown that their regrowth in this region is colocalized with sites of mossy fiber 
sprouting [242]. Thus an outgrowth of axonal structures that has been previously 
implicated in epileptogenesis seems to coincide with a reorganization of post-
synaptic structures, all of which is occurring in a region that seems to be critical 
in the development of temporal lobe epilepsy.  
 
Conclusion: 
 These studies describe a novel increase in CaN activity after both TBI and 
SE, and demonstrate an increase in CaN in crude SPM fractions after both 
conditions. In TBI, these changes were shown to persist for 2 weeks in cortical 
samples and up to 4 weeks in hippocampal samples. Immunohistochemical 
studies confirmed that this increase in SPM CaN represented an increase in the 
amount of enzyme in hippocampal dendrites. The pathological implications of 
these changes include potential mechanisms for decreased cognitive function 
and epileptogenesis. Finally, we presented one physiological consequence of 
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increased dendritic CaN in SE: dendritic spine loss. We demonstrated a CaN-
dependent cellular mechanism for this decrease in spine density involving the 
actin-depolymerizing factor, cofilin. These results help further our understanding 
of the pathologies set in motion by these two models of neuronal injury, and may 
provide the basis for future clinical treatments, ideally decreasing the impact of 
neuronal injury on patient’s quality of life.  
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